Northwest Biotherapeutics, Inc. Receives Patent Coverage - 500 Beiträge pro Seite
eröffnet am 21.03.05 14:19:09 von
neuester Beitrag 09.08.07 12:05:44 von
neuester Beitrag 09.08.07 12:05:44 von
Beiträge: 3.501
ID: 967.743
ID: 967.743
Aufrufe heute: 2
Gesamt: 104.334
Gesamt: 104.334
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
heute 18:26 | 1869 | |
vor 10 Minuten | 1467 | |
vor 34 Minuten | 1252 | |
heute 18:52 | 1047 | |
vor 21 Minuten | 1045 | |
vor 51 Minuten | 917 | |
vor 31 Minuten | 903 | |
heute 17:49 | 866 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.497,94 | +0,01 | 177 | |||
2. | 2. | 164,04 | -0,65 | 71 | |||
3. | 14. | 5,5260 | -1,11 | 48 | |||
4. | 6. | 4,1500 | +0,24 | 43 | |||
5. | 9. | 0,6906 | +12,73 | 38 | |||
6. | 4. | 0,1925 | 0,00 | 32 | |||
7. | 30. | 0,3340 | +76,72 | 31 | |||
8. | 39. | 6,4260 | +1,39 | 30 |
Press Release Source: Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. Receives Patent Coverage for Antibodies to Primary and Metastatic Cancer Protein
Monday March 21, 8:00 am ET
BOTHELL, Wash., March 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has been issued a patent for antibodies to a protein that plays an important role in human cancer, both in primary tumors and in metastasis.
ADVERTISEMENT
The protein, known as CXCR4, is a chemokine receptor, which is over expressed in more than 65% of human cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. The patent issued is United States patent No. 6,863,887, "Therapeutic and Diagnostic Applications Based on the Role of the CXCR4 Gene in Tumorigenesis." The CXCR4 protein is unique in that it plays an important role in three fundamental aspects of cancer: cancer cell proliferation, invasion and migration, resulting in the seeding of metastatic cells at distant sites such as bone, lung and brain. It is rare for a cancer-related protein to play an important role in all three functional aspects of cancer cells, across many types of cancers. As such, CXCR4 offers an exceptional therapeutic opportunity to prevent proliferation of primary tumors, as well as to prevent metastases.
The patent issued to Northwest Biotherapeutics provides broad coverage for the use of antibodies in preventing and inhibiting the proliferation of cells that over express CXCR4, and for the killing of such cells. Additional issued claims cover the use of antibodies to CXCR4 that are conjugated with a radioactive substance, toxin or drug.
"We are particularly pleased with the CXCR4 patent which came from our gene discovery program, and which will significantly add to our product candidate pipeline," stated Alton Boynton, Ph.D., President, Chief Operating Officer, and co-founder of Northwest Biotherapeutics. "Our preclinical work clearly demonstrates an important role for CXCR4 and its ligand, CXCL12, in tumor cell proliferation, cell migration/invasion and metastasis; three critical functions of cancer cells. The central role of CXCR4 in all three functional aspects of cancer cells, provides multiple therapeutic possibilities, and certainly makes CXCR4 a premier target for novel treatments."
The pre-clinical work by Northwest Biotherapeutics is consistent with the extensive research by others, demonstrating that monoclonal antibodies to CXCR4 can prevent cancer cell proliferation, migration, and establishment of distant metastatic sites using several animal models, including those for breast cancer. Researchers have found that tumors often outgrow their blood supply, and thereby create hypoxic or low-oxygen conditions. The hypoxia results in the expression of CXCR4 which promotes the survival of tumor cells in the hypoxic environment by enabling the cancer cells to proliferate, and migrate away from areas of low oxygen, thus seeding distant metastatic sites in other organs. A positive correlation has been shown to exist in human cancer between CXCR4 expression and establishment of metastatic disease for example in, breast cancer, kidney cancer and acute childhood lymphocytic leukemia.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. Three technologies form the basis of our product candidates: a dendritic cell-based immunotherapy platform applicable to multiple cancers and currently cleared by the FDA for a Phase III clinical trial in non-metastatic hormone independent prostate cancer, and a Phase II clinical trial for Glioblastoma multiforme; a therapeutic monoclonal antibody product candidate, CXCR4, applicable to multiple cancer types; and an antibody-based imaging agent for metastatic prostate cancer.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to successfully clear the FDA for Phase I clinical trials for CXCR4 in cancer patients, the clinical trial process including the ability to enroll patients in the planned Phase III trial of DCVAX®-Prostate, and Phase II DCVax-Brain clinical trial, and the ability to complete these trials on a timely basis, and whether these clinical trials will demonstrate safety and efficacy, and, the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
--------------------------------------------------------------------------------
Source: Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. Receives Patent Coverage for Antibodies to Primary and Metastatic Cancer Protein
Monday March 21, 8:00 am ET
BOTHELL, Wash., March 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has been issued a patent for antibodies to a protein that plays an important role in human cancer, both in primary tumors and in metastasis.
ADVERTISEMENT
The protein, known as CXCR4, is a chemokine receptor, which is over expressed in more than 65% of human cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. The patent issued is United States patent No. 6,863,887, "Therapeutic and Diagnostic Applications Based on the Role of the CXCR4 Gene in Tumorigenesis." The CXCR4 protein is unique in that it plays an important role in three fundamental aspects of cancer: cancer cell proliferation, invasion and migration, resulting in the seeding of metastatic cells at distant sites such as bone, lung and brain. It is rare for a cancer-related protein to play an important role in all three functional aspects of cancer cells, across many types of cancers. As such, CXCR4 offers an exceptional therapeutic opportunity to prevent proliferation of primary tumors, as well as to prevent metastases.
The patent issued to Northwest Biotherapeutics provides broad coverage for the use of antibodies in preventing and inhibiting the proliferation of cells that over express CXCR4, and for the killing of such cells. Additional issued claims cover the use of antibodies to CXCR4 that are conjugated with a radioactive substance, toxin or drug.
"We are particularly pleased with the CXCR4 patent which came from our gene discovery program, and which will significantly add to our product candidate pipeline," stated Alton Boynton, Ph.D., President, Chief Operating Officer, and co-founder of Northwest Biotherapeutics. "Our preclinical work clearly demonstrates an important role for CXCR4 and its ligand, CXCL12, in tumor cell proliferation, cell migration/invasion and metastasis; three critical functions of cancer cells. The central role of CXCR4 in all three functional aspects of cancer cells, provides multiple therapeutic possibilities, and certainly makes CXCR4 a premier target for novel treatments."
The pre-clinical work by Northwest Biotherapeutics is consistent with the extensive research by others, demonstrating that monoclonal antibodies to CXCR4 can prevent cancer cell proliferation, migration, and establishment of distant metastatic sites using several animal models, including those for breast cancer. Researchers have found that tumors often outgrow their blood supply, and thereby create hypoxic or low-oxygen conditions. The hypoxia results in the expression of CXCR4 which promotes the survival of tumor cells in the hypoxic environment by enabling the cancer cells to proliferate, and migrate away from areas of low oxygen, thus seeding distant metastatic sites in other organs. A positive correlation has been shown to exist in human cancer between CXCR4 expression and establishment of metastatic disease for example in, breast cancer, kidney cancer and acute childhood lymphocytic leukemia.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. Three technologies form the basis of our product candidates: a dendritic cell-based immunotherapy platform applicable to multiple cancers and currently cleared by the FDA for a Phase III clinical trial in non-metastatic hormone independent prostate cancer, and a Phase II clinical trial for Glioblastoma multiforme; a therapeutic monoclonal antibody product candidate, CXCR4, applicable to multiple cancer types; and an antibody-based imaging agent for metastatic prostate cancer.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to successfully clear the FDA for Phase I clinical trials for CXCR4 in cancer patients, the clinical trial process including the ability to enroll patients in the planned Phase III trial of DCVAX®-Prostate, and Phase II DCVax-Brain clinical trial, and the ability to complete these trials on a timely basis, and whether these clinical trials will demonstrate safety and efficacy, and, the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
--------------------------------------------------------------------------------
Source: Northwest Biotherapeutics
Hi Wayne99,
ich verfolge die Aktie seit einigen Wochen. Wurde erstmals darauf aufmerksam, als eine Meldung bzgl. Zulassung eines Krebsmedikamentes ins Board gestellt wurde.
Danach wurde es leider wieder sehr still um die Aktie.
Könntest Du mir die wichtigsten Passagen bitte übersetzen und deren Bedeutung für die Aktie.
Welche Kursziele siehst Du (bitte mit Begründung)?
Über eine kurzfristige Antwort würde ich mich sehr freuen.
Mit bestem Dank im voraus!
ich verfolge die Aktie seit einigen Wochen. Wurde erstmals darauf aufmerksam, als eine Meldung bzgl. Zulassung eines Krebsmedikamentes ins Board gestellt wurde.
Danach wurde es leider wieder sehr still um die Aktie.
Könntest Du mir die wichtigsten Passagen bitte übersetzen und deren Bedeutung für die Aktie.
Welche Kursziele siehst Du (bitte mit Begründung)?
Über eine kurzfristige Antwort würde ich mich sehr freuen.
Mit bestem Dank im voraus!
#2 Bin leider in Eile, diese Meldung ist aber sehr positiv für die Company (Patenterteilung für einen Antikörper) , die MK liegt momentan gerade mal bei 4,0 Mio. US-$
"Nordwestlicher Biotherapeutics (OTC Board: NWBT.OB - Nachrichten) heute gab bekannt, dass es ein Patent für Antikörper zu einem Protein ausgegeben worden ist, das eine wichtige Rolle in Menschenkrebs sowohl in primären Geschwülsten als auch in der Metastase spielt. "
"Nordwestlicher Biotherapeutics (OTC Board: NWBT.OB - Nachrichten) heute gab bekannt, dass es ein Patent für Antikörper zu einem Protein ausgegeben worden ist, das eine wichtige Rolle in Menschenkrebs sowohl in primären Geschwülsten als auch in der Metastase spielt. "
Danke Wayne99!
Hab meinem Namen leider alle Ehre gemacht und letztendlich zum Tageshöchstkurs von 0,23 EUR gekauft...
Hatte nämlich eigentlich damit gerechnet, dass die Aktie -wie nach Bekanntgabe der letzten Meldung - bis mindestens 0,50 EUR hochläuft.
Naja, bei einer momentanen Marktkapitalisierung von nur gut 4 Mio. EUR sollte die Aktie nach solch einer Meldung in nächster Zeit noch genug Luft nach "oben" haben.
Wäre schön, wenn jemand Zahlenmaterial aus 2004 ins Board setzen könnte (Quartalszahlen, Barmittelbestand, etc.), damit man einen detaillierteren Eindruck von der Aktie erhält.
Gruß,
Prof.Hastig
Hab meinem Namen leider alle Ehre gemacht und letztendlich zum Tageshöchstkurs von 0,23 EUR gekauft...
Hatte nämlich eigentlich damit gerechnet, dass die Aktie -wie nach Bekanntgabe der letzten Meldung - bis mindestens 0,50 EUR hochläuft.
Naja, bei einer momentanen Marktkapitalisierung von nur gut 4 Mio. EUR sollte die Aktie nach solch einer Meldung in nächster Zeit noch genug Luft nach "oben" haben.
Wäre schön, wenn jemand Zahlenmaterial aus 2004 ins Board setzen könnte (Quartalszahlen, Barmittelbestand, etc.), damit man einen detaillierteren Eindruck von der Aktie erhält.
Gruß,
Prof.Hastig
Ja, da hast du das Tageshoch erwischt - allerdings kam letztes Mal der Run erst am 2-ten Tag zustande - wenn auch durch eine wilde Puscherei im Board
Infos zu NWBT findest du hier:
http://www.otcbb.com/asp/default.asp
Einfach bei Symbol oben NWBT eingeben........
Infos zu NWBT findest du hier:
http://www.otcbb.com/asp/default.asp
Einfach bei Symbol oben NWBT eingeben........
Ein weiteres Patent hat Phase2 der klinischen Tests schon durchlaufen und befindet sich in der abschliessenden 3.Phase! Fantasie und nicht ganz unbegründet...
Guten Morgen,
ich bin begeistert und denke der Kurs wird sich bald mit einem Euro vertraut machen müssen.
Freue mich schon.
ProfessorHastig du kannst dich auch auf eine enorme Steigerung freuen. Hast nicht zuviel bezahlt. Kann alles sehr schnell gehen. Bin überzeugt es gibt bald nichts mehr unter 0,60 Euro.
mfg
Eure Wachsblume
ich bin begeistert und denke der Kurs wird sich bald mit einem Euro vertraut machen müssen.
Freue mich schon.
ProfessorHastig du kannst dich auch auf eine enorme Steigerung freuen. Hast nicht zuviel bezahlt. Kann alles sehr schnell gehen. Bin überzeugt es gibt bald nichts mehr unter 0,60 Euro.
mfg
Eure Wachsblume
Guten Morgen allerseits,
was ich ehrlich gesagt nicht ganz verstehe, ist die Tatsache, dass der Kurs in den USA gestern nicht explodiert ist.
Ich denke doch, dass der Kurs der Aktie im Amiland gemacht wird und bei einem Schlusskurs von 0,27 US-$ sehe ich heute nicht besonderes Steigerungspotential.
Oder sehe ich das falsch?
Und noch was: Im 5-Jahres-Chart ist zu sehen, dass der Kurs der Aktie vor 3-4 Jahren wesentlich höher notierte (5 US-$). Könnte das die vorweggenommene Phantasie für die letzten doch sehr positiven Patents-Meldungen gewesen sein? Bis ein Medikament die gesamten klinischen Testphasen durchlaufen hat, vergehen ja auch schon ein paar Jahre, oder?
Ich hoffe, dass der Kurs auch ohne die üblichen Pusher-Blättchen steigen wird.
In diesem Sinne wünsche ich allen NWBT-Investierten und denen, die es noch werden, einen positiven Handelstag!
Prof.Hastig
was ich ehrlich gesagt nicht ganz verstehe, ist die Tatsache, dass der Kurs in den USA gestern nicht explodiert ist.
Ich denke doch, dass der Kurs der Aktie im Amiland gemacht wird und bei einem Schlusskurs von 0,27 US-$ sehe ich heute nicht besonderes Steigerungspotential.
Oder sehe ich das falsch?
Und noch was: Im 5-Jahres-Chart ist zu sehen, dass der Kurs der Aktie vor 3-4 Jahren wesentlich höher notierte (5 US-$). Könnte das die vorweggenommene Phantasie für die letzten doch sehr positiven Patents-Meldungen gewesen sein? Bis ein Medikament die gesamten klinischen Testphasen durchlaufen hat, vergehen ja auch schon ein paar Jahre, oder?
Ich hoffe, dass der Kurs auch ohne die üblichen Pusher-Blättchen steigen wird.
In diesem Sinne wünsche ich allen NWBT-Investierten und denen, die es noch werden, einen positiven Handelstag!
Prof.Hastig
0,18 EUR - aber die Börse muss man ja auch nicht begreifen!!!
Da hat eine Biotech-Aktie das große Glück, eine äußerst positive Meldung veröffentlichen zu können, und nach einer kleinen Anfangseuphorie fällt der Kurs wieder auf Insolvenzniveau!
Jede insolvente Pommesbude wird aufgrund von Mantel-SPEKULATIONEN(!) auf eine zweistellige MK hochgepusht, und NWBT dümpelt trotz positiven Zukunftsaussichten mit einer MK von nicht einmal 3,5 Mio EUR vor sich hin.
Seid mal ehrlich: Das kann doch wohl nicht Euer ernst sein?!
AUFWACHEN !!!
Hätte ich mehr Kohle, dann würde ich den Laden aufkaufen!!!
Alle (noch) Nichtinvestierten werden diesen Schnäppchenkursen wohl bald nachtrauern!
Alle, die detailliertere Infos zu NWBT haben, bitte ich, diese ins Board zu stellen, um die momentane Chance bei dieser unterbewerteten Perle deutlich zu machen.
Danke!
Prof.Hastig
Da hat eine Biotech-Aktie das große Glück, eine äußerst positive Meldung veröffentlichen zu können, und nach einer kleinen Anfangseuphorie fällt der Kurs wieder auf Insolvenzniveau!
Jede insolvente Pommesbude wird aufgrund von Mantel-SPEKULATIONEN(!) auf eine zweistellige MK hochgepusht, und NWBT dümpelt trotz positiven Zukunftsaussichten mit einer MK von nicht einmal 3,5 Mio EUR vor sich hin.
Seid mal ehrlich: Das kann doch wohl nicht Euer ernst sein?!
AUFWACHEN !!!
Hätte ich mehr Kohle, dann würde ich den Laden aufkaufen!!!
Alle (noch) Nichtinvestierten werden diesen Schnäppchenkursen wohl bald nachtrauern!
Alle, die detailliertere Infos zu NWBT haben, bitte ich, diese ins Board zu stellen, um die momentane Chance bei dieser unterbewerteten Perle deutlich zu machen.
Danke!
Prof.Hastig
Na ja NWBT hat ja in den zwei Tagen vorher schon 100% zugelegt
Unter 0,20Dollar wird es heute wohl noch gehen.
Unter 0,20Dollar wird es heute wohl noch gehen.
Wow!!!
Wer hat sich denn heute gleich 35.850 Stück zu 0,22 EUR gegönnt? -Glückwunsch!!!
Bei dieser Investitionshöhe wird derjenige wohl mehr wissen als wir "Ottonormalverbraucher"...
Ich hoffe, dass andere jetzt auch aufwachen und auf den rollenden Zug aufspringen!
Mit jeder neuen Meldung wird das noch verborgene Potential dieser massiv unterbewerteten Biotech-Aktie weiter offengelegt, bis jeder Laie erkennt, dass die heutigen Befürworter dieser Perle damals doch ein bißchen recht hatten...
Nur, dass dann ein ganz anderer Preis für diesen Diamanten zu zahlen sein wird...
Wee will see!
Prof.Hastig
Wer hat sich denn heute gleich 35.850 Stück zu 0,22 EUR gegönnt? -Glückwunsch!!!
Bei dieser Investitionshöhe wird derjenige wohl mehr wissen als wir "Ottonormalverbraucher"...
Ich hoffe, dass andere jetzt auch aufwachen und auf den rollenden Zug aufspringen!
Mit jeder neuen Meldung wird das noch verborgene Potential dieser massiv unterbewerteten Biotech-Aktie weiter offengelegt, bis jeder Laie erkennt, dass die heutigen Befürworter dieser Perle damals doch ein bißchen recht hatten...
Nur, dass dann ein ganz anderer Preis für diesen Diamanten zu zahlen sein wird...
Wee will see!
Prof.Hastig
Times & Sales
Uhrzeit Kurs Volumen
letztes kumuliert
10:01:48 0,22 5.000 48.682
10:01:14 0,55 33.682 43.682
09:13:38 0,229 10.000 10.000
09:02:24 0,215 0 0
Quelle: Onvista
Sehen meine müden Augen falsch oder hat unsere Rakete (jedenfalls zwischenzeitlich...) fett gezündet!!!
Wer 33.682 Stück zu 0,55 EUR kauft, muss mehr wissen!!! Ich denke, dass durch die hohe Stückzahl nicht genügend Investierte ihre Stücke zu diesen Schnäppchenkursen verschenken wollten!
Ich denke, die bevorstehende Hammermeldung wird den Kurs noch über diese Regionen um 0,55 EUR explodieren lassen!
Glückwunsch an alle, die investiert sind und sich entspannt zurücklehnen können...
Der Run auf unsere Perle wurde von diversen Insidern bereits eingeläutet. Alle anderen, die NWBT noch auf ihrer Watchlist haben, sollten langsam aufwachen oder sich langsam mit der Enttäuschung über eine verpasste Chance vertraut machen!!!
Aber wie gesagt: Jeder ist seines eigenen Glückes Schmied!!!
Wee will see!
Prof.Hastig
Uhrzeit Kurs Volumen
letztes kumuliert
10:01:48 0,22 5.000 48.682
10:01:14 0,55 33.682 43.682
09:13:38 0,229 10.000 10.000
09:02:24 0,215 0 0
Quelle: Onvista
Sehen meine müden Augen falsch oder hat unsere Rakete (jedenfalls zwischenzeitlich...) fett gezündet!!!
Wer 33.682 Stück zu 0,55 EUR kauft, muss mehr wissen!!! Ich denke, dass durch die hohe Stückzahl nicht genügend Investierte ihre Stücke zu diesen Schnäppchenkursen verschenken wollten!
Ich denke, die bevorstehende Hammermeldung wird den Kurs noch über diese Regionen um 0,55 EUR explodieren lassen!
Glückwunsch an alle, die investiert sind und sich entspannt zurücklehnen können...
Der Run auf unsere Perle wurde von diversen Insidern bereits eingeläutet. Alle anderen, die NWBT noch auf ihrer Watchlist haben, sollten langsam aufwachen oder sich langsam mit der Enttäuschung über eine verpasste Chance vertraut machen!!!
Aber wie gesagt: Jeder ist seines eigenen Glückes Schmied!!!
Wee will see!
Prof.Hastig
Das war ein Fehltrade und wurde anulliert
Dazu noch folgende Meldung von gestern:
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
--------------------------------------------------------------------------------
31-Mar-2005
Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure.
The Registrant announced today that it has filed Form 12b-25 with the Securities and Exchange Commission in order to extend the filing date for its Form 10-K for the year ended December 31, 2004 to allow the registrant`s independent auditor, Peterson Sullivan PLLC, additional time to complete the audit of the registrant`s financial statements. On January 31, 2005 the company filed Form 8-K stating that KPMG LLP had resigned as the company`s independent auditors.
The delay of filing the Annual Report on Form 10-K is not the result of the need to restate any prior period financial results. By extending the filing, the Registrant expects to file its Annual Report on Form 10-K no later than April 15, 2005
Dazu noch folgende Meldung von gestern:
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
--------------------------------------------------------------------------------
31-Mar-2005
Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure.
The Registrant announced today that it has filed Form 12b-25 with the Securities and Exchange Commission in order to extend the filing date for its Form 10-K for the year ended December 31, 2004 to allow the registrant`s independent auditor, Peterson Sullivan PLLC, additional time to complete the audit of the registrant`s financial statements. On January 31, 2005 the company filed Form 8-K stating that KPMG LLP had resigned as the company`s independent auditors.
The delay of filing the Annual Report on Form 10-K is not the result of the need to restate any prior period financial results. By extending the filing, the Registrant expects to file its Annual Report on Form 10-K no later than April 15, 2005
Das Filling sollte eigentlich keine negative Auswirkung auf den Kurs haben,
:
:
Guten Morgen!
Es ist echt deprimierend , dass sich anscheinend niemand mehr mit NWBT auseinandersetzt und dass der Kurs so lustlos vor sich hindümpelt...
Bin ich denn wirklich zu optimistisch, oder warum springt die Aktie trotz positiver Meldungen nicht nachhaltig an? Sind die Meldungen denn gar nichts wert?
Würde mich echt über mehr Beteiligung in diesem Thread freuen. Jegliche Kritik (negativ wie positiv) wird gern zur Kenntnis genommen...
Prof.Hastig
Es ist echt deprimierend , dass sich anscheinend niemand mehr mit NWBT auseinandersetzt und dass der Kurs so lustlos vor sich hindümpelt...
Bin ich denn wirklich zu optimistisch, oder warum springt die Aktie trotz positiver Meldungen nicht nachhaltig an? Sind die Meldungen denn gar nichts wert?
Würde mich echt über mehr Beteiligung in diesem Thread freuen. Jegliche Kritik (negativ wie positiv) wird gern zur Kenntnis genommen...
Prof.Hastig
@professorhastig
habe mich vor ein paar Tagen mal mit deinem Tip beschäftigt, sozusagen mehr so im Stillen...
Um eine breitere Allgemeinheit wirksam anzuprechen hättest du evtl. was von 100.000% in die Überschrift einfügen müssen, da stehen scheinbar echt viele drauf...
Aber jetzt mal ganz im Ernst, ich habe mir eine kleine Position gesichert, sozusagen für die "lange Bank".
Bei Gelegenheit stelle ich dir mal noch ein paar Infos rein.
Gruß Bio
habe mich vor ein paar Tagen mal mit deinem Tip beschäftigt, sozusagen mehr so im Stillen...
Um eine breitere Allgemeinheit wirksam anzuprechen hättest du evtl. was von 100.000% in die Überschrift einfügen müssen, da stehen scheinbar echt viele drauf...
Aber jetzt mal ganz im Ernst, ich habe mir eine kleine Position gesichert, sozusagen für die "lange Bank".
Bei Gelegenheit stelle ich dir mal noch ein paar Infos rein.
Gruß Bio
@professorhastig
...muß mich bei dieser Gelegenheit korrigieren, da du ja nicht Urheber dieses Threads bist und somit auch keinen Einfluß auf die Ausgestaltung der Überschrift hattest.
...muß mich bei dieser Gelegenheit korrigieren, da du ja nicht Urheber dieses Threads bist und somit auch keinen Einfluß auf die Ausgestaltung der Überschrift hattest.
was ist das für eine Markierung x in den 3, 6, 12-Monatscharts?
War da Feiertag oder habe ich was versäumt?
War da Feiertag oder habe ich was versäumt?
...neue Art von UFOs, sind jetzt nämlich verschwunden...
irgendwie kommt da ja langsam richtig Bewegung beim Volumen rein.
Für alle, die sich mal so richtig durch die Zahlen durchwühlen wollen stelle ich mal die "10k" rein.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…
Bin auch dabei, ich glaube man braucht Geduld, bei der nächsten Meldung wird die Post abgehen!
Wenn es so weitergeht, sehen wir die 0,01 EUR auch noch...
Wenn jemand Interesse an NWBT hat und für interessante Informationen etwas investieren möchte:
http://reports.finance.yahoo.com/w0?r=29046388:1
Da gibt es alles Aktuelle rund um die Aktie per 21.04.2005.
Vielleicht lohnt es sich ja...
We will see!
Prof.Hastig
http://reports.finance.yahoo.com/w0?r=29046388:1
Da gibt es alles Aktuelle rund um die Aktie per 21.04.2005.
Vielleicht lohnt es sich ja...
We will see!
Prof.Hastig
[posting]16.434.677 von ProfessorHastig am 22.04.05 12:33:38[/posting]Für 0 Dokumente auch noch $50 bezahlen ???
War wohl ein Witz...
War wohl ein Witz...
Ich habe einige davon, irgendwann müssten doch Neuigkeiten
kommen, die sind dann sicher nicht schlecht, oder?
kommen, die sind dann sicher nicht schlecht, oder?
Hat vielleicht jemand Neuigkeiten?
... und warum dieses:
NWBT USD 0,180 0,230 + 0,050 + 27,78 % 5.720 27.000
09. Mai 15:32
mfg
kurttilly
NWBT USD 0,180 0,230 + 0,050 + 27,78 % 5.720 27.000
09. Mai 15:32
mfg
kurttilly
In den USA schon wieder 25 % im Plus!!!
Wann geht es bei uns nach oben?
Wann geht es bei uns nach oben?
hier überhaupt nicht,
weil alle die 100 st. haben,
aus lauter angst nchts machen.
siehe mal umsätze bei uns und amiland.
weil alle die 100 st. haben,
aus lauter angst nchts machen.
siehe mal umsätze bei uns und amiland.
Hallo NW-Bio-Fans!
Kein Interesse mehr an "Bord" ????
Northwest Bio + 16%
mfg
kurttilly
Kein Interesse mehr an "Bord" ????
Northwest Bio + 16%
mfg
kurttilly
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
--------------------------------------------------------------------------------
18-May-2005
Entry Material Agreement, Financial Obligation Matter, Financial St
ITEM 1.01 Entry Into a Material Definitive Agreement.
Northwest Biotherapeutics, Inc. (the "Company") announced today that, on May 13, 2005, it received a $450,000 loan from Toucan Capital Fund II, L.P. ("Toucan"). The loan accrues interest at 10% per year, matures on May 13, 2006, and the principal and interest is convertible into capital stock of the Company, generally at Toucan`s option, prior to repayment.
The principal and interest on the loan is currently convertible at $0.04 per share (subject to adjustment). In connection with this new loan, the Company has issued a warrant to Toucan, which is exercisable for up to 4.5 million shares of the Company`s capital stock. The exercise price of the warrant is $0.04 per share subject to certain adjustments. The Company believes that the additional $450,000 received from Toucan on May 13, 2005 will be sufficient to cover short-term payables to approximately June 15, 2005, exclusive of the aggregate loan repayments due Toucan. In addition, the Company has a $500,000 note (plus accrued interest) from Toucan maturing on June 11, 2005 and additional notes from Toucan in the aggregate principal amount of $600,000 (plus accrued interest) maturing on June 26, 2005. The Company is in discussions withToucan to negotiate a potential extension of these obligations, but may not be able to do so. If the Company fails to negotiate an extension or make other arrangements to refinance these obligations, the Company will need additional financing on or before June 11, 2005 in order to satisfy these obligations. There can be no assurance that such additional financing would be available on acceptable terms, or at all.
To date, the Company has issued ten promissory notes to Toucan pursuant to which Toucan has loaned the Company an aggregate of $5.25 million. In connection with the issuance of promissory notes to Toucan, the Company has issued and Toucan has received warrants that are currently exercisable for an aggregate of up to 107.5 million shares of the Company`s capital stock.
In connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Recapitalization Agreement (the "Recapitalization Agreement"), dated as of July 30, 2004, amended on October 22, 2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005 and on May 13, 2005 between the parties ("Amendment No. 6"). Amendment No. 6 updated certain representations and warranties of the parties made in the Recapitalization Agreement and made certain technical changes in the Recapitalization Agreement in order to facilitate the May 13, 2005 bridge loan described herein.
Also in connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Binding Term Sheet dated April 26, 2004, and amended and restated on October 22, 2004 as further amended on December 27, 2004, January 26, 2005, April 12, 2005 and May 13, 2005 between the parties (the "Term Sheet"). The Term Sheet, as amended, reduced warrant coverage in the potential private placement by $450,000.
The Recapitalization Agreement calls for a two-stage recapitalization of the Company consisting of a bridge period and an equity financing period. The equity financing period commenced on January 26, 2005 when Toucan purchased 32,500,000 shares of the Company`s Series A Cumulative Convertible Preferred Stock at a purchase price of $0.04 per share (for aggregate purchase price of $1,300,000). The equity financing period will last up to 12 months. During the equity financing period, the Company intends to sell up to $40 million of convertible preferred stock in accordance with the terms of the Recapitalization Agreement. Any additional financing is contingent upon the Company complying with covenants in the Recapitalization Agreement, as amended, and locating additional investors who are willing to invest in the Company on the terms proposed.
The foregoing description of Amendment No. 6, the note, the warrant and the Term Sheet, all of which are filed as exhibits to the Form 8-K, are qualified in their entirety by reference to the full text of the agreements.
--------------------------------------------------------------------------------
Table of Contents
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement.
The information contained under Item 1.01 of this report is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
10.1 Amendment No. 6 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P.,
dated May 13, 2005.
10.2 Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory
Note in the principal amount of $450,000 between Northwest Biotherapeutics,
Inc. and Toucan Capital Fund II, L.P. dated May 13, 2005.
10.3 Warrant to purchase securities of the Company dated May 13, 2005 issued to
Toucan Capital Fund II, L.P.
10.4 Amendment to Amended and Restated Binding Term Sheet dated May 13, 2005.
--------------------------------------------------------------------------------
18-May-2005
Entry Material Agreement, Financial Obligation Matter, Financial St
ITEM 1.01 Entry Into a Material Definitive Agreement.
Northwest Biotherapeutics, Inc. (the "Company") announced today that, on May 13, 2005, it received a $450,000 loan from Toucan Capital Fund II, L.P. ("Toucan"). The loan accrues interest at 10% per year, matures on May 13, 2006, and the principal and interest is convertible into capital stock of the Company, generally at Toucan`s option, prior to repayment.
The principal and interest on the loan is currently convertible at $0.04 per share (subject to adjustment). In connection with this new loan, the Company has issued a warrant to Toucan, which is exercisable for up to 4.5 million shares of the Company`s capital stock. The exercise price of the warrant is $0.04 per share subject to certain adjustments. The Company believes that the additional $450,000 received from Toucan on May 13, 2005 will be sufficient to cover short-term payables to approximately June 15, 2005, exclusive of the aggregate loan repayments due Toucan. In addition, the Company has a $500,000 note (plus accrued interest) from Toucan maturing on June 11, 2005 and additional notes from Toucan in the aggregate principal amount of $600,000 (plus accrued interest) maturing on June 26, 2005. The Company is in discussions withToucan to negotiate a potential extension of these obligations, but may not be able to do so. If the Company fails to negotiate an extension or make other arrangements to refinance these obligations, the Company will need additional financing on or before June 11, 2005 in order to satisfy these obligations. There can be no assurance that such additional financing would be available on acceptable terms, or at all.
To date, the Company has issued ten promissory notes to Toucan pursuant to which Toucan has loaned the Company an aggregate of $5.25 million. In connection with the issuance of promissory notes to Toucan, the Company has issued and Toucan has received warrants that are currently exercisable for an aggregate of up to 107.5 million shares of the Company`s capital stock.
In connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Recapitalization Agreement (the "Recapitalization Agreement"), dated as of July 30, 2004, amended on October 22, 2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005 and on May 13, 2005 between the parties ("Amendment No. 6"). Amendment No. 6 updated certain representations and warranties of the parties made in the Recapitalization Agreement and made certain technical changes in the Recapitalization Agreement in order to facilitate the May 13, 2005 bridge loan described herein.
Also in connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Binding Term Sheet dated April 26, 2004, and amended and restated on October 22, 2004 as further amended on December 27, 2004, January 26, 2005, April 12, 2005 and May 13, 2005 between the parties (the "Term Sheet"). The Term Sheet, as amended, reduced warrant coverage in the potential private placement by $450,000.
The Recapitalization Agreement calls for a two-stage recapitalization of the Company consisting of a bridge period and an equity financing period. The equity financing period commenced on January 26, 2005 when Toucan purchased 32,500,000 shares of the Company`s Series A Cumulative Convertible Preferred Stock at a purchase price of $0.04 per share (for aggregate purchase price of $1,300,000). The equity financing period will last up to 12 months. During the equity financing period, the Company intends to sell up to $40 million of convertible preferred stock in accordance with the terms of the Recapitalization Agreement. Any additional financing is contingent upon the Company complying with covenants in the Recapitalization Agreement, as amended, and locating additional investors who are willing to invest in the Company on the terms proposed.
The foregoing description of Amendment No. 6, the note, the warrant and the Term Sheet, all of which are filed as exhibits to the Form 8-K, are qualified in their entirety by reference to the full text of the agreements.
--------------------------------------------------------------------------------
Table of Contents
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement.
The information contained under Item 1.01 of this report is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
10.1 Amendment No. 6 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P.,
dated May 13, 2005.
10.2 Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory
Note in the principal amount of $450,000 between Northwest Biotherapeutics,
Inc. and Toucan Capital Fund II, L.P. dated May 13, 2005.
10.3 Warrant to purchase securities of the Company dated May 13, 2005 issued to
Toucan Capital Fund II, L.P.
10.4 Amendment to Amended and Restated Binding Term Sheet dated May 13, 2005.
...nach wie vor noch dabei.
Gruß, bio
Gruß, bio
...ebenso nach wie vor dabei!!!
Hab zudem seit Tagen eine limitierte Kauforder über 20k im Markt, die bisher leider noch nicht ausgeführt wurde...
NWBT wird uns noch alle reich machen...
We will see!
Prof.Hastig
Hab zudem seit Tagen eine limitierte Kauforder über 20k im Markt, die bisher leider noch nicht ausgeführt wurde...
NWBT wird uns noch alle reich machen...
We will see!
Prof.Hastig
Bin auch noch dabei und warte auf Neuigkeiten!
Es kann eigentlich nur Gutes kommen!!
Es kann eigentlich nur Gutes kommen!!
Hier tut sich ja garnichts, wann ist mit Neuigkeiten zu rechnen, ich bin noch dabei!!
Ich glaube ich besitze als einzigster noch diese Aktien, oder?
Nein, es gibt auch noch andere Leidgenossen, die auf möglichst positive Meldungen warten ......
mfg
kurttilly
mfg
kurttilly
Mist!!!
Hatte den ganzen Monat Mai eine limitierte Kauforder über 20k im Markt, die per Ultimo Mai jetzt ausgelaufen ist.
Obwohl der Kurs sogar zeitweise bis 0,12 EUR gesunken war, konnte meine Order mit Limit 0,125 EUR in Frankfurt anscheinend an keinem Tag im Mai bedient werden.
Aktueller Kurs im Amiland: 0,20 US$ (+5,82%; Volumen 57k).
Bei einem aktuellen Umrechnungskurs von 1 EUR ~ 1,25 US$ wäre der faire Kurs in Deutschland bei 0,16 EUR, hätte also noch Nachholpotential...
Hoffe, dass von NWBT im Juni wieder mal ne positive Meldung veröffentlicht werden kann, damit ne neue Rally beginnen kann!!!
We will see!
Prof.Hastig
Hatte den ganzen Monat Mai eine limitierte Kauforder über 20k im Markt, die per Ultimo Mai jetzt ausgelaufen ist.
Obwohl der Kurs sogar zeitweise bis 0,12 EUR gesunken war, konnte meine Order mit Limit 0,125 EUR in Frankfurt anscheinend an keinem Tag im Mai bedient werden.
Aktueller Kurs im Amiland: 0,20 US$ (+5,82%; Volumen 57k).
Bei einem aktuellen Umrechnungskurs von 1 EUR ~ 1,25 US$ wäre der faire Kurs in Deutschland bei 0,16 EUR, hätte also noch Nachholpotential...
Hoffe, dass von NWBT im Juni wieder mal ne positive Meldung veröffentlicht werden kann, damit ne neue Rally beginnen kann!!!
We will see!
Prof.Hastig
Press Release Source: Northwest Biotherapeutics, Inc.
Brain Cancer Treatment to Undergo Broader Testing Based on Encouraging Phase I Clinical Trials
Wednesday June 1, 7:00 am ET
DCVax(R)-Brain Shows Substantial Delay in Disease Progression and Improvement in Patient Survival in Two Phase I Clinical Trials; FDA Clears Northwest Biotherapeutics` DCVax(R)-Brain for large Phase II Clinical Trial
BOTHELL, Wash., June 1 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has received clearance from the Food and Drug Administration (FDA) to begin assessment of its dendritic cell-based product candidate, DCVax®-Brain, in a large Phase II clinical trial with approximately 150 patients at 12-15 sites throughout the United States. DCVax®-Brain is a personalized vaccine that is made from a patient`s own cells and mobilizes the patient`s immune system to attack his or her brain cancer.
ADVERTISEMENT
The upcoming Phase II trial is based upon promising clinical data from two Phase I clinical trials carried out at UCLA by Linda Liau, M.D., Ph.D., in patients with Glioblastoma multiforme (GBM), the most lethal form of brain cancer. In these two Phase I trials, a total of 25 patients were treated with DCVax® -Brain. Seventeen of these were newly diagnosed GBM patients, and eight were recurrent GBM patients. DCVax-Brain® delivered substantial delays in the time to disease progression and substantial extension of survival times in both groups of patients, compared with the standard of care treatment for such patients. The improvements in time to progression and survival time were significant for both groups of patients, but were larger for newly diagnosed patients than for patients with later stage recurrent disease. In each of the two Phase I trials, the patients received only an initial series of three DCVax®-Brain injections over six weeks, with no booster shots.
With existing standard of care treatment, newly diagnosed GBM patients historically have a median time to disease progression of 8 months and median survival of only 15 months. With DCVax®-Brain, the newly diagnosed patients in the two Phase I trials have a median time to progression of 15 months and median survival time in excess of 26 months. No material toxicity was seen in any of the patients.
Recurrent GBM patients have an even bleaker prognosis with existing standard of care treatment. Historically, their median time to disease progression is only 5 months, and median survival is only 10 months. With DCVax®-Brain, the recurrent GBM patients in the Phase I trial show a median time to disease progression of 13 months, and median survival time of 16 months. No material toxicity was seen.
Dr. Liau stated, "Based upon data seen in two Phase I studies, DCVax® Brain allowed patients not only to live longer but to enjoy more time before disease progression. Glioblastoma multiforme is an aggressive and lethal form of brain cancer. Currently, physicians have little to offer patients with this difficult diagnosis. Broader Phase II clinical studies of DCVax®-Brain will allow us to build upon the promising data seen in our two Phase I studies, and may one day represent a better therapeutic alternative for patients with this deadly tumor type."
Northwest Biotherapeutics` upcoming Phase II trial will focus on newly diagnosed GBM patients, administering DCVax®-Brain early in the course of the disease for maximum impact. In addition, the Phase II trial will include an ongoing regime of booster shots in addition to the initial series of injections.
"FDA clearance of this Phase II trial for brain cancer represents the second major clinical milestone achievement this year for Northwest Biotherapeutics, following FDA clearance in January of a large Phase III trial for prostate cancer," stated Alton L. Boynton, Ph.D., President and Chief Operating Officer. "We are excited about the data to date, showing substantially greater delays in disease progression and improvements in patient survival than any existing treatments have been able to deliver for patients. We are also pleased to see the lack of any material toxicity in patients receiving our DCVax® products."
DCVax® treatments use the patient`s own dendritic cells, which are obtained through a simple blood draw. The dendritic cells are then processed, and "taught" to mobilize the patient`s immune system to kill tumors, and are then placed back into the patient`s body through a simple injection under the skin.
Northwest Biotherapeutics also has DCVax® products for other cancers in clinical trials and in pre-clinical development. In January of this year, Northwest Biotherapeutics received FDA clearance to commence a 612 patient Phase III clinical trial for DCVax®-Prostate, a promising treatment for prostate cancer patients whose disease is no longer being kept in check through hormone therapy, but who have not yet developed metastases. Most prostate cancer patients pass through this stage in the course of the disease, and there is currently no effective therapy for these patients. The Company`s Phase III trial will be conducted at 40-50 sites throughout the United States, starting later this year.
About Glioblastoma multiforme
Brain cancer is diagnosed in approximately 200,000 patients per year, of which approximately 40,000 or more are primary brain tumors that do not arise from metastasis of other kinds of cancers, such as breast, lung, or colorectal. Glioblastoma multiforme is the most aggressive and lethal form of primary brain cancer. In addition to their morbidity and mortality in adults, brain tumors are the leading cause of death from solid tumor cancers in those under the age of 20.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer without significant toxicity. The company has two lead product candidates:
DCVax®-Prostate is entering a Phase III clinical trial for treatment of non-metastatic hormone independent prostate cancer;
DCVax®-Brain is entering a Phase II clinical trial for newly diagnosed Glioblastoma multiforme.
The company has three technologies that form the basis of its product candidates: a dendritic cell-based immunotherapy platform applicable to multiple cancers; a therapeutic monoclonal antibody technology applicable to multiple cancer types; and a monoclonal antibody-based imaging approach for diagnosis of metastatic prostate cancer.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
--------------------------------------------------------------------------------
Source: Northwest Biotherapeutics, Inc.
Brain Cancer Treatment to Undergo Broader Testing Based on Encouraging Phase I Clinical Trials
Wednesday June 1, 7:00 am ET
DCVax(R)-Brain Shows Substantial Delay in Disease Progression and Improvement in Patient Survival in Two Phase I Clinical Trials; FDA Clears Northwest Biotherapeutics` DCVax(R)-Brain for large Phase II Clinical Trial
BOTHELL, Wash., June 1 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has received clearance from the Food and Drug Administration (FDA) to begin assessment of its dendritic cell-based product candidate, DCVax®-Brain, in a large Phase II clinical trial with approximately 150 patients at 12-15 sites throughout the United States. DCVax®-Brain is a personalized vaccine that is made from a patient`s own cells and mobilizes the patient`s immune system to attack his or her brain cancer.
ADVERTISEMENT
The upcoming Phase II trial is based upon promising clinical data from two Phase I clinical trials carried out at UCLA by Linda Liau, M.D., Ph.D., in patients with Glioblastoma multiforme (GBM), the most lethal form of brain cancer. In these two Phase I trials, a total of 25 patients were treated with DCVax® -Brain. Seventeen of these were newly diagnosed GBM patients, and eight were recurrent GBM patients. DCVax-Brain® delivered substantial delays in the time to disease progression and substantial extension of survival times in both groups of patients, compared with the standard of care treatment for such patients. The improvements in time to progression and survival time were significant for both groups of patients, but were larger for newly diagnosed patients than for patients with later stage recurrent disease. In each of the two Phase I trials, the patients received only an initial series of three DCVax®-Brain injections over six weeks, with no booster shots.
With existing standard of care treatment, newly diagnosed GBM patients historically have a median time to disease progression of 8 months and median survival of only 15 months. With DCVax®-Brain, the newly diagnosed patients in the two Phase I trials have a median time to progression of 15 months and median survival time in excess of 26 months. No material toxicity was seen in any of the patients.
Recurrent GBM patients have an even bleaker prognosis with existing standard of care treatment. Historically, their median time to disease progression is only 5 months, and median survival is only 10 months. With DCVax®-Brain, the recurrent GBM patients in the Phase I trial show a median time to disease progression of 13 months, and median survival time of 16 months. No material toxicity was seen.
Dr. Liau stated, "Based upon data seen in two Phase I studies, DCVax® Brain allowed patients not only to live longer but to enjoy more time before disease progression. Glioblastoma multiforme is an aggressive and lethal form of brain cancer. Currently, physicians have little to offer patients with this difficult diagnosis. Broader Phase II clinical studies of DCVax®-Brain will allow us to build upon the promising data seen in our two Phase I studies, and may one day represent a better therapeutic alternative for patients with this deadly tumor type."
Northwest Biotherapeutics` upcoming Phase II trial will focus on newly diagnosed GBM patients, administering DCVax®-Brain early in the course of the disease for maximum impact. In addition, the Phase II trial will include an ongoing regime of booster shots in addition to the initial series of injections.
"FDA clearance of this Phase II trial for brain cancer represents the second major clinical milestone achievement this year for Northwest Biotherapeutics, following FDA clearance in January of a large Phase III trial for prostate cancer," stated Alton L. Boynton, Ph.D., President and Chief Operating Officer. "We are excited about the data to date, showing substantially greater delays in disease progression and improvements in patient survival than any existing treatments have been able to deliver for patients. We are also pleased to see the lack of any material toxicity in patients receiving our DCVax® products."
DCVax® treatments use the patient`s own dendritic cells, which are obtained through a simple blood draw. The dendritic cells are then processed, and "taught" to mobilize the patient`s immune system to kill tumors, and are then placed back into the patient`s body through a simple injection under the skin.
Northwest Biotherapeutics also has DCVax® products for other cancers in clinical trials and in pre-clinical development. In January of this year, Northwest Biotherapeutics received FDA clearance to commence a 612 patient Phase III clinical trial for DCVax®-Prostate, a promising treatment for prostate cancer patients whose disease is no longer being kept in check through hormone therapy, but who have not yet developed metastases. Most prostate cancer patients pass through this stage in the course of the disease, and there is currently no effective therapy for these patients. The Company`s Phase III trial will be conducted at 40-50 sites throughout the United States, starting later this year.
About Glioblastoma multiforme
Brain cancer is diagnosed in approximately 200,000 patients per year, of which approximately 40,000 or more are primary brain tumors that do not arise from metastasis of other kinds of cancers, such as breast, lung, or colorectal. Glioblastoma multiforme is the most aggressive and lethal form of primary brain cancer. In addition to their morbidity and mortality in adults, brain tumors are the leading cause of death from solid tumor cancers in those under the age of 20.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer without significant toxicity. The company has two lead product candidates:
DCVax®-Prostate is entering a Phase III clinical trial for treatment of non-metastatic hormone independent prostate cancer;
DCVax®-Brain is entering a Phase II clinical trial for newly diagnosed Glioblastoma multiforme.
The company has three technologies that form the basis of its product candidates: a dendritic cell-based immunotherapy platform applicable to multiple cancers; a therapeutic monoclonal antibody technology applicable to multiple cancer types; and a monoclonal antibody-based imaging approach for diagnosis of metastatic prostate cancer.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
--------------------------------------------------------------------------------
Source: Northwest Biotherapeutics, Inc.
Könnte jemand die Meldung bitte in der deutschen Version ins Board setzen?
In den USA hat die Meldung schon eingeschlagen:
Volumen: 376,3k (!!!!!!)
Last Price: 0,23 US$ (= +15%!!!) (~ 0,185 EUR!!!)
Tageshoch: 0,25 US$ !!!
Könnte heute in Deutschland ein nettes Kursfeuerwerk geben!!! Genug Nachholpotential ist ja vorhanden...
Und ich armer Tor habe meine 20k zu 0,125 EUR im Mai nicht bekommen
We will see!
Prof.Hastig
In den USA hat die Meldung schon eingeschlagen:
Volumen: 376,3k (!!!!!!)
Last Price: 0,23 US$ (= +15%!!!) (~ 0,185 EUR!!!)
Tageshoch: 0,25 US$ !!!
Könnte heute in Deutschland ein nettes Kursfeuerwerk geben!!! Genug Nachholpotential ist ja vorhanden...
Und ich armer Tor habe meine 20k zu 0,125 EUR im Mai nicht bekommen
We will see!
Prof.Hastig
Bin Deiner Meinung kann nur nach oben gehen, es werden weitere erfreuliche Meldungen kommen!!
Yeahhhh!!!!
In den USA wurde innerhalb der 1. Stunde nach Börseneröffnung bereits 112,5k (!!!) gehandelt!!!
Letzter Kurs: 0,249 US$ (~ 20,5 EUR)
Tageshoch: 0,255 US$
In Deutschland pirschen wir uns gerade an die 0,20 EUR-Marke heran! Vielleicht geht es bald auf zu neuen Höhen...
I hope so!
Prof.Hastig
In den USA wurde innerhalb der 1. Stunde nach Börseneröffnung bereits 112,5k (!!!) gehandelt!!!
Letzter Kurs: 0,249 US$ (~ 20,5 EUR)
Tageshoch: 0,255 US$
In Deutschland pirschen wir uns gerade an die 0,20 EUR-Marke heran! Vielleicht geht es bald auf zu neuen Höhen...
I hope so!
Prof.Hastig
Hallo, hier tut sich garnichts mehr, halten oder verkaufen, wer hat eine Meinung bzw. Neuigkeit?
Gibt es irgendwann einmal eine neue Nachricht?
@fussballtrainer
Im Moment ist die Nachrichtenlage fürwahr etwas (be)dürftig, hat aber zumindest den Vorteil, dass keine "badnews" dabei sind.
Ist natürlich immer so eine äußerst nervige Angelegenheit, wenn man über einen längeren Zeitraum von einem solch kleinen Unternehmen nichts hört.
Für den "Sommer" sind ja lt. nachfolgender Ankündigung noch mit Ergebnisbekanntgaben zu rechnen, bei positiven News geht´s dann mal wieder richtig ab.
Our lead product candidates are immunotherapy treatments that safely generate and enhance immune system responses to effectively treat multiple types of cancer.
DCVax®-Brain: We anticipate enrolling patients with newly diagnosed Glioblastoma multiforme in the summer of 2005 in a 143 patient, FDA cleared Phase II clinical trial in 12-15 clinical centers in the United States.
DCVax®-Prostate: We anticipate enrolling patients with non-metastatic, hormone independent prostate cancer in Q4 of 2005 in a 612 patient, FDA cleared Phase III clinical trial in 40 to 50 clinical centers in the United States.
Im Moment ist die Nachrichtenlage fürwahr etwas (be)dürftig, hat aber zumindest den Vorteil, dass keine "badnews" dabei sind.
Ist natürlich immer so eine äußerst nervige Angelegenheit, wenn man über einen längeren Zeitraum von einem solch kleinen Unternehmen nichts hört.
Für den "Sommer" sind ja lt. nachfolgender Ankündigung noch mit Ergebnisbekanntgaben zu rechnen, bei positiven News geht´s dann mal wieder richtig ab.
Our lead product candidates are immunotherapy treatments that safely generate and enhance immune system responses to effectively treat multiple types of cancer.
DCVax®-Brain: We anticipate enrolling patients with newly diagnosed Glioblastoma multiforme in the summer of 2005 in a 143 patient, FDA cleared Phase II clinical trial in 12-15 clinical centers in the United States.
DCVax®-Prostate: We anticipate enrolling patients with non-metastatic, hormone independent prostate cancer in Q4 of 2005 in a 612 patient, FDA cleared Phase III clinical trial in 40 to 50 clinical centers in the United States.
.....
und schon die ersten Käufe in Berlin !
0,16 €c
gruß kurttilly
und schon die ersten Käufe in Berlin !
0,16 €c
gruß kurttilly
vielleicht haben da nur die meisten Angst vor der eigenen Courage bekommen.
Mitte März, spätestens jedoch Anfang Juni waren wohl die meisten "Zugestiegenen" der Ansicht dass es hier schnell und heftig nach oben gehen wird, allein schon charttechnisch bedingt.
Die etwas größeren Umsätze in dieser Zeit dürften vor allem Trader gewesen sein, die das typische "Ex-Neue-Markt-Werte-Zocker-Signal" zu erkennen geglaubt hatten. Die Amis sehen das jedoch halt etwas anders..
Mehr Nachhaltigkeit bei den Kursveränderungen traue ich NWBT aber vor allem auf Basis guter Forschungsergebnisse zu. Treffen diese ein gibt es ein schönes Spektakel bei der Performance, im negativen Fall wird das Unternehmen in die Belanglosigkeit starten.
Mitte März, spätestens jedoch Anfang Juni waren wohl die meisten "Zugestiegenen" der Ansicht dass es hier schnell und heftig nach oben gehen wird, allein schon charttechnisch bedingt.
Die etwas größeren Umsätze in dieser Zeit dürften vor allem Trader gewesen sein, die das typische "Ex-Neue-Markt-Werte-Zocker-Signal" zu erkennen geglaubt hatten. Die Amis sehen das jedoch halt etwas anders..
Mehr Nachhaltigkeit bei den Kursveränderungen traue ich NWBT aber vor allem auf Basis guter Forschungsergebnisse zu. Treffen diese ein gibt es ein schönes Spektakel bei der Performance, im negativen Fall wird das Unternehmen in die Belanglosigkeit starten.
Hallo
Kann mir jemand sagen wann mit Kursgewinnen und in welcher Höhe zu rechnen ist?
Kann mir jemand sagen wann mit Kursgewinnen und in welcher Höhe zu rechnen ist?
Diese Frage habe ich auch schon gestellt aber ich glaube da kann oder will uns keiner Auskunft geben, warten, warten, warten!!!
Der weitere Verlauf hängt ganz von den Ergebnissen der laufenden Tests ab.
Brain Cancer Treatment to Undergo Broader Testing Based on Encouraging Phase I Clinical Trials
Wednesday June 1, 7:00 am ET
DCVax(R)-Brain Shows Substantial Delay in Disease Progression and Improvement in Patient Survival in Two Phase I Clinical Trials; FDA Clears Northwest Biotherapeutics` DCVax(R)-Brain for large Phase II Clinical Trial
BOTHELL, Wash., June 1 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has received clearance from the Food and Drug Administration (FDA) to begin assessment of its dendritic cell-based product candidate, DCVax®-Brain, in a large Phase II clinical trial with approximately 150 patients at 12-15 sites throughout the United States. DCVax®-Brain is a personalized vaccine that is made from a patient`s own cells and mobilizes the patient`s immune system to attack his or her brain cancer.
Zu den Terminen usw. solltet ihr euch an die Firma direkt wenden
Brain Cancer Treatment to Undergo Broader Testing Based on Encouraging Phase I Clinical Trials
Wednesday June 1, 7:00 am ET
DCVax(R)-Brain Shows Substantial Delay in Disease Progression and Improvement in Patient Survival in Two Phase I Clinical Trials; FDA Clears Northwest Biotherapeutics` DCVax(R)-Brain for large Phase II Clinical Trial
BOTHELL, Wash., June 1 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has received clearance from the Food and Drug Administration (FDA) to begin assessment of its dendritic cell-based product candidate, DCVax®-Brain, in a large Phase II clinical trial with approximately 150 patients at 12-15 sites throughout the United States. DCVax®-Brain is a personalized vaccine that is made from a patient`s own cells and mobilizes the patient`s immune system to attack his or her brain cancer.
Zu den Terminen usw. solltet ihr euch an die Firma direkt wenden
..wie auch immer, irgendjemand versucht sich zumindest schnell einzudecken....
Scheinbar kommen nächste Woche Neuigkeiten und der Kurs wird explodieren!
.....schaut euch mal das kursziel an:
http://stockcharts.com/def/servlet/SC.pnf?chart=nwbt,PLTADAN…
gruß kurttilly
http://stockcharts.com/def/servlet/SC.pnf?chart=nwbt,PLTADAN…
gruß kurttilly
Ich finde das Kursziel nicht, vielleicht kannst Du es einstellen, Danke!!
@Fußballtrainer
.... KZ 1,25
markiere einfach meinen Link, gehe auf kopieren und setze in oben in die Adresse www. .. ein.
gruß kurttilly
.... KZ 1,25
markiere einfach meinen Link, gehe auf kopieren und setze in oben in die Adresse www. .. ein.
gruß kurttilly
Hallo zusammen!
Es ist ziemlich ruhig geworden um NW Bio,
ist denn nun endlich ein Boden gefunden ???
Umsätze steigen langsam wieder ???
mfg kurttilly
Es ist ziemlich ruhig geworden um NW Bio,
ist denn nun endlich ein Boden gefunden ???
Umsätze steigen langsam wieder ???
mfg kurttilly
Gibt es in den USA etwa auch ein Sommerloch?
Geringer Umsatz keine Neuigkeiten!
Geringer Umsatz keine Neuigkeiten!
Press Release Source: Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics Announces Appointment of Paul Zeltzer, MD as Medical Director
Tuesday August 2, 7:30 am ET
Personalized Vaccine for Brain Cancer Entering Phase II Clinical Trials
BOTHELL, Wash., Aug. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced the appointment of Paul Zeltzer, MD, as Medical Director for the company. Dr. Zeltzer will provide medical expertise and direction for NWBT`s clinical trial programs, focusing initially on DCVax®-Brain, a personalized dendritic cell vaccine for Glioblastoma Multiforme (GBM), the most lethal form of brain cancer. The FDA-allowed Phase II clinical trial for DCVax®-Brain is set to commence this fall.
ADVERTISEMENT
"Dr. Zeltzer joins Northwest Biotherapeutics at a very strategic point in our rebuilding and recapitalization. Over the past 18 months, we have upgraded our GMP manufacturing processes for increased efficiency, worked with key medical opinion leaders, and regulatory and clinical advisors, and focused on advancing our two lead product candidates in the clinic. We have tightly controlled our spending, and have positioned the Company for a financing which will cover our Phase II clinical trial of DCVax®-Brain, and our Phase III clinical trial of DCVax®-Prostate, both trials powered to be pivotal trials. Dr. Zeltzer`s expertise in the key areas of neuro-oncology, immunotherapy, and clinical trials will guide and further advance the development of our personalized vaccines against cancer. We are pleased to have him with us," stated Alton Boynton, PhD, President of Northwest Biotherapeutics.
Dr. Paul Zeltzer commented on his appointment, "Having worked on prior dendritic cell vaccines, I see real therapeutic advantages in DCVax®-Brain and DCVax®-Prostate as compared to current treatments offered to patients with GBM and prostate cancer. The approach and science are solid, and could lead to a true advancement in the way we treat these diseases. I am further encouraged by the validation of this approach as seen in early clinical trials, conducted by the Company and independent researchers and look forward to advancing these important product candidates through late-stage clinical testing and into patient`s lives."
Dr. Zeltzer previously directed National Cancer Institute-sponsored clinical trials for leukemia and brain tumors, and has edited two major text books in Oncology and Neuro-oncology. He has over 130 publications on the molecular biology, treatment results, and long-term outcomes of cancer. Dr. Zeltzer`s expertise in the field of immunotherapy includes early work using antigen presenting cells while at the University of California Irvine, and dendritic cell-based immunotherapy while at Cedars-Sinai Hospital in Los Angeles, where he held the position of Neuro-oncologist at the Maxine Dunitz Neurosurgical Institute. Dr. Zeltzer is also a specialist in the diagnosis and treatment of brain tumors in adults and children. He was Associate Professor at University of Texas Health Science Center at San Antonio; Head, Brain Tumor Program, Children`s Hospital Los Angeles; and Professor and Chief, Pediatric Hematology Oncology at University of California, Irvine. He currently serves as Clinical Professor, Departments of Neurosurgery and Pediatrics, UCLA Center for Health Sciences in addition to his position at Northwest Biotherapeutics.
Positive Findings in Phase I Studies of DCVax®-Brain: Life Extended With No Toxicity
Northwest Biotherapeutics` Phase II clinical trial for DCVax®-Brain, presently scheduled to commence this fall, is based upon promising clinical data from two Phase I clinical trials carried out at UCLA by Linda Liau, MD, PhD, in patients with GBM. In these Phase I trials, 25 patients were treated with DCVax® -Brain. Seventeen of these were newly diagnosed GBM patients, and eight were recurrent GBM patients. DCVax®-Brain delivered substantial delays in the time to disease progression and substantial extension of survival times in both groups of patients (newly diagnosed and recurrent), compared with all existing approved treatments. At least two other independent clinical trials by other investigators have produced similar results.
Newly diagnosed GBM patients historically have had a median time to disease progression of only 8 months, and median survival of only 14-15 months. With DCVax®-Brain, the newly diagnosed patients in the first Phase I trial have a median time to progression of nearly 21 months and median survival time in excess of 32 months. In the second Phase I trial, which is still ongoing, 8 of 10 patients have yet to progress after a median time of over 16.3 months and median survival to date of over 18 months. Both the median time to progression and the median survival are still increasing. No treatment-related serious adverse events have been seen in any of the patients.
GBM patients with recurrent disease historically have had an even bleaker prognosis with existing approved treatments. Historically, the median time to disease progression is only 5 months, and median survival is only 10 months. With DCVax®-Brain, the recurrent GBM patients in the Phase I trial showed a median time to disease progression of almost 13 months, and median survival time in excess of 16 months. Again, no treatment-related serious adverse events were seen in any of the patients.
About Glioblastoma Multiforme
According to the American Cancer Society, cancer in the brain is diagnosed in approximately 200,000 patients per year in the United States, of which for 2005, 18,500 are primary brain tumors that arise within the brain, and are not metastases from another type of cancer in the body. The majority of primary brain cancers are diagnosed as GBM, the most aggressive and lethal form of brain cancer. Brain tumors are the leading cause of death from solid cancers in children under the age of 20.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized vaccines that harness the body`s natural defenses to create cancer therapies with greater efficacy than current approved treatments. In addition, these therapies are designed to be reasonably priced for wide access by patients, and to have little or no toxicity because they are made with a patient`s own dendritic cells. The Company`s two lead product candidates are DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; and DCVax®-Brain, a personalized dendritic cell vaccine for the treatment of newly diagnosed GBM, which is entering a large Phase II clinical trial. The Company is also developing therapeutic antibodies for the treatment of cancer as its second platform technology. For further information please visit the Company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will," "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax® -Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
--------------------------------------------------------------------------------
Source: Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics Announces Appointment of Paul Zeltzer, MD as Medical Director
Tuesday August 2, 7:30 am ET
Personalized Vaccine for Brain Cancer Entering Phase II Clinical Trials
BOTHELL, Wash., Aug. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced the appointment of Paul Zeltzer, MD, as Medical Director for the company. Dr. Zeltzer will provide medical expertise and direction for NWBT`s clinical trial programs, focusing initially on DCVax®-Brain, a personalized dendritic cell vaccine for Glioblastoma Multiforme (GBM), the most lethal form of brain cancer. The FDA-allowed Phase II clinical trial for DCVax®-Brain is set to commence this fall.
ADVERTISEMENT
"Dr. Zeltzer joins Northwest Biotherapeutics at a very strategic point in our rebuilding and recapitalization. Over the past 18 months, we have upgraded our GMP manufacturing processes for increased efficiency, worked with key medical opinion leaders, and regulatory and clinical advisors, and focused on advancing our two lead product candidates in the clinic. We have tightly controlled our spending, and have positioned the Company for a financing which will cover our Phase II clinical trial of DCVax®-Brain, and our Phase III clinical trial of DCVax®-Prostate, both trials powered to be pivotal trials. Dr. Zeltzer`s expertise in the key areas of neuro-oncology, immunotherapy, and clinical trials will guide and further advance the development of our personalized vaccines against cancer. We are pleased to have him with us," stated Alton Boynton, PhD, President of Northwest Biotherapeutics.
Dr. Paul Zeltzer commented on his appointment, "Having worked on prior dendritic cell vaccines, I see real therapeutic advantages in DCVax®-Brain and DCVax®-Prostate as compared to current treatments offered to patients with GBM and prostate cancer. The approach and science are solid, and could lead to a true advancement in the way we treat these diseases. I am further encouraged by the validation of this approach as seen in early clinical trials, conducted by the Company and independent researchers and look forward to advancing these important product candidates through late-stage clinical testing and into patient`s lives."
Dr. Zeltzer previously directed National Cancer Institute-sponsored clinical trials for leukemia and brain tumors, and has edited two major text books in Oncology and Neuro-oncology. He has over 130 publications on the molecular biology, treatment results, and long-term outcomes of cancer. Dr. Zeltzer`s expertise in the field of immunotherapy includes early work using antigen presenting cells while at the University of California Irvine, and dendritic cell-based immunotherapy while at Cedars-Sinai Hospital in Los Angeles, where he held the position of Neuro-oncologist at the Maxine Dunitz Neurosurgical Institute. Dr. Zeltzer is also a specialist in the diagnosis and treatment of brain tumors in adults and children. He was Associate Professor at University of Texas Health Science Center at San Antonio; Head, Brain Tumor Program, Children`s Hospital Los Angeles; and Professor and Chief, Pediatric Hematology Oncology at University of California, Irvine. He currently serves as Clinical Professor, Departments of Neurosurgery and Pediatrics, UCLA Center for Health Sciences in addition to his position at Northwest Biotherapeutics.
Positive Findings in Phase I Studies of DCVax®-Brain: Life Extended With No Toxicity
Northwest Biotherapeutics` Phase II clinical trial for DCVax®-Brain, presently scheduled to commence this fall, is based upon promising clinical data from two Phase I clinical trials carried out at UCLA by Linda Liau, MD, PhD, in patients with GBM. In these Phase I trials, 25 patients were treated with DCVax® -Brain. Seventeen of these were newly diagnosed GBM patients, and eight were recurrent GBM patients. DCVax®-Brain delivered substantial delays in the time to disease progression and substantial extension of survival times in both groups of patients (newly diagnosed and recurrent), compared with all existing approved treatments. At least two other independent clinical trials by other investigators have produced similar results.
Newly diagnosed GBM patients historically have had a median time to disease progression of only 8 months, and median survival of only 14-15 months. With DCVax®-Brain, the newly diagnosed patients in the first Phase I trial have a median time to progression of nearly 21 months and median survival time in excess of 32 months. In the second Phase I trial, which is still ongoing, 8 of 10 patients have yet to progress after a median time of over 16.3 months and median survival to date of over 18 months. Both the median time to progression and the median survival are still increasing. No treatment-related serious adverse events have been seen in any of the patients.
GBM patients with recurrent disease historically have had an even bleaker prognosis with existing approved treatments. Historically, the median time to disease progression is only 5 months, and median survival is only 10 months. With DCVax®-Brain, the recurrent GBM patients in the Phase I trial showed a median time to disease progression of almost 13 months, and median survival time in excess of 16 months. Again, no treatment-related serious adverse events were seen in any of the patients.
About Glioblastoma Multiforme
According to the American Cancer Society, cancer in the brain is diagnosed in approximately 200,000 patients per year in the United States, of which for 2005, 18,500 are primary brain tumors that arise within the brain, and are not metastases from another type of cancer in the body. The majority of primary brain cancers are diagnosed as GBM, the most aggressive and lethal form of brain cancer. Brain tumors are the leading cause of death from solid cancers in children under the age of 20.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized vaccines that harness the body`s natural defenses to create cancer therapies with greater efficacy than current approved treatments. In addition, these therapies are designed to be reasonably priced for wide access by patients, and to have little or no toxicity because they are made with a patient`s own dendritic cells. The Company`s two lead product candidates are DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; and DCVax®-Brain, a personalized dendritic cell vaccine for the treatment of newly diagnosed GBM, which is entering a large Phase II clinical trial. The Company is also developing therapeutic antibodies for the treatment of cancer as its second platform technology. For further information please visit the Company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will," "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax® -Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
--------------------------------------------------------------------------------
Source: Northwest Biotherapeutics, Inc.
Vom 01.08.2005
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
--------------------------------------------------------------------------------
1-Aug-2005
Entry into Material Agreement, Financial Obligation Matter
ITEM 1.01 Entry Into a Material Definitive Agreement.
Northwest Biotherapeutics, Inc. (the "Company") announced today that, on July 26, 2005, it received a $500,000 loan from Toucan Capital Fund II, L.P. ("Toucan"). The loan accrues interest at 10% per year, matures on July 26, 2006, and the principal and interest is convertible into capital stock of the Company, generally at Toucan`s option, prior to repayment.
The principal and interest on the loan is currently convertible at $0.04 per share (subject to adjustment). In connection with this new loan, the Company has issued a warrant to Toucan, which is exercisable for up to 5.0 million shares of the Company`s capital stock. The exercise price of the warrant is $0.04 per share subject to certain adjustments. The Company believes that the additional $500,000 received from Toucan on July 26, 2005 will be sufficient to cover short-term payables to approximately August 15, 2005.
To date, the Company has issued twelve promissory notes to Toucan pursuant to which Toucan has loaned the Company an aggregate of $6.25 million. In connection with the issuance of promissory notes to Toucan, the Company has issued and Toucan has received warrants that are currently exercisable for an aggregate of up to 117.5 million shares of the Company`s capital stock.
In connection with the recent loan from Toucan, the Company and Toucan amended the Amended and Restated Recapitalization Agreement (the "Recapitalization Agreement"), dated as of July 30, 2004, amended on October 22, 2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005 and July 26, 2005 between the parties ("Amendment No. 8"). Amendment No. 8 (i) updated certain representations and warranties of the parties made in the Recapitalization Agreement, (ii) made certain technical changes in the Recapitalization Agreement in order to facilitate the July 26, 2005 bridge loan described herein, and (iii) extended the expiration date of the equity financing period (as described below) from January 26, 2006 to December 31, 2006 (or such later date as mutually agreed by the Company and Toucan).
Also in connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Binding Term Sheet dated April 26, 2004, and amended and restated on October 22, 2004 as further amended on December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005, and July 26, 2005 between the parties (the "Term Sheet"). The amendment to the Term Sheet reduced warrant coverage in the potential private placement by $500,000 and made conforming changes to extend the equity financing period through December 31, 2006 (or such later date as is mutually agreed by the parties hereto).
The Recapitalization Agreement calls for a two-stage recapitalization of the Company consisting of a bridge period and an equity financing period. The equity financing period commenced on January 26, 2005 when Toucan purchased 32,500,000 shares of the Company`s Series A Cumulative Convertible Preferred Stock at a purchase price of $0.04 per share (for aggregate purchase price of $1,300,000). The equity financing period will end on December 31, 2006 (or such later date as is mutually agreed by the parties hereto). During the equity financing period, the Company intends to sell up to $40 million of convertible preferred stock in accordance with the terms of the Recapitalization Agreement. Any additional financing is contingent upon the Company complying with covenants in the Recapitalization Agreement, as amended, and locating additional investors who are willing to invest in the Company on the terms proposed.
In addition, on July 26, 2005 the Company and Toucan agreed to amend the six Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory Notes, representing an aggregate principal of $3.6 million, and originally issued on February 2, March 1, April 26, June 11, July 30, and October 22, 2004, to change the respective maturity dates of each such note to November 1, 2005. Further, the Company and members of management who hold notes, representing an aggregate principal of $235,000 due from the Company, as set forth in the following table, originally dated November 12, 2003, and amended on April 26, 2004, April 12, 2005, and June 16, 2005, agreed on July 26, 2005 to a Fourth Amendment To Convertible Secured Promissory Note changing the maturity dates of each such note to November 15, 2005.
Name Title Principal
Alton L. President, Chief Scientific Officer, Chief
Boynton, Ph.D. Operating Officer and Secretary $ 183,000
Marnix Bosch,
Ph.D. Vice President of Vaccine Research and Development 41,000
Larry L. Controller (Principal Financial and Accounting
Richards Officer) 11,000
Total $ 235,000
The foregoing description of Amendment No. 8, the note, the warrant, the amendment to the Term Sheet, the management note amendments, and the amendments to the Convertible Secured Promissory Notes all of which are filed as exhibits to the Form 8-K, are qualified in their entirety by reference to the full text of the agreements.
--------------------------------------------------------------------------------
Table of Contents
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement.
The information contained under Item 1.01 of this report is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
10.1 Amendment No. 8 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II,
L.P., dated July 26, 2005.
10.2 Loan Agreement, Security Agreement and 10% Convertible, Secured
Promissory Note in the principal amount of $500,000 between Northwest
Biotherapeutics, Inc. and Toucan Capital Fund II, L.P., dated July 26,
2005.
10.3 Warrant to purchase securities of the Company dated July 26, 2005 issued
to Toucan Capital Fund II, L.P.
10.4 Sixth Amendment to Amended and Restated Binding Term Sheet, dated
July 26, 2005.
10.5 Second Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $50,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.6 Second Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $50,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.7 Second Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $500,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.8 First Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $500,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.9 First Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $2,000,000 between the Company and Toucan Capital Fund II,
L.P., dated July 26, 2005.
10.10 First Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $500,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.11 Form of Fourth Amendment To Convertible Secured Promissory Note between
the Company and Holders of the November 12, 2003 Convertible Secured
Promissory Note, dated July 26, 2005.
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
--------------------------------------------------------------------------------
1-Aug-2005
Entry into Material Agreement, Financial Obligation Matter
ITEM 1.01 Entry Into a Material Definitive Agreement.
Northwest Biotherapeutics, Inc. (the "Company") announced today that, on July 26, 2005, it received a $500,000 loan from Toucan Capital Fund II, L.P. ("Toucan"). The loan accrues interest at 10% per year, matures on July 26, 2006, and the principal and interest is convertible into capital stock of the Company, generally at Toucan`s option, prior to repayment.
The principal and interest on the loan is currently convertible at $0.04 per share (subject to adjustment). In connection with this new loan, the Company has issued a warrant to Toucan, which is exercisable for up to 5.0 million shares of the Company`s capital stock. The exercise price of the warrant is $0.04 per share subject to certain adjustments. The Company believes that the additional $500,000 received from Toucan on July 26, 2005 will be sufficient to cover short-term payables to approximately August 15, 2005.
To date, the Company has issued twelve promissory notes to Toucan pursuant to which Toucan has loaned the Company an aggregate of $6.25 million. In connection with the issuance of promissory notes to Toucan, the Company has issued and Toucan has received warrants that are currently exercisable for an aggregate of up to 117.5 million shares of the Company`s capital stock.
In connection with the recent loan from Toucan, the Company and Toucan amended the Amended and Restated Recapitalization Agreement (the "Recapitalization Agreement"), dated as of July 30, 2004, amended on October 22, 2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005 and July 26, 2005 between the parties ("Amendment No. 8"). Amendment No. 8 (i) updated certain representations and warranties of the parties made in the Recapitalization Agreement, (ii) made certain technical changes in the Recapitalization Agreement in order to facilitate the July 26, 2005 bridge loan described herein, and (iii) extended the expiration date of the equity financing period (as described below) from January 26, 2006 to December 31, 2006 (or such later date as mutually agreed by the Company and Toucan).
Also in connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Binding Term Sheet dated April 26, 2004, and amended and restated on October 22, 2004 as further amended on December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005, and July 26, 2005 between the parties (the "Term Sheet"). The amendment to the Term Sheet reduced warrant coverage in the potential private placement by $500,000 and made conforming changes to extend the equity financing period through December 31, 2006 (or such later date as is mutually agreed by the parties hereto).
The Recapitalization Agreement calls for a two-stage recapitalization of the Company consisting of a bridge period and an equity financing period. The equity financing period commenced on January 26, 2005 when Toucan purchased 32,500,000 shares of the Company`s Series A Cumulative Convertible Preferred Stock at a purchase price of $0.04 per share (for aggregate purchase price of $1,300,000). The equity financing period will end on December 31, 2006 (or such later date as is mutually agreed by the parties hereto). During the equity financing period, the Company intends to sell up to $40 million of convertible preferred stock in accordance with the terms of the Recapitalization Agreement. Any additional financing is contingent upon the Company complying with covenants in the Recapitalization Agreement, as amended, and locating additional investors who are willing to invest in the Company on the terms proposed.
In addition, on July 26, 2005 the Company and Toucan agreed to amend the six Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory Notes, representing an aggregate principal of $3.6 million, and originally issued on February 2, March 1, April 26, June 11, July 30, and October 22, 2004, to change the respective maturity dates of each such note to November 1, 2005. Further, the Company and members of management who hold notes, representing an aggregate principal of $235,000 due from the Company, as set forth in the following table, originally dated November 12, 2003, and amended on April 26, 2004, April 12, 2005, and June 16, 2005, agreed on July 26, 2005 to a Fourth Amendment To Convertible Secured Promissory Note changing the maturity dates of each such note to November 15, 2005.
Name Title Principal
Alton L. President, Chief Scientific Officer, Chief
Boynton, Ph.D. Operating Officer and Secretary $ 183,000
Marnix Bosch,
Ph.D. Vice President of Vaccine Research and Development 41,000
Larry L. Controller (Principal Financial and Accounting
Richards Officer) 11,000
Total $ 235,000
The foregoing description of Amendment No. 8, the note, the warrant, the amendment to the Term Sheet, the management note amendments, and the amendments to the Convertible Secured Promissory Notes all of which are filed as exhibits to the Form 8-K, are qualified in their entirety by reference to the full text of the agreements.
--------------------------------------------------------------------------------
Table of Contents
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement.
The information contained under Item 1.01 of this report is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
10.1 Amendment No. 8 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II,
L.P., dated July 26, 2005.
10.2 Loan Agreement, Security Agreement and 10% Convertible, Secured
Promissory Note in the principal amount of $500,000 between Northwest
Biotherapeutics, Inc. and Toucan Capital Fund II, L.P., dated July 26,
2005.
10.3 Warrant to purchase securities of the Company dated July 26, 2005 issued
to Toucan Capital Fund II, L.P.
10.4 Sixth Amendment to Amended and Restated Binding Term Sheet, dated
July 26, 2005.
10.5 Second Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $50,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.6 Second Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $50,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.7 Second Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $500,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.8 First Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $500,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.9 First Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $2,000,000 between the Company and Toucan Capital Fund II,
L.P., dated July 26, 2005.
10.10 First Amendment To Amended And Restated Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Note in the principle
amount of $500,000 between the Company and Toucan Capital Fund II, L.P.,
dated July 26, 2005.
10.11 Form of Fourth Amendment To Convertible Secured Promissory Note between
the Company and Holders of the November 12, 2003 Convertible Secured
Promissory Note, dated July 26, 2005.
kaum kommen hier nach längerer Zeit wieder die ersten guten Meldungen gehen die ersten Shares wieder ab wie die Rennferkel..
Geht ja unheimlich ab!
Wie sieht es in den USA aus?
Wie sieht es in den USA aus?
[posting]17.425.850 von Fussballtrainer am 02.08.05 17:26:59[/posting]In USA tote Hose gestern:
SK NWBT.OB Aug 2 0.142 -0.003 -2.07% 0.142 + 0.149 14,100 N/A
SK NWBT.OB Aug 2 0.142 -0.003 -2.07% 0.142 + 0.149 14,100 N/A
Heute aber dafür kräftiges Lebenszeichen:
NWBT.OB 1:20pm 0.18 +0.038 +26.76% 0.17 + 0.18 140,640
NWBT.OB 1:20pm 0.18 +0.038 +26.76% 0.17 + 0.18 140,640
...wurde aber auch mal wieder Zeit. Nach den guten News der letzen Tage müßte aber schon noch mehr drin sein!
[posting]17.440.171 von bioperformer am 03.08.05 21:07:00[/posting]Ist dir an den Umsätzen aufgefallen, das ab 19:30 Uhr unserer Zeit nichts mehr passiert ist in den USA ?
Ich denke der weitere Verlauf des Kurses wird an den nächsten Untersuchungsergebnissen hängen, sollten die positiv ausfallen ist der Wert ein Wahnsinnsschnäppchen bei der MK
Ich denke der weitere Verlauf des Kurses wird an den nächsten Untersuchungsergebnissen hängen, sollten die positiv ausfallen ist der Wert ein Wahnsinnsschnäppchen bei der MK
so isses, nur noch zwei unwesentliche Käufe.
Diese heutige Kaufaktion hat aber System. Achte mal auf die gekauften Mengen: 50k, 20k, 15k, 15k, dawischen mal etwas Kleinvieh wie auch jetzt zuletzt.
Ich würde mal mutmaßen dass der Kurs heute nicht mehr runtergeht..
Diese heutige Kaufaktion hat aber System. Achte mal auf die gekauften Mengen: 50k, 20k, 15k, 15k, dawischen mal etwas Kleinvieh wie auch jetzt zuletzt.
Ich würde mal mutmaßen dass der Kurs heute nicht mehr runtergeht..
[posting]17.440.299 von bioperformer am 03.08.05 21:23:36[/posting]Es ist halt Geduld angesagt oder das Glück am Tag X vor dem PC zu sitzen
Hallo Bio,
ich muß mich mal wieder melden. Meinst du hier ist noch mehr drin? Ich habe mir eine kleine Position gesichert, würde aber auch gerne nachlegen. Was meinst du ?
Besten Dank im voraus.
Gruss prom
ich muß mich mal wieder melden. Meinst du hier ist noch mehr drin? Ich habe mir eine kleine Position gesichert, würde aber auch gerne nachlegen. Was meinst du ?
Besten Dank im voraus.
Gruss prom
Hallo prom,
habe folgende Überlegung zu dem Thema in Verbindung mit den News der letzten Tage:
NWBT.OB hat nach einer Möglichkeit der Finanzierung gesucht und diese auch gefunden. Diese Finanzspritze wäre wohl nicht gereicht worden wenn man sozusagen beim Geber hätte nicht überzeugen können.
Dies werte ich mal als Indiz dafür, dass man sicherlich fachlich etwas Reizvolles in der Hinterhand zu haben scheint, denn sonst hätte man wohl dezent die Tür gewiesen bekommen.
Ebenfalls interessant die personelle Verstärkung, was immerhin Anlass bietet zur positiven, aber auch spekulativen Seite zu neigen und sich die Frage zu stellen kommen da weitere positive News?
Zusätzlich heute auch noch gleich der entschlossene Kursanstieg der schon etwas andeuten könnte...
...wie gesagt, wenn was kommt dann kommt es dicke!
Hilft dir jetzt wahrscheinlich auch nicht recht viel weiter aber die Entscheidung zum Kauf kann ich dir nicht abnehmen.
Gruß, Bio
habe folgende Überlegung zu dem Thema in Verbindung mit den News der letzten Tage:
NWBT.OB hat nach einer Möglichkeit der Finanzierung gesucht und diese auch gefunden. Diese Finanzspritze wäre wohl nicht gereicht worden wenn man sozusagen beim Geber hätte nicht überzeugen können.
Dies werte ich mal als Indiz dafür, dass man sicherlich fachlich etwas Reizvolles in der Hinterhand zu haben scheint, denn sonst hätte man wohl dezent die Tür gewiesen bekommen.
Ebenfalls interessant die personelle Verstärkung, was immerhin Anlass bietet zur positiven, aber auch spekulativen Seite zu neigen und sich die Frage zu stellen kommen da weitere positive News?
Zusätzlich heute auch noch gleich der entschlossene Kursanstieg der schon etwas andeuten könnte...
...wie gesagt, wenn was kommt dann kommt es dicke!
Hilft dir jetzt wahrscheinlich auch nicht recht viel weiter aber die Entscheidung zum Kauf kann ich dir nicht abnehmen.
Gruß, Bio
...wie ich nach den positiven News der letzten Tage schon vermutete schließen wir auf Tageshöchststand mit einem Plus von 26%!!
auch heute gehts hier anscheinend weiter nach Norden, derzeit 0,19 ..
die Käufer von vorgestern scheinen wieder da zu sein..
... und weckten auch das Interesse in diesen Wert!
Durchaus positiver News-Flow die letzten Wochen!
Die Börse reagiert halt manchmal mit Absicht verzögert!
Durchaus positiver News-Flow die letzten Wochen!
Die Börse reagiert halt manchmal mit Absicht verzögert!
das könnte heute neuen Volumenrekord geben, da bislang schon 187k über den Tresen gingen.
Langsam aber sicher geht es nach oben und wenn die News erst kommen wird es locker 100 % nach oben gehen!
Weis jemand warum heute in Amerika noch nichts gehandelt wurde? Wurde die Aktie vom Handel ausgesetzt?
[posting]17.494.058 von prom am 09.08.05 17:15:13[/posting]Nein, wieso ? Ist wohl nur wieder eingeschlafen bis zur nächsten News
NWBT.OB 11:35am 0.195 -0.005 -2.50% 0.195 0.20 12,000 N/A Chart, Profile, more... 48,939 5,000 5,000 12,000
NWBT.OB 11:35am 0.195 -0.005 -2.50% 0.195 0.20 12,000 N/A Chart, Profile, more... 48,939 5,000 5,000 12,000
Hallo, sollen wir noch weiter auf Neuigkeiten warten?
Hier sollten irgendwann auch wieder Neuigkeiten anstehen!!
Ich bin noch dabei aber ich glaube ich bin der Letzte!!!!
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
9-Sep-2005
Entry into Material Agreement, Financial Obligation Matter
ITEM 1.01 Entry Into a Material Definitive Agreement.
Northwest Biotherapeutics, Inc. (the "Company") announced today that, on September 7, 2005, it received a $500,000 loan from Toucan Capital Fund II, L.P. ("Toucan"). The loan accrues interest at 10% per year, matures on September 7, 2006, and the principal and interest is convertible into capital stock of the Company, generally at Toucan`s option, prior to repayment.
The principal and interest on the loan is currently convertible at $0.04 per share (subject to adjustment). In connection with this new loan, the Company has issued a warrant to Toucan, which is exercisable for up to 5.0 million shares of the Company`s capital stock. The exercise price of the warrant is $0.04 per share subject to certain adjustments. The Company believes that the additional $500,000 received from Toucan on September 7, 2005 will be sufficient to cover short-term payables through approximately early October 2005.
To date, the Company has issued thirteen promissory notes to Toucan pursuant to which Toucan has loaned the Company an aggregate of $6.75 million. In connection with the issuance of promissory notes to Toucan, the Company has issued and Toucan has received warrants that are currently exercisable for an aggregate of up to 122.5 million shares of the Company`s capital stock.
In connection with the recent loan from Toucan, the Company and Toucan amended the Amended and Restated Recapitalization Agreement (the "Recapitalization Agreement"), dated as of July 30, 2004, amended on October 22, 2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005, July 26, 2005 and September 7, 2005 between the parties ("Amendment No. 9"). Amendment No. 9 (i) updated certain representations and warranties of the parties made in the Recapitalization Agreement, and
(ii) made certain technical changes in the Recapitalization Agreement in order to facilitate the September 7, 2005 bridge loan described herein. Also in connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Binding Term Sheet dated April 26, 2004, and amended and restated on October 22, 2004 as further amended on December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005, July 26, 2005 and September 7, 2005 between the parties (the "Term Sheet"). The amendment to the Term Sheet reduced warrant coverage in the potential private placement by $500,000. The Recapitalization Agreement calls for a two-stage recapitalization of the Company consisting of a bridge period and an equity financing period. The equity financing period commenced on January 26, 2005 when Toucan purchased 32,500,000 shares of the Company`s Series A Cumulative Convertible Preferred Stock at a purchase price of $0.04 per share (for aggregate purchase price of $1,300,000). The equity financing period will end on December 31, 2006 (or such later date as is mutually agreed by the Company and Toucan). During the equity financing period, the Company intends to sell up to $40 million of convertible preferred stock in accordance with the terms of the Recapitalization Agreement. Any additional financing is contingent upon the Company complying with covenants in the Recapitalization Agreement, as amended, and locating additional investors who are willing to invest in the Company on the terms proposed. The foregoing description of Amendment No. 9, the note, the warrant, and the amendment to the Term Sheet, all of which are filed as exhibits to the Form 8-K, are qualified in their entirety by reference to the full text of the agreements.
Table of Contents
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement.
The information contained under Item 1.01 of this report is incorporated by reference herein.
Item 7.01 Regulation FD Disclosure.
The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On August 29, 2005, Soma Partners, LLC filed a notice of petition to vacate the arbitration award with the supreme court of the state of New York requesting that the May 24, 2005 findings of the arbitrator in favor of the Company be vacated. As previously reported, the Company considered the claims brought by Soma Partners, LLC in the arbitration to be unfounded, the Company defended against all such claims vigorously, and the arbitrator`s decision upheld all of the Company`s defenses. The Company believes that this renewed action by Soma Partners, LLC is without merit and the Company intends to defend it vigorously. See page 25 of the Company`s Form 10-Q for the quarter ended June 30, 2005, filed with the Securities and Exchange Commission on August 15, 2005, for a more detailed description of the original matter. Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
10.1 Amendment No. 9 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P.,
dated September 7, 2005.
10.2 Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory
Note in the principal amount of $500,000 between Northwest Biotherapeutics,
Inc. and Toucan Capital Fund II, L.P., dated September 7, 2005.
10.3 Warrant to purchase securities of the Company dated September 7, 2005
issued to Toucan Capital Fund II, L.P.
10.4 Seventh Amendment to Amended and Restated Binding Term Sheet, dated
September 7, 2005.
9-Sep-2005
Entry into Material Agreement, Financial Obligation Matter
ITEM 1.01 Entry Into a Material Definitive Agreement.
Northwest Biotherapeutics, Inc. (the "Company") announced today that, on September 7, 2005, it received a $500,000 loan from Toucan Capital Fund II, L.P. ("Toucan"). The loan accrues interest at 10% per year, matures on September 7, 2006, and the principal and interest is convertible into capital stock of the Company, generally at Toucan`s option, prior to repayment.
The principal and interest on the loan is currently convertible at $0.04 per share (subject to adjustment). In connection with this new loan, the Company has issued a warrant to Toucan, which is exercisable for up to 5.0 million shares of the Company`s capital stock. The exercise price of the warrant is $0.04 per share subject to certain adjustments. The Company believes that the additional $500,000 received from Toucan on September 7, 2005 will be sufficient to cover short-term payables through approximately early October 2005.
To date, the Company has issued thirteen promissory notes to Toucan pursuant to which Toucan has loaned the Company an aggregate of $6.75 million. In connection with the issuance of promissory notes to Toucan, the Company has issued and Toucan has received warrants that are currently exercisable for an aggregate of up to 122.5 million shares of the Company`s capital stock.
In connection with the recent loan from Toucan, the Company and Toucan amended the Amended and Restated Recapitalization Agreement (the "Recapitalization Agreement"), dated as of July 30, 2004, amended on October 22, 2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005, July 26, 2005 and September 7, 2005 between the parties ("Amendment No. 9"). Amendment No. 9 (i) updated certain representations and warranties of the parties made in the Recapitalization Agreement, and
(ii) made certain technical changes in the Recapitalization Agreement in order to facilitate the September 7, 2005 bridge loan described herein. Also in connection with the recent loan from Toucan, the Company and Toucan agreed to amend the Amended and Restated Binding Term Sheet dated April 26, 2004, and amended and restated on October 22, 2004 as further amended on December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June 16, 2005, July 26, 2005 and September 7, 2005 between the parties (the "Term Sheet"). The amendment to the Term Sheet reduced warrant coverage in the potential private placement by $500,000. The Recapitalization Agreement calls for a two-stage recapitalization of the Company consisting of a bridge period and an equity financing period. The equity financing period commenced on January 26, 2005 when Toucan purchased 32,500,000 shares of the Company`s Series A Cumulative Convertible Preferred Stock at a purchase price of $0.04 per share (for aggregate purchase price of $1,300,000). The equity financing period will end on December 31, 2006 (or such later date as is mutually agreed by the Company and Toucan). During the equity financing period, the Company intends to sell up to $40 million of convertible preferred stock in accordance with the terms of the Recapitalization Agreement. Any additional financing is contingent upon the Company complying with covenants in the Recapitalization Agreement, as amended, and locating additional investors who are willing to invest in the Company on the terms proposed. The foregoing description of Amendment No. 9, the note, the warrant, and the amendment to the Term Sheet, all of which are filed as exhibits to the Form 8-K, are qualified in their entirety by reference to the full text of the agreements.
Table of Contents
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement.
The information contained under Item 1.01 of this report is incorporated by reference herein.
Item 7.01 Regulation FD Disclosure.
The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On August 29, 2005, Soma Partners, LLC filed a notice of petition to vacate the arbitration award with the supreme court of the state of New York requesting that the May 24, 2005 findings of the arbitrator in favor of the Company be vacated. As previously reported, the Company considered the claims brought by Soma Partners, LLC in the arbitration to be unfounded, the Company defended against all such claims vigorously, and the arbitrator`s decision upheld all of the Company`s defenses. The Company believes that this renewed action by Soma Partners, LLC is without merit and the Company intends to defend it vigorously. See page 25 of the Company`s Form 10-Q for the quarter ended June 30, 2005, filed with the Securities and Exchange Commission on August 15, 2005, for a more detailed description of the original matter. Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
10.1 Amendment No. 9 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P.,
dated September 7, 2005.
10.2 Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory
Note in the principal amount of $500,000 between Northwest Biotherapeutics,
Inc. and Toucan Capital Fund II, L.P., dated September 7, 2005.
10.3 Warrant to purchase securities of the Company dated September 7, 2005
issued to Toucan Capital Fund II, L.P.
10.4 Seventh Amendment to Amended and Restated Binding Term Sheet, dated
September 7, 2005.
Danke für Deine Ausführungen und was besagt bzw. was hälts Du davon?
Gestern in Deutschland endlich einmal wieder "richtiger Handel"!
18.600 Stücke, SK 0,15 EUR.
Ich habe meine Geduld noch lange nicht verloren bzw. meine Hoffnung aufgegeben! Im Gegenteil: Wer sich zu diesen unterirdischen Kursen eindeckt, wird sich bald sehr freuen können!!!
Die MK von < 3 Mio EUR ist ein schlechter Witz!
Bei der nächsten positiven Meldung explodiert der Kurs! Ganz davon zu schweigen, wenn eine Zulassung erfolgen sollte...
Dann wären selbst 1000% Kurssteigerung ein Witz!!!
We will see!
Prof.Hastig
18.600 Stücke, SK 0,15 EUR.
Ich habe meine Geduld noch lange nicht verloren bzw. meine Hoffnung aufgegeben! Im Gegenteil: Wer sich zu diesen unterirdischen Kursen eindeckt, wird sich bald sehr freuen können!!!
Die MK von < 3 Mio EUR ist ein schlechter Witz!
Bei der nächsten positiven Meldung explodiert der Kurs! Ganz davon zu schweigen, wenn eine Zulassung erfolgen sollte...
Dann wären selbst 1000% Kurssteigerung ein Witz!!!
We will see!
Prof.Hastig
Hallo zusammen,
kann jemand etwas über den Anstieg in Berling auf 0,20€ sagen, und das ohne Handel ????
Liegt was in der Luft bei NW Bio ???
mfg
kurttilly
kann jemand etwas über den Anstieg in Berling auf 0,20€ sagen, und das ohne Handel ????
Liegt was in der Luft bei NW Bio ???
mfg
kurttilly
habe meine Teilchen auch immer noch - und das ist gut so..
Berlin würde mich auch interessieren obwohl ich in Frankfurt dabei bin!!!
In den USA wurde auch einige gehandelt, bvielleicht kommt nächste Woche w2as, hoffen wir es mal!
In den USA wurde auch einige gehandelt, bvielleicht kommt nächste Woche w2as, hoffen wir es mal!
Press Release Source: Northwest Biotherapeutics
Northwest Biotherapeutics Announces Clinical Advisory Board for Brain Cancer Program
Tuesday September 20, 9:03 pm ET
Experts Guide Development of Promising Personalized Vaccine in Late Stage Trial for Most Lethal Form of Brain Cancer
BOTHELL, Wash., Sept. 20 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) announced today that a Clinical Advisory Board (CAB) has been appointed to guide the Company in its late stage clinical trial for a personalized vaccine treatment for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Northwest Biotherapeutics` vaccine, DCVax®-Brain, uses a patient`s own dendritic cells to mobilize the body`s full immune system against cancer. DCVax®-Brain showed very promising results in two Phase I clinical trials and a large, multi-center Phase II clinical trial is planned for this Fall.
ADVERTISEMENT
Comprised of world-renowned oncologists, neurosurgeons, neurologists and neuroscientists, the Clinical Advisory Board will play an important role in guiding the upcoming large Phase II trial. In addition, it is anticipated that the leading medical centers with which the CAB members are affiliated may be among the first sites at which enrollment for the Phase II trial will begin.
"We are proud to have such a distinguished Clinical Advisory Board with some of the world`s most respected and experienced experts in the fields of brain cancer, neurology, and clinical design, who will work together to advance our personalized vaccines for the benefit of patients with Glioblastoma multiforme," said Alton Boynton, Ph.D., President and Chief Operating Officer of Northwest Biotherapeutics.
Linda Liau, M.D., Ph.D., a neurosurgeon from the University of California at Los Angeles (UCLA) served as principal investigator for two Phase I clinical trials of DCVax®-Brain in patients with newly diagnosed and recurrent GBM, and will Chair Northwest Biotherapeutics` Clinical Advisory Board for DCVax®-Brain. "DCVax®-Brain has shown outstanding therapeutic promise in early clinical testing. We have patients living cancer-free and exceeding standard survival times for GBM, the most aggressive form of brain cancer. The Clinical Advisory Board is eager to begin its work to advance the development of DCVax®-Brain so that an increasing number of patients will have access to it as soon as possible."
The Northwest Biotherapeutics Clinical Advisory Board for DCVax®-Brain is comprised of:
Linda Liau, M.D., Ph.D. - Chair
Dr. Liau is Director of the Malignant Brain Tumor Program at the UCLA School of Medicine, and an Associate Professor of Neurosurgery at the University of California at Los Angeles (UCLA). Dr. Liau is a well-respected neurosurgeon and has served as a clinical investigator for trials of investigational new drugs. She serves on the Editorial Boards of the Journals of Neuro-Oncology, Neuro-Oncology, and Surgical Neurology. She holds a B.S. and B.A. from Brown University, an M.D. from Stanford and a Ph.D. in Molecular Neuroscience from UCLA.
Darell D. Bigner, M.D., Ph.D.
Dr. Bigner serves as the Edwin L. Jones, Jr. and Lucille Finch Jones Cancer Research Professor of Pathology, and Professor of Surgery at the Duke Comprehensive Cancer Center, Duke University Medical Center. He is also Chief of the Division of Experimental Pathology Research and Vice Chair of Research in the Department of Surgery. Dr. Bigner`s main area of research is the causes, mechanisms of transformation and altered growth control and new therapy for primary and metastatic tumors of the central nervous system. Dr. Bigner holds a B.S. from the University of Georgia, and an M.D. and Ph.D. from Duke University.
Henry Brem, M.D.
Dr. Henry Brem is the Director of the Department of Neurosurgery, Harvey Cushing Professor of Neurosurgery, Professor of Ophthalmology, and Oncology for The Johns Hopkins Hospital. He is also Director of the Hunterian Neurosurgical Research Laboratory at Johns Hopkins. His practice specializes in the surgical treatment of pituitary tumors, meningiomas, skull base tumors, and other solid brain tumors. He has developed new clinical treatments for brain tumors including the local delivery of chemotherapeutic agents in biodegradable polymers, Gliadel wafer, for which a patent was issued and a product approved by the FDA. Dr. Brem received his A.B. from New York University, and M.D. from Harvard Medical School.
Tom Mikkelsen, M.D.
Dr. Mikkelsen serves in the Eugene & Marcia Applebaum Lab of Molecular Therapeutics and is Co-Director, Hermelin Brain Tumor Center, Josephine Ford Cancer Center, at the Henry Ford Hospital Detroit, Michigan. Dr. Mikkelsen is also Staff Neuro-Oncologist, Division of Neurology, Department of Medicine, for the William Beaumont Cancer Center, in Royal Oak, Michigan. Dr. Mikkelsen received his B.S. degree from the University of Alberta and his M.D. from the University of Calgary.
Steven S. Brem, M.D.
Dr. Brem is Chief of the Neurosurgery Service, Director, Neuro-Oncology research laboratory, and Division Chief, Neuro-Oncology, for the H. Lee Moffitt Cancer Center & Research Institute of the University of South Florida. Dr. Brem also serves as a New Approaches to Brain Tumor Therapy (NABTT) Investigator. His research interests include frameless image-guided surgery, surgery of brain metastasis and malignant tumors, experimental therapeutics, anti-angiogenesis therapies, pituitary surgery and skull base surgery. Dr. Brem received a B.A. from Rutgers University and an M.D. from Harvard Medical School.
About Glioblastoma Multiforme
Brain cancer is diagnosed in approximately 200,000 patients per year, of which approximately 20,000 are primary tumors that arise within the brain and are not metastatic lesions from elsewhere in the body. Approximately 60% of primary brain cancers are diagnosed as GBM, the most aggressive and lethal form.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s two lead product candidates are:
DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial;
DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial.
CXCR4 is a therapeutic monoclonal antibody for treatment of solid tumors, and is in late pre-clinical development.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. Participation by Dr. Brem as a member of the Clinical Advisory Board does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Source: Northwest Biotherapeutics
Northwest Biotherapeutics Announces Clinical Advisory Board for Brain Cancer Program
Tuesday September 20, 9:03 pm ET
Experts Guide Development of Promising Personalized Vaccine in Late Stage Trial for Most Lethal Form of Brain Cancer
BOTHELL, Wash., Sept. 20 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) announced today that a Clinical Advisory Board (CAB) has been appointed to guide the Company in its late stage clinical trial for a personalized vaccine treatment for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Northwest Biotherapeutics` vaccine, DCVax®-Brain, uses a patient`s own dendritic cells to mobilize the body`s full immune system against cancer. DCVax®-Brain showed very promising results in two Phase I clinical trials and a large, multi-center Phase II clinical trial is planned for this Fall.
ADVERTISEMENT
Comprised of world-renowned oncologists, neurosurgeons, neurologists and neuroscientists, the Clinical Advisory Board will play an important role in guiding the upcoming large Phase II trial. In addition, it is anticipated that the leading medical centers with which the CAB members are affiliated may be among the first sites at which enrollment for the Phase II trial will begin.
"We are proud to have such a distinguished Clinical Advisory Board with some of the world`s most respected and experienced experts in the fields of brain cancer, neurology, and clinical design, who will work together to advance our personalized vaccines for the benefit of patients with Glioblastoma multiforme," said Alton Boynton, Ph.D., President and Chief Operating Officer of Northwest Biotherapeutics.
Linda Liau, M.D., Ph.D., a neurosurgeon from the University of California at Los Angeles (UCLA) served as principal investigator for two Phase I clinical trials of DCVax®-Brain in patients with newly diagnosed and recurrent GBM, and will Chair Northwest Biotherapeutics` Clinical Advisory Board for DCVax®-Brain. "DCVax®-Brain has shown outstanding therapeutic promise in early clinical testing. We have patients living cancer-free and exceeding standard survival times for GBM, the most aggressive form of brain cancer. The Clinical Advisory Board is eager to begin its work to advance the development of DCVax®-Brain so that an increasing number of patients will have access to it as soon as possible."
The Northwest Biotherapeutics Clinical Advisory Board for DCVax®-Brain is comprised of:
Linda Liau, M.D., Ph.D. - Chair
Dr. Liau is Director of the Malignant Brain Tumor Program at the UCLA School of Medicine, and an Associate Professor of Neurosurgery at the University of California at Los Angeles (UCLA). Dr. Liau is a well-respected neurosurgeon and has served as a clinical investigator for trials of investigational new drugs. She serves on the Editorial Boards of the Journals of Neuro-Oncology, Neuro-Oncology, and Surgical Neurology. She holds a B.S. and B.A. from Brown University, an M.D. from Stanford and a Ph.D. in Molecular Neuroscience from UCLA.
Darell D. Bigner, M.D., Ph.D.
Dr. Bigner serves as the Edwin L. Jones, Jr. and Lucille Finch Jones Cancer Research Professor of Pathology, and Professor of Surgery at the Duke Comprehensive Cancer Center, Duke University Medical Center. He is also Chief of the Division of Experimental Pathology Research and Vice Chair of Research in the Department of Surgery. Dr. Bigner`s main area of research is the causes, mechanisms of transformation and altered growth control and new therapy for primary and metastatic tumors of the central nervous system. Dr. Bigner holds a B.S. from the University of Georgia, and an M.D. and Ph.D. from Duke University.
Henry Brem, M.D.
Dr. Henry Brem is the Director of the Department of Neurosurgery, Harvey Cushing Professor of Neurosurgery, Professor of Ophthalmology, and Oncology for The Johns Hopkins Hospital. He is also Director of the Hunterian Neurosurgical Research Laboratory at Johns Hopkins. His practice specializes in the surgical treatment of pituitary tumors, meningiomas, skull base tumors, and other solid brain tumors. He has developed new clinical treatments for brain tumors including the local delivery of chemotherapeutic agents in biodegradable polymers, Gliadel wafer, for which a patent was issued and a product approved by the FDA. Dr. Brem received his A.B. from New York University, and M.D. from Harvard Medical School.
Tom Mikkelsen, M.D.
Dr. Mikkelsen serves in the Eugene & Marcia Applebaum Lab of Molecular Therapeutics and is Co-Director, Hermelin Brain Tumor Center, Josephine Ford Cancer Center, at the Henry Ford Hospital Detroit, Michigan. Dr. Mikkelsen is also Staff Neuro-Oncologist, Division of Neurology, Department of Medicine, for the William Beaumont Cancer Center, in Royal Oak, Michigan. Dr. Mikkelsen received his B.S. degree from the University of Alberta and his M.D. from the University of Calgary.
Steven S. Brem, M.D.
Dr. Brem is Chief of the Neurosurgery Service, Director, Neuro-Oncology research laboratory, and Division Chief, Neuro-Oncology, for the H. Lee Moffitt Cancer Center & Research Institute of the University of South Florida. Dr. Brem also serves as a New Approaches to Brain Tumor Therapy (NABTT) Investigator. His research interests include frameless image-guided surgery, surgery of brain metastasis and malignant tumors, experimental therapeutics, anti-angiogenesis therapies, pituitary surgery and skull base surgery. Dr. Brem received a B.A. from Rutgers University and an M.D. from Harvard Medical School.
About Glioblastoma Multiforme
Brain cancer is diagnosed in approximately 200,000 patients per year, of which approximately 20,000 are primary tumors that arise within the brain and are not metastatic lesions from elsewhere in the body. Approximately 60% of primary brain cancers are diagnosed as GBM, the most aggressive and lethal form.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s two lead product candidates are:
DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial;
DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial.
CXCR4 is a therapeutic monoclonal antibody for treatment of solid tumors, and is in late pre-clinical development.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. Participation by Dr. Brem as a member of the Clinical Advisory Board does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Source: Northwest Biotherapeutics
Press Release Source: Northwest Biotherapeutics
Northwest Biotherapeutics to Present at the Williamsburg BioProcessing Foundation Conference
Thursday September 22, 7:30 am ET
BOTHELL, Wash., Sept. 22 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that the company will be presenting at the Williamsburg BioProcessing Foundation Cell and Tissue BioProcessing Conference 10th Annual Meeting in Newport Beach, California being held September 26th - 28th, 2005.
ADVERTISEMENT
click here
The presentation will be given by Marnix Bosch, Ph.D., Vice President, Vaccine Research and Development of Northwest Biotherapeutics. Dr. Bosch`s presentation is entitled, "DCVax®, a Versatile Dendritic Cell-Based Therapeutic Vaccine Platform for Cancer, and its Application to the Clinic," and is scheduled for Monday, September 26th at 8:30 am in the Four Seasons Newport Beach Hotel.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are: DCVax®- Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial, and CXCR4 is a therapeutic monoclonal antibody for treatment of solid tumors, and is in late preclinical development.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Source: Northwest Biotherapeutics
Northwest Biotherapeutics to Present at the Williamsburg BioProcessing Foundation Conference
Thursday September 22, 7:30 am ET
BOTHELL, Wash., Sept. 22 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that the company will be presenting at the Williamsburg BioProcessing Foundation Cell and Tissue BioProcessing Conference 10th Annual Meeting in Newport Beach, California being held September 26th - 28th, 2005.
ADVERTISEMENT
click here
The presentation will be given by Marnix Bosch, Ph.D., Vice President, Vaccine Research and Development of Northwest Biotherapeutics. Dr. Bosch`s presentation is entitled, "DCVax®, a Versatile Dendritic Cell-Based Therapeutic Vaccine Platform for Cancer, and its Application to the Clinic," and is scheduled for Monday, September 26th at 8:30 am in the Four Seasons Newport Beach Hotel.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are: DCVax®- Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial, and CXCR4 is a therapeutic monoclonal antibody for treatment of solid tumors, and is in late preclinical development.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax®-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Source: Northwest Biotherapeutics
Hallo an alle NW Bio-Investierten,
es wird doch langsam Zeit, daß sich etwas rührt, nicht nur hier an Board, sondern auch bei der Aktie!!
Mfg kurttilly
es wird doch langsam Zeit, daß sich etwas rührt, nicht nur hier an Board, sondern auch bei der Aktie!!
Mfg kurttilly
charttechnisch scheint es jetzt wieder interessant zu werden...
Hallo bio,
schön mal wieder von dir zu hören. Ich warte schon seit Tagen auf den Ausbruch. Der Chart sieht wirklich gut aus. Noch besser wäre es wenn was positives vom Unternehmen kommen würde. Ich denke aber das hier noch was zu verdienen ist.
Gruß prom
schön mal wieder von dir zu hören. Ich warte schon seit Tagen auf den Ausbruch. Der Chart sieht wirklich gut aus. Noch besser wäre es wenn was positives vom Unternehmen kommen würde. Ich denke aber das hier noch was zu verdienen ist.
Gruß prom
wieder sind ein paar Tage vergangen und nicht einmal mehr an der OTC gibts mehr nennenswerte Umsätze...
Gerade sind die ersten 350 Stücke des Tages gehandelt worden, immerhin um 21:00...
was sagt uns das?
Richtig, niemand hat mehr Lust zu verkaufen, es ist aber auch niemand da der mal richtig auf Einkaufstour geht!!
Wenn ich das noch so richtig in Erinnerung habe(:laugh, befinden wir uns gerade in einer PHASE III, die sicher noch im Herbst (wie angekündigt) Wissenswertes mit sich bringen wird.
Werft auch mal wieder einen Blick auf den Chart, der erscheint ebenfalls recht interessant - für mich riecht es hier förmlich nach Ausbruch
Gerade sind die ersten 350 Stücke des Tages gehandelt worden, immerhin um 21:00...
was sagt uns das?
Richtig, niemand hat mehr Lust zu verkaufen, es ist aber auch niemand da der mal richtig auf Einkaufstour geht!!
Wenn ich das noch so richtig in Erinnerung habe(:laugh, befinden wir uns gerade in einer PHASE III, die sicher noch im Herbst (wie angekündigt) Wissenswertes mit sich bringen wird.
Werft auch mal wieder einen Blick auf den Chart, der erscheint ebenfalls recht interessant - für mich riecht es hier förmlich nach Ausbruch
Hallo bio,
genau richtig. Der Chart sagt es ist was im Busch und zwar positives. Warum niemand kauft ist mir aber auch ein Rätsel.
Gruß prom
genau richtig. Der Chart sagt es ist was im Busch und zwar positives. Warum niemand kauft ist mir aber auch ein Rätsel.
Gruß prom
hallo prom,
wird schon werden - haben wir bis hierher Geduld gehabt, schaffen wir den Rest auch noch...
schönes WE
wird schon werden - haben wir bis hierher Geduld gehabt, schaffen wir den Rest auch noch...
schönes WE
Irgendwann im Oktober wird es Nachrichten geben und dann geht es steil nach oben, Geduld!!!
Hilfe,sie bewegt sich...
HALLO ich glaube ich werde mir auch mal10000Stück ins Depo legen. Die Chance ist da aber auch das Risiko!?
Läuft denn der Phase III - Test überhaupt schon ? Ich kann mich nur an die Meldung erinnern: "...will begin later this year" Habe über den Start bis jetzt noch nichts gelesen. Ich habe eigentlich mit Ergebnissen nicht vor Q2/06 gerechnet. Ausserdem rechne ich noch mit einer Kapitalerhöhung. Es ist ja schon viel Geld verbrannt worden. Und es wäre sinnvoller, das Ganze wieder mit etwas mehr Eigenkapital zu unterlegen. Ich weiss nicht, ob es für die Bilanz der Firma so gut wäre, wenn Toucan bis zum Ende der Forschung alles mit Krediten (zu 10,5 %) finanziert. Will aber die Aktie nicht schlecht machen. Ist ein hoffnungsvoller Wert.
Wann kommen endlich Neuigkeiten?
ICH glaube nun ist ein günstiger Augenblick ,um sich einige Aktien ins DEPO zu legen ,.zu einem Kurs von 0,14US$.ODER was sagt ihr denn dazu???
Es scheint es kommen bald Neuigkeiten, in den USA tut sich was!! Geh rein, ein Tipp!!
Schreib mal einer was, ist immer noch Geduld angesagt?
Bin heute rausgegangen kaum Umsatz in den USA:
Fußballtainer glaube ich hat Recht:
Es kommt Bewegung in NW-Bio!!!
kurtilly
Es kommt Bewegung in NW-Bio!!!
kurtilly
Hier passiert nichts mehr, jedenfalls im Moment nicht!
Gibt es was Neues!
Verkaufen oder Halten?
Gibt es was Neues!
Verkaufen oder Halten?
Stellt Euch vor gestern wurden in den USA ein par Aktien gehandelt, tut sich was oder nur Strohfeuer!!
Man muß halt auf Neuigkeiten hoffen und warten.Und Geduld haben.
... und dann geht`s mit Umsätzen nach Norden ..
mfg kurttilly
mfg kurttilly
Keine guten Nachrichten. Habe heute ein Posting gesehen, in dem steht, dass der Phase III - Test abgebrochen wurde. Warum die Firma keine Börsenmeldung rausgegeben hat...? Ich habe jedenfalls keine gesehen. Ich kopiere den Link mal hier rein. Macht Euch selbst ein Bild. Ziemlich enttäuschend, die Sache. Weil sich der Bericht über den Phase II - Test eigentlich sehr hoffnungsvoll las.
http://clinicaltrials.gov/show/NCT00043212
http://clinicaltrials.gov/show/NCT00043212
[posting]19.233.232 von stupidgame am 10.12.05 12:34:47[/posting]Meinst du das aus dem CSO-Board ?
Liest sich nicht sehr gut, aber warum wurde das nicht gemeldet - wenn das nicht kursbewegend ist was dann ?
.......
die phase III für das prostatakrebsmittel wurde vorzeitig abgebrochen (terminated anstatt completed). die gründe habe ich noch nicht rausgefunden, da sich alles in beredtes schweigen hüllt.
[vermutung]
schwerwiegende nebenwirkungen
erwiesene wirkungslosigkeit des meds
[/vermutung]
für ihr zweites mittel DCVac-brain (gegen hirntumore) haben sie von der FDA schon im juni die zulassung zum phase II test bekommen.
anfang september wurde die studie von nwbt auch angemeldet aber sie ist immer noch nicht für die probandenanmeldung freigegeben.
mit invests bei nwbt würde ich mich noch etwas zurückhalten.
mit der aktuellen kostenspirale wird nwbt bei toucan einen schweren stand haben. die schmeissen nicht lange gutes geld dem schlechten nach....
dcvac-prostate studie
http://clinicaltrials.gov/show/NCT00043212
kontaktinfo der university san diego
http://cancer.ucsd.edu/PatientCare/ClinicalTrials/study_deta…
dcvac-brain studie
http://www.clinicaltrials.gov/ct/show/NCT00045968?order=1 .......
Liest sich nicht sehr gut, aber warum wurde das nicht gemeldet - wenn das nicht kursbewegend ist was dann ?
.......
die phase III für das prostatakrebsmittel wurde vorzeitig abgebrochen (terminated anstatt completed). die gründe habe ich noch nicht rausgefunden, da sich alles in beredtes schweigen hüllt.
[vermutung]
schwerwiegende nebenwirkungen
erwiesene wirkungslosigkeit des meds
[/vermutung]
für ihr zweites mittel DCVac-brain (gegen hirntumore) haben sie von der FDA schon im juni die zulassung zum phase II test bekommen.
anfang september wurde die studie von nwbt auch angemeldet aber sie ist immer noch nicht für die probandenanmeldung freigegeben.
mit invests bei nwbt würde ich mich noch etwas zurückhalten.
mit der aktuellen kostenspirale wird nwbt bei toucan einen schweren stand haben. die schmeissen nicht lange gutes geld dem schlechten nach....
dcvac-prostate studie
http://clinicaltrials.gov/show/NCT00043212
kontaktinfo der university san diego
http://cancer.ucsd.edu/PatientCare/ClinicalTrials/study_deta…
dcvac-brain studie
http://www.clinicaltrials.gov/ct/show/NCT00045968?order=1 .......
[posting]19.251.989 von wayne99 am 12.12.05 07:44:16[/posting]Ja, das Posting meinte ich. Auf der Government-Trial-Seite steht ja eindeutig: TERMINATED. Ich weiss nicht, ob sie verpflichtet sind, darüber eine Börsenmitteilung rauszugeben. Wenn nicht, finde ich das schon einen schwerwiegenden Mangel in den Bestimmungen. Allerdings wurde auf Newswire auch niemals der Beginn des Tests gemeldet.
MfG.
MfG.
Die Hoffnung stirbt zuletzt!
2006 wird ein tolles Jahr!!
2006 wird ein tolles Jahr!!
Gibt´s was neues?
feiertag in usa - leider nix neues aus usa.
oder hat jemand eine andere info???
gruß
gm
oder hat jemand eine andere info???
gruß
gm
Da geht bald die Post ab. Strong buy. In USA auch schöne Umsätze.
na, hoffentlich geht´s so weiter!!!
Endlich fette News!!!
Kurs zieht gewaltig an!!!
RT 0.18 $
Northwest Biotherapeutics to Present New Data on CXCR4 at the Molecular Medicine Tri-Conference
CXCR4 Target Plays Central Role in Cancer Progression in More Than 75% of Cancers
BOTHELL, Wash., Feb. 17 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced that the company will be presenting new preclinical data on a monoclonal antibody to CXCR4 at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri- Conference, February 21st-24th at the Moscone North Convention Center in San Francisco, California. CXCR4 is one of the most important cancer targets discovered in recent years, because it plays a central role in all three stages of cancer progression, and because it does so in over 75% of all cancers. Northwest Biotherapeutics will participate in the Preclinical Development poster session at the CHI conference on Wednesday, February 22nd and Thursday, February 23rd. Company President, Alton L. Boynton will be available to discuss the findings and the planned development of CXCR4 as a promising new cancer therapy target.
CXCR4 is over-expressed in more than 75% of cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. NWBT has previously completed and reported on several preclinical studies using monoclonal antibodies to block CXCR4 receptor function, and reported significant inhibition of cancer cell proliferation, motility and invasion in multiple preclinical models both in vitro and in vivo.
NWBT`s study results are supported by a growing body of scientific literature confirming the key role of CXCR4 in all three major stages of cancer progression. Last month, researchers at the Vanderbilt-Ingram Cancer Center announced results from a preclinical study of CXCR4 in glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Reid Thompson, M.D., director of Neurosurgical Oncology, and his colleague, Moneeb Ehtesham, M.D., assistant professor of Neurological Surgery and Cancer Biology, were able to show a link between the expression of CXCR4 and the invasive behavior of brain tumor cells. This groundbreaking work supports NWBT`s own data indicating that blocking the expression of CXCR4 could result in an effective treatment option for those suffering from a wide variety of cancers.
It is well documented and accepted that CXCR4 plays an important role in all three fundamental aspects of cancer: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. `It is rare for a cancer-related protein to play an important role in all three functional stages of cancer cells, let alone to do so across many types of cancers,` stated Dr. Alton Boynton. He continued, `CXCR4 offers an exceptional therapeutic opportunity to prevent proliferation of primary tumors and to prevent the metastatic spread of the disease.`
In March 2005, Northwest Biotherapeutics announced that its United States patent had issued covering the broad use of CXCR4 antibodies for cancer therapeutics.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are: DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as `expects,` `believes,` `intends,` and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax(R)-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.
Source: PR Newswire (February 17, 2006 - 8:01 AM EST)
News by QuoteMedia
www.quotemedia.com
Kurs zieht gewaltig an!!!
RT 0.18 $
Northwest Biotherapeutics to Present New Data on CXCR4 at the Molecular Medicine Tri-Conference
CXCR4 Target Plays Central Role in Cancer Progression in More Than 75% of Cancers
BOTHELL, Wash., Feb. 17 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced that the company will be presenting new preclinical data on a monoclonal antibody to CXCR4 at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri- Conference, February 21st-24th at the Moscone North Convention Center in San Francisco, California. CXCR4 is one of the most important cancer targets discovered in recent years, because it plays a central role in all three stages of cancer progression, and because it does so in over 75% of all cancers. Northwest Biotherapeutics will participate in the Preclinical Development poster session at the CHI conference on Wednesday, February 22nd and Thursday, February 23rd. Company President, Alton L. Boynton will be available to discuss the findings and the planned development of CXCR4 as a promising new cancer therapy target.
CXCR4 is over-expressed in more than 75% of cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. NWBT has previously completed and reported on several preclinical studies using monoclonal antibodies to block CXCR4 receptor function, and reported significant inhibition of cancer cell proliferation, motility and invasion in multiple preclinical models both in vitro and in vivo.
NWBT`s study results are supported by a growing body of scientific literature confirming the key role of CXCR4 in all three major stages of cancer progression. Last month, researchers at the Vanderbilt-Ingram Cancer Center announced results from a preclinical study of CXCR4 in glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Reid Thompson, M.D., director of Neurosurgical Oncology, and his colleague, Moneeb Ehtesham, M.D., assistant professor of Neurological Surgery and Cancer Biology, were able to show a link between the expression of CXCR4 and the invasive behavior of brain tumor cells. This groundbreaking work supports NWBT`s own data indicating that blocking the expression of CXCR4 could result in an effective treatment option for those suffering from a wide variety of cancers.
It is well documented and accepted that CXCR4 plays an important role in all three fundamental aspects of cancer: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. `It is rare for a cancer-related protein to play an important role in all three functional stages of cancer cells, let alone to do so across many types of cancers,` stated Dr. Alton Boynton. He continued, `CXCR4 offers an exceptional therapeutic opportunity to prevent proliferation of primary tumors and to prevent the metastatic spread of the disease.`
In March 2005, Northwest Biotherapeutics announced that its United States patent had issued covering the broad use of CXCR4 antibodies for cancer therapeutics.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are: DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as `expects,` `believes,` `intends,` and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to enroll patients in the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax(R)-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.
Source: PR Newswire (February 17, 2006 - 8:01 AM EST)
News by QuoteMedia
www.quotemedia.com
Geduld zahlt sich aus....
[posting]20.260.679 von unic am 17.02.06 17:50:24[/posting]Kann mir einer das halbwegs übersetzten!
[posting]20.268.084 von Gummihund am 18.02.06 10:37:04[/posting]So, habe ein gutes Übersetzungsprogramm gefunden:
www.abacho.de
(p.s.: abacho ist übrigens eine geniale aktie)
BOTHELL, Waschen. am 17. Febr/PRNewswire-FirstCall/-Nordwesten Biotherapeutics (Nachrichten) (ANSCHLAGBRETT: NWBT.OB) heute gab bekannt, dass die Gesellschaft neue vorklinische Daten auf einem monoclonal Antikörper zu CXCR4 am Cambridge die 13. Jährliche Molekulare Medizin des Instituts von Healthtech Tri-Konferenz, am 21. Februar 24. am Moscone Nordtagungszentrum in San Francisco, Kalifornien präsentieren wird. CXCR4 ist eines der wichtigsten Krebs-Ziele entdeckt in den letzten Jahren, weil es eine Hauptrolle in allen drei Stufen des Krebs-Fortschritts spielt, und weil es so in mehr als 75 % aller Krebse tut. Nordwestlicher Biotherapeutics wird an der Vorklinischen Entwicklungsposter-Sitzung auf der CHI Konferenz am Mittwoch, dem 22. Februar und Donnerstag, der 23. Februar teilnehmen. Firmenpräsident, Alton L. Boynton wird verfügbar sein, um die Ergebnisse und die geplante Entwicklung von CXCR4 als ein vielversprechendes neues Krebs-Therapie-Ziel zu besprechen. CXCR4 wird in mehr als 75 % von Krebsen einschließlich des Busens überausgedrückt, der Lunge, des Doppelpunkts, der Vorsteherdrüse, der Niere, des Melanoms, des Gehirns, esophageal, Bauchspeicheldrüsen-, und vieler Formen der Leukämie, und Kindheitskrebse wie akute lymphocytic Leukämie und neuroblastoma Eierstock-. NWBT hat vorher vollendet und über mehrere vorklinische Studien berichtet, die monoclonal Antikörper zur Empfänger-Funktion des Blocks CXCR4 verwenden, und bedeutende Hemmung der Krebs-Zellenproliferation, motility und Invasion in vielfachen vorklinischen Modellen sowohl in vitro als auch in vivo gemeldet. Die Studienergebnisse von NWBT werden durch einen wachsenden Körper der wissenschaftlichen Literatur unterstützt, die die Schlüsselrolle von CXCR4 in allen drei Hauptstufen des Krebs-Fortschritts bestätigt. Im letzten Monat gaben Forscher am Vanderbilt-Ingram Krebs-Zentrum Ergebnisse von einer vorklinischen Studie von CXCR4 in glioblastoma multiforme (GBM), die aggressivste Form des Gehirnkrebss bekannt. Reid Thompson, M.D., Direktor von Neurochirurgischem Oncology, und seinem Kollegen, Moneeb Ehtesham, M.D., Helfer-Professor der Neurologischen Chirurgie- und Krebs-Biologie, waren im Stande, eine Verbindung zwischen dem Ausdruck von CXCR4 und dem angreifenden Benehmen von Gehirngeschwulst-Zellen zu zeigen. Die eigenen Daten von NWBT von Unterstützungen der Arbeit dieses groundbreaking, die anzeigen, dass das Blockieren des Ausdrucks von CXCR4 auf eine wirksame Behandlungsauswahl für diejenigen hinauslaufen konnte, die unter einem großen Angebot an Krebsen leiden. Es wird gut dokumentiert und akzeptierte, dass CXCR4 eine wichtige Rolle in allen drei grundsätzlichen Aspekten des Krebss spielt: Proliferation der primären Geschwulst, Wanderung von Geschwulst-Zellen weg von der primären Geschwulst, und Invasion und Errichtung von Metastasen an entfernten Seiten wie Knochen, Lunge und Gehirn. " Das ist für ein Protein über den Krebs selten, um eine wichtige Rolle in allen drei funktionellen Stufen von Krebs-Zellen zu spielen, ganz zu schweigen von, so über viele Typen von Krebsen zu tun," setzte Dr Alton Boynton fest. Er setzte fort, "bietet CXCR4 eine außergewöhnliche therapeutische Gelegenheit an, Proliferation von primären Geschwülsten zu verhindern und die Metastatic-Ausbreitung der Krankheit zu verhindern." Im März 2005 gab Nordwestlicher Biotherapeutics bekannt, dass sein USA-Patent die Bedeckung des breiten Gebrauches von CXCR4 Antikörpern für die Krebs-Therapeutik ausgegeben hatte. Über den Nordwestlichen Biotherapeutics Nordwesten ist Biotherapeutics eine Biotechnologie-Gesellschaft konzentriert, Immuntherapie-Produkte entwickelnd, die Krebse effektiver behandeln als gegenwärtige Behandlungen ohne Giftigkeit auf einer rentablen Basis. Die Gesellschaft hat zwei breite Plattform-Technologien: Dendritic-Zelle stützte Impfstoffe, und therapeutische Antikörper. Die drei Leitungsproduktkandidaten der Gesellschaft sind: DCVax (R) - Vorsteherdrüse, ein personifizierter dendritic Zellenimpfstoff für die Behandlung des Hormons unabhängiger non-metastatic Vorsteherdrüse-Krebs, der in eine Phase III klinische Probe eingeht; DCVax (R) - Gehirn, ein personifizierter dendritic Zellenimpfstoff für die Behandlung kürzlich diagnostizierten Glioblastoma multiforme, der in eine große Phase II klinische Probe eingeht; und CXCR4 ein therapeutischer monoclonal Antikörper in der späten vorklinischen Entwicklung für die Behandlung des Krebss. Für die weitere Information, besuchen Sie bitte die Firmenwebsite an http: // www.nwbio.com/. Behauptungen machten in dieser Pressemitteilung, die nicht sind, sind historische Tatsachen vorausschauende Behauptungen im Sinne des Privaten Sicherheitsstreitigkeitsreformgesetzes von 1995. Wörter wie "erwarten", "glaubt", "bestimmt", und ähnliche Ausdrücke sind beabsichtigt, um vorausschauende Behauptungen zu identifizieren. Wirkliche Ergebnisse können sich materiell von denjenigen unterscheiden, die in jeder vorausschauenden Behauptung geplant sind. Spezifisch gibt es mehrere wichtige Faktoren, die wirkliche Ergebnisse veranlassen konnten, sich materiell von denjenigen zu unterscheiden, die wie die Fähigkeit der Gesellschaft vorausgesehen sind, zusätzliche Hauptstadt, mit der Fähigkeit der Gesellschaft verbundene Gefahren zu erheben, Patienten in die geplante Probe der Phase III mit DCVax (R) - Vorsteherdrüse einzuschreiben und die Probe auf einer rechtzeitigen Basis, die Unklarheit des klinischen Probe-Prozesses zu vollenden, und ob DCVax-Vorsteherdrüse Sicherheit und Wirkung, Gefahren vereinigt mit der geplanten Phase II klinische Probe mit DCVax (R) - Gehirn und die geplante Phase I klinische Probe für nichtkleinen Zellenlungenkrebs demonstrieren und gehen wird und Hals-Krebs, und die rechtzeitige Leistung von Dritten. Die Zusatzinformation auf diesen und anderen Faktoren, die die Ergebnisse der Gesellschaft betreffen konnten, wird in seine Sicherheit und Austauschkommissionsfeilstaub eingeschlossen. Schließlich kann es andere Faktoren nicht erwähnt oben oder eingeschlossen in den SEC Feilstaub der Gesellschaft geben, der wirkliche Ergebnisse veranlassen kann, sich materiell diejenigen zu unterscheiden, die in jeder vorausschauenden Behauptung geplant sind. Sie sollten nicht übermäßiges Vertrauen auf irgendwelchen vorausschauenden Behauptungen legen. Die Gesellschaft nimmt keine Verpflichtung an, irgendwelche vorausschauenden Behauptungen infolge der neuen Information, zukünftigen Ereignisse oder Entwicklungen, außer, wie erforderlich, nach Sicherheitsgesetzen zu aktualisieren.
www.abacho.de
(p.s.: abacho ist übrigens eine geniale aktie)
BOTHELL, Waschen. am 17. Febr/PRNewswire-FirstCall/-Nordwesten Biotherapeutics (Nachrichten) (ANSCHLAGBRETT: NWBT.OB) heute gab bekannt, dass die Gesellschaft neue vorklinische Daten auf einem monoclonal Antikörper zu CXCR4 am Cambridge die 13. Jährliche Molekulare Medizin des Instituts von Healthtech Tri-Konferenz, am 21. Februar 24. am Moscone Nordtagungszentrum in San Francisco, Kalifornien präsentieren wird. CXCR4 ist eines der wichtigsten Krebs-Ziele entdeckt in den letzten Jahren, weil es eine Hauptrolle in allen drei Stufen des Krebs-Fortschritts spielt, und weil es so in mehr als 75 % aller Krebse tut. Nordwestlicher Biotherapeutics wird an der Vorklinischen Entwicklungsposter-Sitzung auf der CHI Konferenz am Mittwoch, dem 22. Februar und Donnerstag, der 23. Februar teilnehmen. Firmenpräsident, Alton L. Boynton wird verfügbar sein, um die Ergebnisse und die geplante Entwicklung von CXCR4 als ein vielversprechendes neues Krebs-Therapie-Ziel zu besprechen. CXCR4 wird in mehr als 75 % von Krebsen einschließlich des Busens überausgedrückt, der Lunge, des Doppelpunkts, der Vorsteherdrüse, der Niere, des Melanoms, des Gehirns, esophageal, Bauchspeicheldrüsen-, und vieler Formen der Leukämie, und Kindheitskrebse wie akute lymphocytic Leukämie und neuroblastoma Eierstock-. NWBT hat vorher vollendet und über mehrere vorklinische Studien berichtet, die monoclonal Antikörper zur Empfänger-Funktion des Blocks CXCR4 verwenden, und bedeutende Hemmung der Krebs-Zellenproliferation, motility und Invasion in vielfachen vorklinischen Modellen sowohl in vitro als auch in vivo gemeldet. Die Studienergebnisse von NWBT werden durch einen wachsenden Körper der wissenschaftlichen Literatur unterstützt, die die Schlüsselrolle von CXCR4 in allen drei Hauptstufen des Krebs-Fortschritts bestätigt. Im letzten Monat gaben Forscher am Vanderbilt-Ingram Krebs-Zentrum Ergebnisse von einer vorklinischen Studie von CXCR4 in glioblastoma multiforme (GBM), die aggressivste Form des Gehirnkrebss bekannt. Reid Thompson, M.D., Direktor von Neurochirurgischem Oncology, und seinem Kollegen, Moneeb Ehtesham, M.D., Helfer-Professor der Neurologischen Chirurgie- und Krebs-Biologie, waren im Stande, eine Verbindung zwischen dem Ausdruck von CXCR4 und dem angreifenden Benehmen von Gehirngeschwulst-Zellen zu zeigen. Die eigenen Daten von NWBT von Unterstützungen der Arbeit dieses groundbreaking, die anzeigen, dass das Blockieren des Ausdrucks von CXCR4 auf eine wirksame Behandlungsauswahl für diejenigen hinauslaufen konnte, die unter einem großen Angebot an Krebsen leiden. Es wird gut dokumentiert und akzeptierte, dass CXCR4 eine wichtige Rolle in allen drei grundsätzlichen Aspekten des Krebss spielt: Proliferation der primären Geschwulst, Wanderung von Geschwulst-Zellen weg von der primären Geschwulst, und Invasion und Errichtung von Metastasen an entfernten Seiten wie Knochen, Lunge und Gehirn. " Das ist für ein Protein über den Krebs selten, um eine wichtige Rolle in allen drei funktionellen Stufen von Krebs-Zellen zu spielen, ganz zu schweigen von, so über viele Typen von Krebsen zu tun," setzte Dr Alton Boynton fest. Er setzte fort, "bietet CXCR4 eine außergewöhnliche therapeutische Gelegenheit an, Proliferation von primären Geschwülsten zu verhindern und die Metastatic-Ausbreitung der Krankheit zu verhindern." Im März 2005 gab Nordwestlicher Biotherapeutics bekannt, dass sein USA-Patent die Bedeckung des breiten Gebrauches von CXCR4 Antikörpern für die Krebs-Therapeutik ausgegeben hatte. Über den Nordwestlichen Biotherapeutics Nordwesten ist Biotherapeutics eine Biotechnologie-Gesellschaft konzentriert, Immuntherapie-Produkte entwickelnd, die Krebse effektiver behandeln als gegenwärtige Behandlungen ohne Giftigkeit auf einer rentablen Basis. Die Gesellschaft hat zwei breite Plattform-Technologien: Dendritic-Zelle stützte Impfstoffe, und therapeutische Antikörper. Die drei Leitungsproduktkandidaten der Gesellschaft sind: DCVax (R) - Vorsteherdrüse, ein personifizierter dendritic Zellenimpfstoff für die Behandlung des Hormons unabhängiger non-metastatic Vorsteherdrüse-Krebs, der in eine Phase III klinische Probe eingeht; DCVax (R) - Gehirn, ein personifizierter dendritic Zellenimpfstoff für die Behandlung kürzlich diagnostizierten Glioblastoma multiforme, der in eine große Phase II klinische Probe eingeht; und CXCR4 ein therapeutischer monoclonal Antikörper in der späten vorklinischen Entwicklung für die Behandlung des Krebss. Für die weitere Information, besuchen Sie bitte die Firmenwebsite an http: // www.nwbio.com/. Behauptungen machten in dieser Pressemitteilung, die nicht sind, sind historische Tatsachen vorausschauende Behauptungen im Sinne des Privaten Sicherheitsstreitigkeitsreformgesetzes von 1995. Wörter wie "erwarten", "glaubt", "bestimmt", und ähnliche Ausdrücke sind beabsichtigt, um vorausschauende Behauptungen zu identifizieren. Wirkliche Ergebnisse können sich materiell von denjenigen unterscheiden, die in jeder vorausschauenden Behauptung geplant sind. Spezifisch gibt es mehrere wichtige Faktoren, die wirkliche Ergebnisse veranlassen konnten, sich materiell von denjenigen zu unterscheiden, die wie die Fähigkeit der Gesellschaft vorausgesehen sind, zusätzliche Hauptstadt, mit der Fähigkeit der Gesellschaft verbundene Gefahren zu erheben, Patienten in die geplante Probe der Phase III mit DCVax (R) - Vorsteherdrüse einzuschreiben und die Probe auf einer rechtzeitigen Basis, die Unklarheit des klinischen Probe-Prozesses zu vollenden, und ob DCVax-Vorsteherdrüse Sicherheit und Wirkung, Gefahren vereinigt mit der geplanten Phase II klinische Probe mit DCVax (R) - Gehirn und die geplante Phase I klinische Probe für nichtkleinen Zellenlungenkrebs demonstrieren und gehen wird und Hals-Krebs, und die rechtzeitige Leistung von Dritten. Die Zusatzinformation auf diesen und anderen Faktoren, die die Ergebnisse der Gesellschaft betreffen konnten, wird in seine Sicherheit und Austauschkommissionsfeilstaub eingeschlossen. Schließlich kann es andere Faktoren nicht erwähnt oben oder eingeschlossen in den SEC Feilstaub der Gesellschaft geben, der wirkliche Ergebnisse veranlassen kann, sich materiell diejenigen zu unterscheiden, die in jeder vorausschauenden Behauptung geplant sind. Sie sollten nicht übermäßiges Vertrauen auf irgendwelchen vorausschauenden Behauptungen legen. Die Gesellschaft nimmt keine Verpflichtung an, irgendwelche vorausschauenden Behauptungen infolge der neuen Information, zukünftigen Ereignisse oder Entwicklungen, außer, wie erforderlich, nach Sicherheitsgesetzen zu aktualisieren.
Strong buy! Super Meldung, Northwest Bio ist auf dem richtigen Weg.
Form 8-K for NORTHWEST BIOTHERAPEUTICS INC
21-Feb-2006
Financial Obligation Matter
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement.
On February 14, 2006, Northwest Biotherapeutics, Inc. (the "Company") and The Regents of the University of California entered into a clinical study for the University of California at Los Angeles ("UCLA") to carry out a booster vaccination immunotherapy program. This program involves patients that previously received at UCLA a dendritic cell based immunization, DCVax®-Brain, consisting of autologous dendritic cells loaded with autologous tumor cells. The clinical program is in accordance with the Company`s protocol entitled "Phase I Clinical Trial Evaluating Booster of DCVax®-Brain for Treatment of Glioblastoma". During the study, patients will receive up to five boosters over a 12 month period.
The Company will pay approximately $216,000, over the course of the study. The Company will incur no other costs in connection with this study, unless prior approval by the parties is made in writing. Item 7.01 Regulation FD Disclosure.
The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On January 31, 2006, Soma Partners, LLC filed with the Supreme Court of the state of New York a notice of petition to reverse or modify the court`s December 30, 2005 denial and dismissal of Soma Partners` August 29, 2005 petition to vacate the May 24, 2005 arbitration award in favor of the Company. See page 25 of the Company`s Quarterly Report on Form 10-Q for the quarter ended June 30, 2005, filed with the SEC on August 15, 2005, for a description of this matter.
21-Feb-2006
Financial Obligation Matter
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement.
On February 14, 2006, Northwest Biotherapeutics, Inc. (the "Company") and The Regents of the University of California entered into a clinical study for the University of California at Los Angeles ("UCLA") to carry out a booster vaccination immunotherapy program. This program involves patients that previously received at UCLA a dendritic cell based immunization, DCVax®-Brain, consisting of autologous dendritic cells loaded with autologous tumor cells. The clinical program is in accordance with the Company`s protocol entitled "Phase I Clinical Trial Evaluating Booster of DCVax®-Brain for Treatment of Glioblastoma". During the study, patients will receive up to five boosters over a 12 month period.
The Company will pay approximately $216,000, over the course of the study. The Company will incur no other costs in connection with this study, unless prior approval by the parties is made in writing. Item 7.01 Regulation FD Disclosure.
The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On January 31, 2006, Soma Partners, LLC filed with the Supreme Court of the state of New York a notice of petition to reverse or modify the court`s December 30, 2005 denial and dismissal of Soma Partners` August 29, 2005 petition to vacate the May 24, 2005 arbitration award in favor of the Company. See page 25 of the Company`s Quarterly Report on Form 10-Q for the quarter ended June 30, 2005, filed with the SEC on August 15, 2005, for a description of this matter.
Brain Cancer Patients Living Longer and Doing Better After Personalized Vaccine Therapy
Wednesday February 22, 8:00 am ET
Unprecedented Improvement in Survival Results in FDA Allowance of Booster Shots for Trial Participants
BOTHELL, Wash., Feb. 22 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB - News) today released updated findings from a Phase I clinical trial of the personalized cancer vaccine, DCVax®-Brain, showing that patients are surviving more than twice as long with DCVax®-Brain as with either of the two therapeutics currently approved by the FDA for Glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Based upon these findings, FDA allowance has been received and Northwest Biotherapeutics has entered into an agreement with the University of California at Los Angeles (UCLA) to begin providing booster shots to clinical trial participants. Dr. Linda Liau, Associate Professor of Neurosurgery and Director of the Malignant Brain Tumor Program at the UCLA School of Medicine, served as Principal Investigator for the trial.
ADVERTISEMENT
Patients in the trial were newly diagnosed with GBM, which affects between 18,000 and 20,000 Americans each year. Beyond surgery to remove the brain tumor and radiation therapy, there are only two treatments for GBM currently approved by the FDA. Those treatments have been shown in clinical trials to extend survival in GBM patients by only 2-3 months. In contrast, in the ongoing DCVax®-Brain Phase I clinical trial at UCLA, patients have experienced much longer extensions of survival, and longer periods before tumor recurrence.
Data from an earlier clinical trial at UCLA demonstrated that patient survival was more than twice as long for patients receiving DCVax®-Brain treatment than for patients receiving either of the two currently FDA-approved therapies. For the current clinical trial, as of February 1st, 2006, the findings appear to be even more significant:
-- 8 of 10 patients are still alive, with median survival of 20.5 months
(and continuing);
-- Survival time now ranges from 11.2 months to 39.0 months (and
continuing);
-- 5 of 10 patients continue to show no signs of cancer, with median
follow-up time of 32 months;
-- To date, median time to progression (i.e., tumor recurrence) is 14.7
months (and continuing);
-- 9 of 10 patients have surpassed the historical median time to
progression of 8 months;
-- 4 of 10 patients have survived over 30 months, and 5 of 10 patients
have survived over 24 months; and
-- 8 of 10 patients to date have surpassed the historical control median
survival of 15 months.
"Findings such as these, where we are seeing over half of our patients with GBM alive after two years, and 4 of 10 patients alive after two and one-half years, with other patients still continuing toward the two-year and two and one-half year marks, present a unique opportunity for us to make a significant difference in the lives of these patients," stated Dr. Alton L. Boynton, President and Chief Operating Officer of Northwest Biotherapeutics. "We believe that the results to date are particularly striking as the patients only received an initial series of injections and no booster shots. Now, with the FDA allowance and the agreement with UCLA, each patient will be able to receive up to five booster shots over the next 12 months. It is our hope that these booster injections will further enhance and sustain the patient`s immune response in attacking the cancer and preventing or delaying its recurrence."
The DCVax®-Brain personalized vaccine in clinical development is a type of immunotherapy designed to stimulate a patient`s own immune system to fight cancer. DCVax®-Brain is a simple injection made up of the patient`s own dendritic cells that have been "educated" to recognize and kill cancer cells bearing the biomarkers of the patient`s tumor. Dr. Boynton explained, "Each of these patients has undergone tumor removal at surgery as part of the current standard of care. We use some of those tumor cells, and the dendritic cells drawn from a sample of the patient`s blood, to teach the immune system to recognize the tumor cells as harmful so the body can work to eradicate them."
Northwest Biotherapeutics has received funding since 2004 from Toucan Capital Fund II, L.P. and Toucan Partners LLC for company operations and to financially support the booster vaccines to participants in this clinical trial. The Company plans to initiate a large Phase II clinical trial of DCVax®-Brain that is powered to serve as a pivotal trial in support of potential product registration. The trial has already been cleared by the U.S. FDA, and is expected to enroll 300 patients nationwide.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial recently cleared by the FDA ; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial recently cleared by the FDA; and monoclonal antibodies to CXCR4, which are in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to initiate, and enroll patients in, the planned Phase II trial of DCVax®-Brain and complete the trial on a timely basis, risks related to the Company`s ability to initiate, and enroll patients in, the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate or DCVax®-Brain will demonstrate safety and efficacy, risks associated with the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Source: Northwest Biotherapeutics, Inc.
Wednesday February 22, 8:00 am ET
Unprecedented Improvement in Survival Results in FDA Allowance of Booster Shots for Trial Participants
BOTHELL, Wash., Feb. 22 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB - News) today released updated findings from a Phase I clinical trial of the personalized cancer vaccine, DCVax®-Brain, showing that patients are surviving more than twice as long with DCVax®-Brain as with either of the two therapeutics currently approved by the FDA for Glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Based upon these findings, FDA allowance has been received and Northwest Biotherapeutics has entered into an agreement with the University of California at Los Angeles (UCLA) to begin providing booster shots to clinical trial participants. Dr. Linda Liau, Associate Professor of Neurosurgery and Director of the Malignant Brain Tumor Program at the UCLA School of Medicine, served as Principal Investigator for the trial.
ADVERTISEMENT
Patients in the trial were newly diagnosed with GBM, which affects between 18,000 and 20,000 Americans each year. Beyond surgery to remove the brain tumor and radiation therapy, there are only two treatments for GBM currently approved by the FDA. Those treatments have been shown in clinical trials to extend survival in GBM patients by only 2-3 months. In contrast, in the ongoing DCVax®-Brain Phase I clinical trial at UCLA, patients have experienced much longer extensions of survival, and longer periods before tumor recurrence.
Data from an earlier clinical trial at UCLA demonstrated that patient survival was more than twice as long for patients receiving DCVax®-Brain treatment than for patients receiving either of the two currently FDA-approved therapies. For the current clinical trial, as of February 1st, 2006, the findings appear to be even more significant:
-- 8 of 10 patients are still alive, with median survival of 20.5 months
(and continuing);
-- Survival time now ranges from 11.2 months to 39.0 months (and
continuing);
-- 5 of 10 patients continue to show no signs of cancer, with median
follow-up time of 32 months;
-- To date, median time to progression (i.e., tumor recurrence) is 14.7
months (and continuing);
-- 9 of 10 patients have surpassed the historical median time to
progression of 8 months;
-- 4 of 10 patients have survived over 30 months, and 5 of 10 patients
have survived over 24 months; and
-- 8 of 10 patients to date have surpassed the historical control median
survival of 15 months.
"Findings such as these, where we are seeing over half of our patients with GBM alive after two years, and 4 of 10 patients alive after two and one-half years, with other patients still continuing toward the two-year and two and one-half year marks, present a unique opportunity for us to make a significant difference in the lives of these patients," stated Dr. Alton L. Boynton, President and Chief Operating Officer of Northwest Biotherapeutics. "We believe that the results to date are particularly striking as the patients only received an initial series of injections and no booster shots. Now, with the FDA allowance and the agreement with UCLA, each patient will be able to receive up to five booster shots over the next 12 months. It is our hope that these booster injections will further enhance and sustain the patient`s immune response in attacking the cancer and preventing or delaying its recurrence."
The DCVax®-Brain personalized vaccine in clinical development is a type of immunotherapy designed to stimulate a patient`s own immune system to fight cancer. DCVax®-Brain is a simple injection made up of the patient`s own dendritic cells that have been "educated" to recognize and kill cancer cells bearing the biomarkers of the patient`s tumor. Dr. Boynton explained, "Each of these patients has undergone tumor removal at surgery as part of the current standard of care. We use some of those tumor cells, and the dendritic cells drawn from a sample of the patient`s blood, to teach the immune system to recognize the tumor cells as harmful so the body can work to eradicate them."
Northwest Biotherapeutics has received funding since 2004 from Toucan Capital Fund II, L.P. and Toucan Partners LLC for company operations and to financially support the booster vaccines to participants in this clinical trial. The Company plans to initiate a large Phase II clinical trial of DCVax®-Brain that is powered to serve as a pivotal trial in support of potential product registration. The trial has already been cleared by the U.S. FDA, and is expected to enroll 300 patients nationwide.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial recently cleared by the FDA ; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial recently cleared by the FDA; and monoclonal antibodies to CXCR4, which are in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to initiate, and enroll patients in, the planned Phase II trial of DCVax®-Brain and complete the trial on a timely basis, risks related to the Company`s ability to initiate, and enroll patients in, the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate or DCVax®-Brain will demonstrate safety and efficacy, risks associated with the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Source: Northwest Biotherapeutics, Inc.
Da bin ich ja gespannt, wie die Aktie auf obige Nachricht reagiert, die Ergebnise der ersten Phase sind äußerst vielversprechend - Phase II ist finanziert und läuft nun an
+40% heute auf 0,28$ , läuft ja ganz gut bis jetzt
RT: NWBT.OB 1:51pm 0.28 +0.08 +40.00% 0.27 + 0.28 553,330
RT: NWBT.OB 1:51pm 0.28 +0.08 +40.00% 0.27 + 0.28 553,330
Immer schön langsam nach oben, die Aktie wird der Renner.
NWBT -- Northwest Biotherapeutics, Inc.
Com ($0.001)
Primary Venue: Dually Quoted on Pink Sheets and OTC Bulletin Board
Best Bid: Unpriced
Best Ask: Unpriced
TRADE DATA Best Bid: 0.2700 Best Ask: 0.2800
Last Sale: 0.2800
Change: +0.0800
Percent Change: +40.00
Tick: Up
Daily High: 0.2800 Daily Low: 0.2100
Opening Price: 0.2300 Volume: 625,330
Annual High: 0.3000
Annual Low: 0.0850
Com ($0.001)
Primary Venue: Dually Quoted on Pink Sheets and OTC Bulletin Board
Best Bid: Unpriced
Best Ask: Unpriced
TRADE DATA Best Bid: 0.2700 Best Ask: 0.2800
Last Sale: 0.2800
Change: +0.0800
Percent Change: +40.00
Tick: Up
Daily High: 0.2800 Daily Low: 0.2100
Opening Price: 0.2300 Volume: 625,330
Annual High: 0.3000
Annual Low: 0.0850
NWBT.OB 2:40pm 0,32 +0.12 +60.00% 0.31 + 0.32 755,830
Jetzt gehts aber ab
Jetzt gehts aber ab
NWBT.OB 2:41pm 0.35 +0.15 +75.00% 0.35 + 0.37 792,155
Einfach nur
Einfach nur
cool was wayne
[posting]20.332.595 von Zentimeter am 22.02.06 20:46:58[/posting]Wird auch Zeit - habe schließlich gestern welche gekauft
Seit meiner Empfehlung über 100%! Aber die letzte news ist der Hammer!!!! in Kürze 0,50! Umsätze fangen gerade erst an sich zu entwickeln und noch keinerlei Hype der einschlägigen Börsenblättchen! COOOOOL!
Hier nochmal ein Detail der news davor! Waaahnsinn!
CXCR4 is over-expressed in more than 75% of cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. NWBT has previously completed and reported on several preclinical studies using monoclonal antibodies to block CXCR4 receptor function, and reported significant inhibition of cancer cell proliferation, motility and invasion in multiple preclinical models both in vitro and in vivo.
CXCR4 is over-expressed in more than 75% of cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. NWBT has previously completed and reported on several preclinical studies using monoclonal antibodies to block CXCR4 receptor function, and reported significant inhibition of cancer cell proliferation, motility and invasion in multiple preclinical models both in vitro and in vivo.
NWBT.OB 3:31pm 0.45 +0.25 +125.00% 0.41 0.45 1,158,760
Wahnsinn
Wahnsinn
Price Data Table
Open 0.23
Previous Close 0.49
Exchange of Last Sale OTCBB
Time of Last Sale 15:41:36
Nach 125% Morgen 30 und Übermorgen 15.....
Na, was ist den die letzten 2 Stunden passiert?
Hab` hier eine richtig fette Ralley versäumt. Mich wundert allerdings, daß auf die Meldung vom 17.02. erst so spät reagiert wird.
RT aktuell 0.45 $
Hab` hier eine richtig fette Ralley versäumt. Mich wundert allerdings, daß auf die Meldung vom 17.02. erst so spät reagiert wird.
RT aktuell 0.45 $
SK 0.45 $
Macht Vorfreude auf Eröffnung in Germany.
Macht Vorfreude auf Eröffnung in Germany.
Die Dimensio der Meldung wird langsam erkannt! Ist geradezu revolutionär! Schön festhalten die Teilchen...
Dimension...
Bei DAB nicht handelbar.
motte
motte
-- 8 of 10 patients are still alive, with median survival of 20.5 months
(and continuing);
-- Survival time now ranges from 11.2 months to 39.0 months (and
continuing);
-- 5 of 10 patients continue to show no signs of cancer, with median
follow-up time of 32 months;
-- To date, median time to progression (i.e., tumor recurrence) is 14.7
months (and continuing);
-- 9 of 10 patients have surpassed the historical median time to
progression of 8 months;
-- 4 of 10 patients have survived over 30 months, and 5 of 10 patients
have survived over 24 months; and
-- 8 of 10 patients to date have surpassed the historical control median
survival of 15 months.
`Findings such as these, where we are seeing over half of our patients with GBM alive after two years, and 4 of 10 patients alive after two and one-half years, with other patients still continuing toward the two-year and two and one-half year marks, present a unique opportunity for us to make a significant difference in the lives of these patients,` stated Dr. Alton L. Boynton, President and Chief Operating Officer of Northwest Biotherapeutics. `We believe that the results to date are particularly striking as the patients only received an initial series of injections and no booster shots. Now, with the FDA allowance and the agreement with UCLA, each patient will be able to receive up to five booster shots over the next 12 months. It is our hope that these booster injections will further enhance and sustain the patient`s immune response in attacking the cancer and preventing or delaying its recurrence.`
(and continuing);
-- Survival time now ranges from 11.2 months to 39.0 months (and
continuing);
-- 5 of 10 patients continue to show no signs of cancer, with median
follow-up time of 32 months;
-- To date, median time to progression (i.e., tumor recurrence) is 14.7
months (and continuing);
-- 9 of 10 patients have surpassed the historical median time to
progression of 8 months;
-- 4 of 10 patients have survived over 30 months, and 5 of 10 patients
have survived over 24 months; and
-- 8 of 10 patients to date have surpassed the historical control median
survival of 15 months.
`Findings such as these, where we are seeing over half of our patients with GBM alive after two years, and 4 of 10 patients alive after two and one-half years, with other patients still continuing toward the two-year and two and one-half year marks, present a unique opportunity for us to make a significant difference in the lives of these patients,` stated Dr. Alton L. Boynton, President and Chief Operating Officer of Northwest Biotherapeutics. `We believe that the results to date are particularly striking as the patients only received an initial series of injections and no booster shots. Now, with the FDA allowance and the agreement with UCLA, each patient will be able to receive up to five booster shots over the next 12 months. It is our hope that these booster injections will further enhance and sustain the patient`s immune response in attacking the cancer and preventing or delaying its recurrence.`
Also Hana steht jetzt bei 6,88! Ist doch mal eine Orientierung.....
Bin schon relativ lange in diesem Wert. Geduld scheint sich ab und zu doch auszuzahlen.
Wenn ich mir die neuesten Studien und Ergebnisse ansehen, dann dürfen wir behaupten, wir haben einen potentiellen
Tenbagger!!!!!!!!!
Wenn ich mir die neuesten Studien und Ergebnisse ansehen, dann dürfen wir behaupten, wir haben einen potentiellen
Tenbagger!!!!!!!!!
Haben wir!
Nachbörslich wird auch noch beträchtlich die 0.45 $ abgegrast!
So was habe ich bei NWBT noch nicht gesehen!
Das macht Spaß auf Morgen!
So was habe ich bei NWBT noch nicht gesehen!
Das macht Spaß auf Morgen!
[posting]20.334.239 von unic am 22.02.06 22:10:37[/posting]Meine Orientierung liegt einiges höher. Nicht morgen aber in naher Zukunft. Bin etwas traurig das ich nicht nochmal billig nachgekauft habe. Einige liegen aber im Depot und das ist gut so. Nur nicht die Nerven verlieren.
Allen investierten viel Erfolg.
Allen investierten viel Erfolg.
americanbulls hat ein WAIT....
Na gut warten wir bis morgen
Na gut warten wir bis morgen
In FWB erster Kurs 0,53€ mit 45k - wenn es nur immer so leicht wäre beim Geldverdienen
NWBT zieht aber heute mächtig nach ... und das ist erst der Anfang !!!.
War ja auch eine Steilvorlage von der OTC-BB!
RT 0.53 EUR
Bid 0.50 / Ask 0.55
War ja auch eine Steilvorlage von der OTC-BB!
RT 0.53 EUR
Bid 0.50 / Ask 0.55
Das Ding fängt an zu fliegen!
Schön, dieses Ei im Nest zu haben.
RT 0.55 EUR
BID 0.53 / ASK 0.59
Schön, dieses Ei im Nest zu haben.
RT 0.55 EUR
BID 0.53 / ASK 0.59
... und die Show geht weiter!
Berlin
RT 0.60 EUR :eek
Ein neuer Stern am Biotech-Himmel. Und dieser wird erst geboren.
Berlin
RT 0.60 EUR :eek
Ein neuer Stern am Biotech-Himmel. Und dieser wird erst geboren.
Hallo, heute werden wir knapp an 1 Euro ran kommen. Ziel bei den Infos wird in Bälde 3-5 Euro sein. Also freuen wir uns.
Einsteigen und Türen schließen bzw. Shares festhalten. Zug ist kurz vor Abfahrt.
Von Anfang an mit dabeisein. Ihr wisst ja, wer zu spät kommt, den bestraft ....
Von Anfang an mit dabeisein. Ihr wisst ja, wer zu spät kommt, den bestraft ....
Ruhe?
seeehr interessant
-- 8 of 10 patients are still alive, with median survival of 20.5 months
(and continuing);
-- Survival time now ranges from 11.2 months to 39.0 months (and
continuing);
-- 5 of 10 patients continue to show no signs of cancer, with median
follow-up time of 32 months;
-- To date, median time to progression (i.e., tumor recurrence) is 14.7
months (and continuing);
-- 9 of 10 patients have surpassed the historical median time to
progression of 8 months;
-- 4 of 10 patients have survived over 30 months, and 5 of 10 patients
have survived over 24 months; and
-- 8 of 10 patients to date have surpassed the historical control median
survival of 15 months.
dass würde doch heissen dass 5 von 10 Patienten mit Gehrin Krebs nach der Behandlung auch 32 Monate nach beginn keine Anzeichen mehr auf Krebs haben
auf "deutsch"
die hälfte der Patienten ist nach der Behandlung vom Krebs geheilt...........
sollte dass auch nur annähernd zutreffen
müsste die Marketcap nicht bei 8 Mio Dollar liegen
sonder wohl eher um dass 100fache mehr bei 800 Millionen Dollar...........
auch wenn mir dass ganze schon fast zu positiv aussieht..............
-- 8 of 10 patients are still alive, with median survival of 20.5 months
(and continuing);
-- Survival time now ranges from 11.2 months to 39.0 months (and
continuing);
-- 5 of 10 patients continue to show no signs of cancer, with median
follow-up time of 32 months;
-- To date, median time to progression (i.e., tumor recurrence) is 14.7
months (and continuing);
-- 9 of 10 patients have surpassed the historical median time to
progression of 8 months;
-- 4 of 10 patients have survived over 30 months, and 5 of 10 patients
have survived over 24 months; and
-- 8 of 10 patients to date have surpassed the historical control median
survival of 15 months.
dass würde doch heissen dass 5 von 10 Patienten mit Gehrin Krebs nach der Behandlung auch 32 Monate nach beginn keine Anzeichen mehr auf Krebs haben
auf "deutsch"
die hälfte der Patienten ist nach der Behandlung vom Krebs geheilt...........
sollte dass auch nur annähernd zutreffen
müsste die Marketcap nicht bei 8 Mio Dollar liegen
sonder wohl eher um dass 100fache mehr bei 800 Millionen Dollar...........
auch wenn mir dass ganze schon fast zu positiv aussieht..............
[posting]20.339.533 von wiener9 am 23.02.06 11:24:14[/posting]Das heisst aber auch:
keine Shares aus der Hand geben! Das wird ein Tenbagger!
und dies kurzfristig!
keine Shares aus der Hand geben! Das wird ein Tenbagger!
und dies kurzfristig!
Was denkt ihr? Wohin gehts wenn Übersee öffnet???
Hi,
beobachte NWBT auch schon seit über 1 Jahr und denke
nun könnte die Rakete mal langsam zünden
Die Mk ist doch immernoch ein Witz!
MfG
gerl
beobachte NWBT auch schon seit über 1 Jahr und denke
nun könnte die Rakete mal langsam zünden
Die Mk ist doch immernoch ein Witz!
MfG
gerl
Hoffe in nördliche Regionen
naja, die kommen immerhin von 5 US Doller.... warten wir mach noch ein wenig...
[posting]20.343.056 von BrsenBunny am 23.02.06 14:22:58[/posting]Rechne mit Eröffnung jenseits von 0.50 $.
BID und ASK setzen sich schon eine gute Stunde vor Eröffnung deutlich Richtung 0.50 ab.
Gruß
BID und ASK setzen sich schon eine gute Stunde vor Eröffnung deutlich Richtung 0.50 ab.
Gruß
Bid steigt kont.
aktuell 0.49 $
aktuell 0.49 $
BID steigt weiter
RT 0.53 $
RT 0.53 $
Sorry,
wollte sagen RT 0.56 $
wollte sagen RT 0.56 $
Erster Kurs?
Eröffnung RT 0.54 $
0,57$ ist doch erst ne Marke
Kurs
RT 0.47 $ Volumen bereits 615 K
Erster Abverkauf und GAP geschlossen. Jetzt kann wieder aufwärts gehen.
RT 0.47 $ Volumen bereits 615 K
Erster Abverkauf und GAP geschlossen. Jetzt kann wieder aufwärts gehen.
erstmal die Ängstlichen rausschütteln
Sieht eher nach Absturz aus.
Das ging aber rasant nach unten bis 0,33$ - da war mein Verkauf am Morgen ja richtig gut - nun aber schon wieder 0,39$
Wa doch nur etwas Schüttelei.
Immer das gleiche!
Kaum gehustet, schon ist der Hühnerhaufen aufgescheucht!
Sind doch immer die gleichen Spielchen ... und funktionieren auch immer wieder.
Kaum gehustet, schon ist der Hühnerhaufen aufgescheucht!
Sind doch immer die gleichen Spielchen ... und funktionieren auch immer wieder.
RT NWBT.OB 10:42am 0.42 -0.03 -6.67% 0.38 + 0.42 1,201,866
Jetzt iss dann aber genug geschüttelt....
immer ruhig das wird schon-that`s OTC
nach solch kräftigen sprung muss auch mal Luft geholt werden-
jedem der sich nicht sicher ist kann ich nur empfehlen-->verkaufen
an den den fakten hat sich nichts geändert
jedem der sich nicht sicher ist kann ich nur empfehlen-->verkaufen
an den den fakten hat sich nichts geändert
bald 10% der aktien gehandelt--respekt
steig du sau
www.nwbio.com/about_executives.php
Na ja, der obere Doc sieht zumindest irgendwie seriös aus.
Na ja, der obere Doc sieht zumindest irgendwie seriös aus.
fesche burschen
Auszug aus der Info vom 17.02. siehe Homepage NWBT.com
Northwest Biotherapeutics will participate in the Preclinical Development poster session at the CHI conference on Wednesday, February 22nd and Thursday, February 23rd. Company President, Alton L. Boynton will be available to discuss the findings and the planned development of CXCR4 as a promising new cancer therapy target.
Frage: hat jemand schon irgendwo etwas über diese veranstaltung gehört (irgendein feedback??).
kann evtl. i. d. n. tagen eine weitere info folgen? oder erläutern die auf dieser veranstaltung nur das, was sie in der info vom 22.02. geschrieben haben??
Northwest Biotherapeutics will participate in the Preclinical Development poster session at the CHI conference on Wednesday, February 22nd and Thursday, February 23rd. Company President, Alton L. Boynton will be available to discuss the findings and the planned development of CXCR4 as a promising new cancer therapy target.
Frage: hat jemand schon irgendwo etwas über diese veranstaltung gehört (irgendein feedback??).
kann evtl. i. d. n. tagen eine weitere info folgen? oder erläutern die auf dieser veranstaltung nur das, was sie in der info vom 22.02. geschrieben haben??
[posting]20.363.665 von gerl28 am 24.02.06 15:17:46[/posting]scheint wohl weiter abwärts zu gehen. schade eigentlich. ich hab die dinger seit einer halben ewigkeit bei 21 cent gekauft. hatte überlegt, ob ich sie bei 50 cent verkaufen sollte. war wohl etwas zögerlich
was meint ihr, halten oder ...
was meint ihr, halten oder ...
...halten und beim nächsten Hype raus.
es MUSS aufwärts gehen.
Halten, Halten, Halten
Halten, Halten, Halten
ich für mein teil werde die aktie noch länger halten und
zu günstigen kursen nachlegen
die tests beginnen doch nun erst an einer grösseren anzahl
erkrankter personen-die finanzielle lage bei NWBT ist erstmal
entspannt und bei positiven ergebnissen wird das teil in die höhe schiessen
ich habe zeit und noch etwas spielgeld zum nachkaufen
zu günstigen kursen nachlegen
die tests beginnen doch nun erst an einer grösseren anzahl
erkrankter personen-die finanzielle lage bei NWBT ist erstmal
entspannt und bei positiven ergebnissen wird das teil in die höhe schiessen
ich habe zeit und noch etwas spielgeld zum nachkaufen
Normalerweise verlieren die Otc Werte nach einem derartigen Hype in den folgenden Tag mindestens 50% ihres
Wertes. Das ist bei NWBT bis heute nicht der Fall.
Einerseits sollte uns das froh stimmen, aber bei
etwas günstigeren Ständen würd ich allerdings schon gerne
nachlegen.
Wertes. Das ist bei NWBT bis heute nicht der Fall.
Einerseits sollte uns das froh stimmen, aber bei
etwas günstigeren Ständen würd ich allerdings schon gerne
nachlegen.
[posting]20.366.349 von vergaser am 24.02.06 17:09:50[/posting]RT 0.42 $
na Leute, unsere Krebsaktie
ist ja im Plus, hätte ich so schnell nicht gedacht.
wer hat denn mitgelitten ??
viele sind wir hier wohl nicht ??
kassier-
ist ja im Plus, hätte ich so schnell nicht gedacht.
wer hat denn mitgelitten ??
viele sind wir hier wohl nicht ??
kassier-
[posting]20.367.471 von kassier am 24.02.06 17:59:19[/posting]Also ich hab`s ausgesessen. Wohl oder übel.
War leider zu gierig. Mein Verstand sagte verkaufen bei 0.5X.
Nur - wirkliche Investoren warten den Hype erstmal ab und steigen ein, wenn das Interesse abflacht und der Wert konsolidiert. Denke, tendenziell dürfte dies momentan anlaufen.
... übrigens RT 0.44 $
War leider zu gierig. Mein Verstand sagte verkaufen bei 0.5X.
Nur - wirkliche Investoren warten den Hype erstmal ab und steigen ein, wenn das Interesse abflacht und der Wert konsolidiert. Denke, tendenziell dürfte dies momentan anlaufen.
... übrigens RT 0.44 $
Hattet ihr Zweifel? Habe das Teil aber ein bisserl getradet, war ja vorauszusehen und 0, 53 waren zu verlockend! Bei 0,28 wieder zugeschlagen....
das wird schon
und die nächste zeit wird`s wohl noch einige news geben
und die nächste zeit wird`s wohl noch einige news geben
[posting]20.368.007 von unic am 24.02.06 18:26:58[/posting]Ja unic,
konsequent. Ich hatte den Finger zu lange am Abzug.
Ach übrigens
RT 0.45 $
Bid 0.44 $
Volumen 643 K
konsequent. Ich hatte den Finger zu lange am Abzug.
Ach übrigens
RT 0.45 $
Bid 0.44 $
Volumen 643 K
[posting]20.368.071 von paloma am 24.02.06 18:30:47[/posting]da habt ihr Recht. -Gier frisst Hirn, möchte mal wissen wann ich nach so viel Jahren mal konsequent werde.
immer meint man, das gibt die Jahrhundertaktie, jetzt ist man dabei...und...und..
--aber zu unseren shares..
...das Wort Krebs weckt alles auf...
wenn da wirklich mal der Durchbruch kommt....das wird wirklich ein Wert der alles bisherige schlagen wird.
kassier--
immer meint man, das gibt die Jahrhundertaktie, jetzt ist man dabei...und...und..
--aber zu unseren shares..
...das Wort Krebs weckt alles auf...
wenn da wirklich mal der Durchbruch kommt....das wird wirklich ein Wert der alles bisherige schlagen wird.
kassier--
http://www.investorshub.com/boards/quotes.asp?ticker=SWKJ&qm…
So und Montag wieder über Pari
So und Montag wieder über Pari
Langsam und unauffällig!
Chart gibt einiges her.
http://isht.comdirect.de/html/detail/main.html?DEBUG=0&hist=…
RT 0.46 $
Chart gibt einiges her.
http://isht.comdirect.de/html/detail/main.html?DEBUG=0&hist=…
RT 0.46 $
Zur Info an alle Longies und Neuinvestierten:
RT 0.48 $
Bid 0.48 Volumen 780 K
RT 0.48 $
Bid 0.48 Volumen 780 K
habe gerade nochmal zugekauft !!!
die Story kann besser sein als bei einem Goldexplorer.
kassier-
die Story kann besser sein als bei einem Goldexplorer.
kassier-
[posting]20.368.574 von kassier am 24.02.06 18:57:15[/posting]Es geht beständig weiter
RT 0.49 $
Bid 0.49 $ Vol. 790K
RT 0.49 $
Bid 0.49 $ Vol. 790K
die letzten PRs waren ja mehr als vielversprechend
dass einzige was die Anleger noch etwas abschrecken dürfte
ist die Tatsache dass die letzte hervorragende Studie auf Klinische Tests der Phase eins beruht
was bedeuted dass eine mögliche Zulassung wohl noch ein paar Jahre dauert
dass einzige was die Anleger noch etwas abschrecken dürfte
ist die Tatsache dass die letzte hervorragende Studie auf Klinische Tests der Phase eins beruht
was bedeuted dass eine mögliche Zulassung wohl noch ein paar Jahre dauert
[posting]20.368.609 von wiener9 am 24.02.06 18:59:47[/posting]Nur der Inhalt der Studie und die Ergebnisse der Phase I sind ja mit Verlaub nicht nur vielversprechende, sondern
bahnbrechende News!
RT 0.50 $
bahnbrechende News!
RT 0.50 $
[posting]20.368.609 von wiener9 am 24.02.06 18:59:47[/posting]da hast du wieder Recht,
ich komme aus der Pharmabranche
da kommen noch Phase 2 und 3 und ne Menge Feldversuche.
wobei es reicht, wenn in Phase 2 eine gute Nachricht kommt,denn dann funzt es wohl.
und wenns was wird, wird das wirklich ein irres Ding.
kassier-
ich komme aus der Pharmabranche
da kommen noch Phase 2 und 3 und ne Menge Feldversuche.
wobei es reicht, wenn in Phase 2 eine gute Nachricht kommt,denn dann funzt es wohl.
und wenns was wird, wird das wirklich ein irres Ding.
kassier-
weiter
RT 0.50 $
Bid 0.5 $ 50 x 25
Vol. 805k
RT 0.50 $
Bid 0.5 $ 50 x 25
Vol. 805k
kontinuierlich UP!
RT 0.51 $
Bid 0.50 $ 50 x 25
Vol. 900k
RT 0.51 $
Bid 0.50 $ 50 x 25
Vol. 900k
Kaum Umsätze und das Ding steigt. Da dreht doch einer was?!
[posting]20.368.905 von HoTsTePPa. am 24.02.06 19:15:57[/posting]ich dreh am rad !!!
[posting]20.368.905 von HoTsTePPa. am 24.02.06 19:15:57[/posting]Kaum Umsätze?
900k sind für NWBT aber absolut außergewöhnlich!
900k sind für NWBT aber absolut außergewöhnlich!
[posting]20.369.009 von paloma am 24.02.06 19:21:44[/posting]ja, 1,9 mio warns gestern am Ende.
so , jetzt gehts auf die Couch und TV
PC laufen lassen und immer mal reinlinsen
bis nach 22 Uhr
kassier-
so , jetzt gehts auf die Couch und TV
PC laufen lassen und immer mal reinlinsen
bis nach 22 Uhr
kassier-
Dieser Anstieg ist gefälliger als letzterer Hype.
Nach dieser Manier macht Shorten keinen Spaß.
weiter
RT 0.51 $ Vol. 918k
Nach dieser Manier macht Shorten keinen Spaß.
weiter
RT 0.51 $ Vol. 918k
Montag fette Beute....
....hätte nicht gedacht, dass wir uns nochmal so erholen.
Schönes Wochenende !
Hoffentlich schieben wir Montag nochmal was nach...
Schönes Wochenende !
Hoffentlich schieben wir Montag nochmal was nach...
gut n8
prima ists gelaufen.
kassier-
prima ists gelaufen.
kassier-
naja so optimistisch bin ich nun nicht unbedingt, waren schnelle 100 Prozent und gut
die vielen Jahre das viele Geld(was sie leider net haben) um dann zu erkennen das man doch was übersehen hat
da gibts andere Kanditaten die weiter sind und net viel teurer, also bei der Auswahl kein Grund zu zocken
die vielen Jahre das viele Geld(was sie leider net haben) um dann zu erkennen das man doch was übersehen hat
da gibts andere Kanditaten die weiter sind und net viel teurer, also bei der Auswahl kein Grund zu zocken
[posting]20.383.100 von Zentimeter am 25.02.06 20:38:46[/posting]welche Werte meinst denn da, zum Beispiel ??
kassier-
kassier-
Buy-If Signal generiert lt. Americanbulls.
Fast 55% Minus
Was ist los??
Ein Karnevals-Geck??
Hat aber nichts mit buy-if aus USA zu tun!!
Müsste in USA auch heute 50% runter gehen -- haha
Dann kauf ich eben schnell nach!!!
Was ist los??
Ein Karnevals-Geck??
Hat aber nichts mit buy-if aus USA zu tun!!
Müsste in USA auch heute 50% runter gehen -- haha
Dann kauf ich eben schnell nach!!!
[posting]20.397.648 von huenerhaufen30 am 27.02.06 09:48:08[/posting]Der Pari-Kurs liegt bei 0.369 EUR. Wirklich Super-Nachkaufgelegenheit.
Da laufen üble Spiele in Frankfurt. Kurs wurde solange künstlich gedrückt, bis ein großer Käufer - 153K - bedient wurde.
Ich habe gekauft.....
Heute noch 0,40 Geld.....
Heute noch 0,40 Geld.....
StammdatenWKN
728853
KursdatenAktuell
0,240
Zeit
27.02.06 09:58:11
Diff. Vortag
-45,45 %
Tages-Vol.
32.095
Geh. Stück
159.173
Geld
0,210
Brief
0,250
Zeit
27.02.06 09:58:15
Geld Stk.
5.000
Brief Stk.
5.000
Vortag
0,440
Eröffnung
0,310
Hoch
0,310
Tief
0,200
ISIN
US66737P1057
Letzte Kurse Zeit Kurs Volumen
09:58:11 0,240 1000
09:43:13 0,200 3173
09:43:10 0,200 153000 SL?
09:11:01 0,310 2000
728853
KursdatenAktuell
0,240
Zeit
27.02.06 09:58:11
Diff. Vortag
-45,45 %
Tages-Vol.
32.095
Geh. Stück
159.173
Geld
0,210
Brief
0,250
Zeit
27.02.06 09:58:15
Geld Stk.
5.000
Brief Stk.
5.000
Vortag
0,440
Eröffnung
0,310
Hoch
0,310
Tief
0,200
ISIN
US66737P1057
Letzte Kurse Zeit Kurs Volumen
09:58:11 0,240 1000
09:43:13 0,200 3173
09:43:10 0,200 153000 SL?
09:11:01 0,310 2000
Geld
0,230
Brief
0,280
Es geht losssssss....
0,230
Brief
0,280
Es geht losssssss....
bin bei 0,2 rein
Das ist richtig!
Denn ich habe eine Kauforder bei 0,25 plaziert
und wurde immer noch nicht ausgeführt!!!
So manchen Markler könnte ich sonst wo hin treten.
Sobald USA eröffnet, und das wohl im Plus, muss er
den aktuellen Kurs anpassen. Bis dahin bescheisst er
die Kleinanleger oder schaut, mit welcher Transaktion er das meisste Geld verdient!!
Und wir kleinen gucken blöd aus der Wäsche... Helau Markler!:O
Denn ich habe eine Kauforder bei 0,25 plaziert
und wurde immer noch nicht ausgeführt!!!
So manchen Markler könnte ich sonst wo hin treten.
Sobald USA eröffnet, und das wohl im Plus, muss er
den aktuellen Kurs anpassen. Bis dahin bescheisst er
die Kleinanleger oder schaut, mit welcher Transaktion er das meisste Geld verdient!!
Und wir kleinen gucken blöd aus der Wäsche... Helau Markler!:O
bin ich besoffen von gestern ????
ich finde keine news...
ohne Grund passiert das nicht, garantiert nicht.
kassier-
ich finde keine news...
ohne Grund passiert das nicht, garantiert nicht.
kassier-
wenn du es garantierts dann solltest du auch den Grund wissen
haste Recht, ich bin auf jeden Fall mit k-order drin, das will ich jetzt wissen, zum Donnerkeil nochamol.
kassier-
kassier-
...hab auch nochmal nachgelegt.
Grüße
Grüße
wenn ein Kurs so reinhaut, müssten beim Feldversuch Leute gestorben sein.. sonst ist die Entwicklung einfach irre.
will mal nachsehen, ob die 153 k eine Order war. vermutlich bestens und bei dünnem Markt.
will mal nachsehen, ob die 153 k eine Order war. vermutlich bestens und bei dünnem Markt.
[posting]20.398.483 von kassier am 27.02.06 10:33:02[/posting]Da war nur ein Umsatz.
Anschließend wurde kont. runtergetaxt. Bis Ziel erreicht.
Super - Nachkaufgelegenheit.
Bin leider voll investiert.
Anschließend wurde kont. runtergetaxt. Bis Ziel erreicht.
Super - Nachkaufgelegenheit.
Bin leider voll investiert.
wie ich sage, dünner Markt, ich bekomme meine paar Dinger nicht mal mehr für 026
jetzt hab ich die Faxen dicke und hab mir RT-Kurse bestellt. die 27 € i.Monat sind mir jetzt auch wurscht.
kassier-
jetzt hab ich die Faxen dicke und hab mir RT-Kurse bestellt. die 27 € i.Monat sind mir jetzt auch wurscht.
kassier-
[posting]20.398.547 von paloma am 27.02.06 10:36:32[/posting]Leider???
Glücklich sein ......
Glücklich sein ......
[posting]20.398.681 von fs2003 am 27.02.06 10:43:52[/posting]Stimmt schon so wie ich es sagte. Hätte zu gerne bei 0.2 EUR zugeschlagen.
Ärgert mich nur, weil ich die Achterbahn-Fahrt der MM-Heinis vom Spielfeld-Rand aus beobachten muß.
Ärgert mich nur, weil ich die Achterbahn-Fahrt der MM-Heinis vom Spielfeld-Rand aus beobachten muß.
ist jemand auch long?
[posting]20.398.774 von Zentimeter am 27.02.06 10:49:41[/posting]ja natürlich bin ich das, ich komme aus der Pharmazie und wenn hier keine neg. news anstehen, gibts überhaupt keinen Grund für so was.
ich habe keine news gefunden bei den amis. diese grosse Einzelorder ist unverständlich zu dem Preis.
der MM gibt mir i.A. keine für 026
so, ich muss jetzt wech bis ca. 14 Uhr.
so long Kassier-
ich habe keine news gefunden bei den amis. diese grosse Einzelorder ist unverständlich zu dem Preis.
der MM gibt mir i.A. keine für 026
so, ich muss jetzt wech bis ca. 14 Uhr.
so long Kassier-
Ja Long bis 5€....
Toucon steckt dahinter.
Von RangingBull:
The plan is up to $40 million dollars from Toucan, in exchange for 90% of the company.
Whether that is how this ultimately plays out remains to be seen. I think each milestone that the company meets, the more money they are getting.
So far, two drugs in clincal trials, and the follow up boosters, and now this cd44 stuff.
Toucon steckt dahinter.
Von RangingBull:
The plan is up to $40 million dollars from Toucan, in exchange for 90% of the company.
Whether that is how this ultimately plays out remains to be seen. I think each milestone that the company meets, the more money they are getting.
So far, two drugs in clincal trials, and the follow up boosters, and now this cd44 stuff.
mit Toucon kurzfristig oder langfristig
Kurs Ende der Woche 1 Dollar?
Kurs Ende der Woche 1 Dollar?
[posting]20.398.774 von Zentimeter am 27.02.06 10:49:41[/posting]Ich gehör`auch dazu und dies schon länger.
Das Potential ist einfach zu verlockend.
Sollten sich die vorläufigen Resultate bei neuen Krebsmedikamenten DCVax und CXCR4 auch nur annähernd in der klinischen Testphase II bestätigen, gibt`s neue Dimensionen in der Krebstherapie ...
und natürlich auch in der Börsenbewertung.
Das Potential ist einfach zu verlockend.
Sollten sich die vorläufigen Resultate bei neuen Krebsmedikamenten DCVax und CXCR4 auch nur annähernd in der klinischen Testphase II bestätigen, gibt`s neue Dimensionen in der Krebstherapie ...
und natürlich auch in der Börsenbewertung.
Weiss man genaueres über den Zeitpunkt der Pase II?
Haben abert doch kein Geld oder?
Wo seht ihr den Kurs kurzfristig?
1 Dollar möglich?
Wo seht ihr den Kurs kurzfristig?
1 Dollar möglich?
Hi,
Der Betrag von 0,44 USD entspricht 0,3714 EUR
Der Betrag von 0,44 USD entspricht 0,3714 EUR
interessanterweise gab es im Sommer2005 eine Anlayse zu Northwest für 130 Euro - 10 Seiten und denke mal nicht dass dies eine Verkaufsempfehlung war.
@gerl28
der Kurs ist alt
bin gespannt auf das heutige bid bei den Amis, vielleicht auch wieder vorbörslich Handel
der Kurs ist alt
bin gespannt auf das heutige bid bei den Amis, vielleicht auch wieder vorbörslich Handel
wird ja ganz schön hochgetaxt jetzt
Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
US Patènt # 6863887
Invèntors: Murphy; Gerald P. (late of Seattle, WA); Murphy; Bridgette (Seattle, WA); Boynton; Alton L. (Redmond, WA); Sehgal; Anil (Seattle, WA)
Assignee: Northwest Biotherapeutics , Inc. (Bothell, WA)
Appl. No.: 647501
Filed: June 15, 2001
PCT Filed: March 29, 1999
PCT NO: PCT/US99/07431
371 Date: June 15, 2001
102(e) Date: June 15, 2001
PCT PUB.NO.: WO99/50461
PCT PUB. Date: October 7, 1999
ABSTRACT
The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants` surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.
--------------------------------------------------------------------------------
1. FIELD OF THE INVÈNTION
The present invèntion relates to the identification of a novel role for the CXCR-4 gene (SEQ ID NO:1) in tumorigenesis, in particular primary brain, breast and colon tumorigenesis. The present invèntion is related to the role of CXCR-4 nucleic acids and polypeptides as diagnostic tools to indicate a pre-cancerous condition or cancer, and therapeutic agents based thereon to inhibit CXCR-4 gene expression and/or activity as a method of treating and/or preventing tumorigenesis.
2. BACKGROUND OF THE INVÈNTION
2.1. Brain Tumors
Brain tumors are among the leading cause of death among young children and adults. A survey by the American Cancer Society has documented that 13,300 people died of brain tumors in 1995 and predicated that over 17,900 would die in 1996 (Parker et al., 1996, CA Cancer J. Clin., 46:5-28). The number of deaths due to brain tumors has been increasing at a significant rate each year. On average, 25,000 Americans are diagnosed with brain cancer yearly. Brain tumors claim the lives of more children than any other form of cancer except leukemia.
The increased incidence of brain tumors is not only evident in children but also in adults. It has been documented that a significant increase in mortality has occurred in adult primary malignant tumors between 1982 and 1996 (Parker et al., 1996, CA Cancer J. Clin., 46:5-28). Glioblastomas, astrocytomas and meningiomas are the most common brain tumors that affect adults (Thapar and Laws, 1993, CA Cancer J. Clin., 43:263-271).
The transformation of normal human brain cells into gliomas occurs as a result of the accumulation of a series of cellular and genetic changes (Sehgal, 1998 Cancer Surv., 25:233-275; vonDiemiling et al., 1995 Glia 15:328-338; Furnari et al., 1995, J. Surg. Oncol. 67:234). These genetic alterations include the loss, gain or amplification of different chromosomes. These genetic changes lead to altered expression of proteins that play important roles in the regulation of normal cell proliferation. Several common genetic alternations at the chromosomal level (loss of 17p, 13q, 9p, 19, 10, 22q, 18q and amplification of 7 and 12q) have been observed (Sehgal et al., 1998, J. Surg. Oncol. 67:23; vonDiemiling et al., 1995, Glia 15:328-338; Furnari et al., 1995, Cancer Surv. 25:233-275). These alterations lead to changes in the expression of several genes (p53, RB, INF.alpha./.beta., CDKN2, MMAC1, DCC, EGFR, PDGF, PDGFr, MDM2, GLI, CDK4 and SAS) during the genesis and progression of human gliomas (Sehgal, 1998, J. Surg. Oncol. 67:234; vonDiemiling et al., 1995, Glia 15:328-338). Recent studies have suggested that altered expression of several other genes (MET, MYC, TGF.beta., CD44, VEGF, NCAML1, p21.sup.waf1/Cip1, trkA, MMRs, C4-2, D2-2) and proteins (cathepsins, tenascin, matrix metalloproteases, tissue inhibitors of metalloproteases, nitric oxide synthetase, integrins, IL 13 receptor, Connexin 43, uPAR`s extracellular matrix proteins and heat shock proteins) are associated with the genesis of human gliomas (Sehgal, 1998, J. Surg. Oncol. 67:234). Taken together these findings point to the fact that accumulation of multiple genetic mutations coupled with extensive changes in gene expression may be a prerequisite in the etiology of human gliomas. Despite identification of these genetic alterations, the exact series of events that leads to the genesis of human gliomas is not clear.
Glioblastoma multiforme are high grade astrocytomas that grow very rapidly and contain cells that are very malignant (Laws and Thapar, 1993, CA Cancer J. Clin., 43:263-271). The molecular basis of glioblastoma multiforme occurrence may involve systematic events at the chromosomal level or at a gene expression level. These may include inactivation of tumor suppressor genes, activation of oncogenes or specific translocations at the chromosomal level. Some genetic changes at the chromosomal level and gene expression level have been well documented for other brain tumors (Furnari et al, 1995, Cancer Surv., 25:233-275). For example, it has been documented that loss of tumor suppressor(s) genes at chromosome 10, mutations in p53, or overexpression of epidermal growth factor receptor, may be major events leading to glioblastoma multiforme. A number of other genes such as EGFR, CD44, .beta.4 integrins, membrane-type metalloproteinase (MT-MMP), p21, p16, p15, myc, and VEGF have been shown to be overexpressed in different types of brain tumors (Faillot et al., Neurosurgery, 39:478-483; Eibl et al, 1995, J. of Neurooncol., 26:165-170; Previtali et al., 1996, Neuropathol. Exp. Neurol., 55:456-465; Yamamoto et al., 1996, Cancer Res., 56:384-392; Jung et al., 1995, Oncogene, 11:2021-2028; Tsuzuki et al., 1996, Cancer, 78:287-293; Chen et al., 1995, Nature Med., 1:638-643; Takano, et al., Cancer Res., 56:2185-2190; Bogler et al., 1995, Glia, 15:308-327). Other genes such as p53 show mutations in the majority of brain tumors (Bogler et al, supra). How the interplay of one more of these genes leads to tumorigenesis is not known but most likely multiple steps are required for neoplastic transformation. The exact series of events that lead to initiation or progression of glioblastoma are not known at present and useful markers for early detection of brain tumors are lacking.
2.2. CXCR-4
Chemokine receptors play an important role in the chemotaxis of T cells and phagocytic cells to areas of inflammation. CXCR-4 was first identified as a cDNA that was amplified using degenerate primers made against leukocyte chemotactic factor receptors (N-formyl peptides, C5a and IL-8) and was termed HM89 (Endres et al., 1996, Cell 87:745). Ligand binding analysis showed that HM89 was not a N-formyl peptide receptor, but sequence analysis clearly demonstrated that it is a member of the G protein coupled receptor family. Cytogenetic analysis indicates that HM89 is localized to human chromosome 2q21 (Benl et al., 1996, Nature 382:829). HM89 was later re-cloned using a rabbit IL-8 receptor cDNA upon screening a human monocyte library and was named LESTR (leukocyte derived seven transmembrane domain receptor (Nagasawa et al. 1996, Nature 382:635); and was again cloned and identified as a co-factor for HIV-1 fusion and entry into CD4+ cells (De Risi et al., 1996, Nature, Genetics 14:457). This co-factor was identical to the previously cloned HM89, and because of its role as a fusion protein between the HIV-1 virus and CD4+ cells it was designated as "fusin". Fusin in conjunction with CD4 is sufficient to allow HIV-1 entry into non-permissive murine 3T3 cells (De Risi et al., 1996, Nature, Genetics 14:457). Sequence analysis indicated that HM89, LESTR and fusin are all the same gene and because of chemo-attraction properties, these genes are now termed CXC-chemokine receptor-4 (CXCR-4). Recently, it is shown that the CD4-independent infection by HIV-1 was mediated by the CXCR-4 receptor (Feng et al., 1996, Science 172:872). The ligand for CXCR-4 was recently cloned and termed PBSF/SDF-1 (Pre-B-cell growth stimulating factor/Stromal cell derived factor-1) (Engelhard et al., 1997, Neurosurgery 41:886). Transgenic mice that lack PBSF/SDF-1 died prenatally and their B-cells and myeloid progenitors were severely reduced in numbers (Harihabu et al., 1997 J. Biol. Chem. 272:28726). This result clearly demonstrates that PBSF/SDF-1 is responsible for B-cell lymphoesis and bone marrow myelopoiesis.
Recent studies demonstrate that CXCR-4 functions as a co-receptor with CD4 for the entry of T-cell tropic strains of HIV into target cells (Nomura et al., 1993, Int. Immunol. 5:1239; Federsppiel et al., 1993, Genomics 16:707). The mechanism by which HIV-1 interacts with the CXCR-4 chemokine receptor and CD4 molecules during infection is unclear. It was also demonstrated that HIV-2 infection of CD4- cells can occur rapidly by utilizing the HIV-1 co-factor CXCR-4 receptor (Loctscher et al., 1994, J. Biol. Chem. 269:232). Interaction and cytopathic effects caused by entry of HIV-2 into CD4- cells were inhibited by a monoclonal antibody to the CXCR-4 protein (Doranz et al., 1997, Immunol. Resh. 16:15) (Feng et al., 1996, Science 272:872). The role of CXCR-4 in HIV infection was further strengthened when its introduction into human and nonhuman CD4- cells allowed HIV-2 infection (Doranz et al., 1997, Immunol. Res. 16:15) (Feng et al., 1996, Science 272:872).
Citation of references herein shall not be construed as an admission that such references are prior art to the present invèntion.
US Patènt # 6863887
Invèntors: Murphy; Gerald P. (late of Seattle, WA); Murphy; Bridgette (Seattle, WA); Boynton; Alton L. (Redmond, WA); Sehgal; Anil (Seattle, WA)
Assignee: Northwest Biotherapeutics , Inc. (Bothell, WA)
Appl. No.: 647501
Filed: June 15, 2001
PCT Filed: March 29, 1999
PCT NO: PCT/US99/07431
371 Date: June 15, 2001
102(e) Date: June 15, 2001
PCT PUB.NO.: WO99/50461
PCT PUB. Date: October 7, 1999
ABSTRACT
The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants` surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.
--------------------------------------------------------------------------------
1. FIELD OF THE INVÈNTION
The present invèntion relates to the identification of a novel role for the CXCR-4 gene (SEQ ID NO:1) in tumorigenesis, in particular primary brain, breast and colon tumorigenesis. The present invèntion is related to the role of CXCR-4 nucleic acids and polypeptides as diagnostic tools to indicate a pre-cancerous condition or cancer, and therapeutic agents based thereon to inhibit CXCR-4 gene expression and/or activity as a method of treating and/or preventing tumorigenesis.
2. BACKGROUND OF THE INVÈNTION
2.1. Brain Tumors
Brain tumors are among the leading cause of death among young children and adults. A survey by the American Cancer Society has documented that 13,300 people died of brain tumors in 1995 and predicated that over 17,900 would die in 1996 (Parker et al., 1996, CA Cancer J. Clin., 46:5-28). The number of deaths due to brain tumors has been increasing at a significant rate each year. On average, 25,000 Americans are diagnosed with brain cancer yearly. Brain tumors claim the lives of more children than any other form of cancer except leukemia.
The increased incidence of brain tumors is not only evident in children but also in adults. It has been documented that a significant increase in mortality has occurred in adult primary malignant tumors between 1982 and 1996 (Parker et al., 1996, CA Cancer J. Clin., 46:5-28). Glioblastomas, astrocytomas and meningiomas are the most common brain tumors that affect adults (Thapar and Laws, 1993, CA Cancer J. Clin., 43:263-271).
The transformation of normal human brain cells into gliomas occurs as a result of the accumulation of a series of cellular and genetic changes (Sehgal, 1998 Cancer Surv., 25:233-275; vonDiemiling et al., 1995 Glia 15:328-338; Furnari et al., 1995, J. Surg. Oncol. 67:234). These genetic alterations include the loss, gain or amplification of different chromosomes. These genetic changes lead to altered expression of proteins that play important roles in the regulation of normal cell proliferation. Several common genetic alternations at the chromosomal level (loss of 17p, 13q, 9p, 19, 10, 22q, 18q and amplification of 7 and 12q) have been observed (Sehgal et al., 1998, J. Surg. Oncol. 67:23; vonDiemiling et al., 1995, Glia 15:328-338; Furnari et al., 1995, Cancer Surv. 25:233-275). These alterations lead to changes in the expression of several genes (p53, RB, INF.alpha./.beta., CDKN2, MMAC1, DCC, EGFR, PDGF, PDGFr, MDM2, GLI, CDK4 and SAS) during the genesis and progression of human gliomas (Sehgal, 1998, J. Surg. Oncol. 67:234; vonDiemiling et al., 1995, Glia 15:328-338). Recent studies have suggested that altered expression of several other genes (MET, MYC, TGF.beta., CD44, VEGF, NCAML1, p21.sup.waf1/Cip1, trkA, MMRs, C4-2, D2-2) and proteins (cathepsins, tenascin, matrix metalloproteases, tissue inhibitors of metalloproteases, nitric oxide synthetase, integrins, IL 13 receptor, Connexin 43, uPAR`s extracellular matrix proteins and heat shock proteins) are associated with the genesis of human gliomas (Sehgal, 1998, J. Surg. Oncol. 67:234). Taken together these findings point to the fact that accumulation of multiple genetic mutations coupled with extensive changes in gene expression may be a prerequisite in the etiology of human gliomas. Despite identification of these genetic alterations, the exact series of events that leads to the genesis of human gliomas is not clear.
Glioblastoma multiforme are high grade astrocytomas that grow very rapidly and contain cells that are very malignant (Laws and Thapar, 1993, CA Cancer J. Clin., 43:263-271). The molecular basis of glioblastoma multiforme occurrence may involve systematic events at the chromosomal level or at a gene expression level. These may include inactivation of tumor suppressor genes, activation of oncogenes or specific translocations at the chromosomal level. Some genetic changes at the chromosomal level and gene expression level have been well documented for other brain tumors (Furnari et al, 1995, Cancer Surv., 25:233-275). For example, it has been documented that loss of tumor suppressor(s) genes at chromosome 10, mutations in p53, or overexpression of epidermal growth factor receptor, may be major events leading to glioblastoma multiforme. A number of other genes such as EGFR, CD44, .beta.4 integrins, membrane-type metalloproteinase (MT-MMP), p21, p16, p15, myc, and VEGF have been shown to be overexpressed in different types of brain tumors (Faillot et al., Neurosurgery, 39:478-483; Eibl et al, 1995, J. of Neurooncol., 26:165-170; Previtali et al., 1996, Neuropathol. Exp. Neurol., 55:456-465; Yamamoto et al., 1996, Cancer Res., 56:384-392; Jung et al., 1995, Oncogene, 11:2021-2028; Tsuzuki et al., 1996, Cancer, 78:287-293; Chen et al., 1995, Nature Med., 1:638-643; Takano, et al., Cancer Res., 56:2185-2190; Bogler et al., 1995, Glia, 15:308-327). Other genes such as p53 show mutations in the majority of brain tumors (Bogler et al, supra). How the interplay of one more of these genes leads to tumorigenesis is not known but most likely multiple steps are required for neoplastic transformation. The exact series of events that lead to initiation or progression of glioblastoma are not known at present and useful markers for early detection of brain tumors are lacking.
2.2. CXCR-4
Chemokine receptors play an important role in the chemotaxis of T cells and phagocytic cells to areas of inflammation. CXCR-4 was first identified as a cDNA that was amplified using degenerate primers made against leukocyte chemotactic factor receptors (N-formyl peptides, C5a and IL-8) and was termed HM89 (Endres et al., 1996, Cell 87:745). Ligand binding analysis showed that HM89 was not a N-formyl peptide receptor, but sequence analysis clearly demonstrated that it is a member of the G protein coupled receptor family. Cytogenetic analysis indicates that HM89 is localized to human chromosome 2q21 (Benl et al., 1996, Nature 382:829). HM89 was later re-cloned using a rabbit IL-8 receptor cDNA upon screening a human monocyte library and was named LESTR (leukocyte derived seven transmembrane domain receptor (Nagasawa et al. 1996, Nature 382:635); and was again cloned and identified as a co-factor for HIV-1 fusion and entry into CD4+ cells (De Risi et al., 1996, Nature, Genetics 14:457). This co-factor was identical to the previously cloned HM89, and because of its role as a fusion protein between the HIV-1 virus and CD4+ cells it was designated as "fusin". Fusin in conjunction with CD4 is sufficient to allow HIV-1 entry into non-permissive murine 3T3 cells (De Risi et al., 1996, Nature, Genetics 14:457). Sequence analysis indicated that HM89, LESTR and fusin are all the same gene and because of chemo-attraction properties, these genes are now termed CXC-chemokine receptor-4 (CXCR-4). Recently, it is shown that the CD4-independent infection by HIV-1 was mediated by the CXCR-4 receptor (Feng et al., 1996, Science 172:872). The ligand for CXCR-4 was recently cloned and termed PBSF/SDF-1 (Pre-B-cell growth stimulating factor/Stromal cell derived factor-1) (Engelhard et al., 1997, Neurosurgery 41:886). Transgenic mice that lack PBSF/SDF-1 died prenatally and their B-cells and myeloid progenitors were severely reduced in numbers (Harihabu et al., 1997 J. Biol. Chem. 272:28726). This result clearly demonstrates that PBSF/SDF-1 is responsible for B-cell lymphoesis and bone marrow myelopoiesis.
Recent studies demonstrate that CXCR-4 functions as a co-receptor with CD4 for the entry of T-cell tropic strains of HIV into target cells (Nomura et al., 1993, Int. Immunol. 5:1239; Federsppiel et al., 1993, Genomics 16:707). The mechanism by which HIV-1 interacts with the CXCR-4 chemokine receptor and CD4 molecules during infection is unclear. It was also demonstrated that HIV-2 infection of CD4- cells can occur rapidly by utilizing the HIV-1 co-factor CXCR-4 receptor (Loctscher et al., 1994, J. Biol. Chem. 269:232). Interaction and cytopathic effects caused by entry of HIV-2 into CD4- cells were inhibited by a monoclonal antibody to the CXCR-4 protein (Doranz et al., 1997, Immunol. Resh. 16:15) (Feng et al., 1996, Science 272:872). The role of CXCR-4 in HIV infection was further strengthened when its introduction into human and nonhuman CD4- cells allowed HIV-2 infection (Doranz et al., 1997, Immunol. Res. 16:15) (Feng et al., 1996, Science 272:872).
Citation of references herein shall not be construed as an admission that such references are prior art to the present invèntion.
@fs2003
und was sagt uns das?
und was sagt uns das?
wieviele Aktien gibt es eigentlich?
19 Millionen STück?
19 Millionen STück?
[posting]20.399.350 von Zentimeter am 27.02.06 11:24:28[/posting]0,44 ist doch von Freitag bei den Amis. Warum wird hier 25% unter pari gehandelt, gab`s da News übers WE oder kann man hier bischen Arbitrage spielen???
Thx TB
Thx TB
wie übersetzt man das?
This study is not yet open for patient recruitment
This study is not yet open for patient recruitment
Bin auf die ersten Analystem-Einstufungen nach der Konferenz vom 21. - 24 Februar gespannt
(Annual Molecular Medicine Tri- Conference, February 21st-24th at the Moscone North Convention Center in San Francisco, California).
Bin mir sicher, daß diese bemerkenswerten Neuigkeiten bei Northwest Bio nicht unkommentiert bleiben.
In diesem Sinne ... Aktien festhalten und keine unreifen Früchte ernten.
(Annual Molecular Medicine Tri- Conference, February 21st-24th at the Moscone North Convention Center in San Francisco, California).
Bin mir sicher, daß diese bemerkenswerten Neuigkeiten bei Northwest Bio nicht unkommentiert bleiben.
In diesem Sinne ... Aktien festhalten und keine unreifen Früchte ernten.
wie kann die Aktie in USA auf 0,44 sein und hier morgens 0,2?????
naja,wäre über eine Antwort per BM an mich dankbar!
naja,wäre über eine Antwort per BM an mich dankbar!
[posting]20.401.033 von paloma am 27.02.06 13:04:12[/posting]kann es sein das der Abschlag gegenüber US-SK 0,44 US$ (=0,37 €) mit dieser Konferenz zusammenhängt??? Bin am Überlegen, 25% unter pari einzusteigen, aber irgendwie kommt mir das doch verdächtig vor. Vieleicht wissen da ja einige schon mehr.
TB
TB
[posting]20.401.260 von Timburg am 27.02.06 13:17:26[/posting]Denke, daß dies eine gezielte Aktion der MM`s in Frankfurt war.
Fishing-Action
Umsatzgenerierung.
Ihr habt ja gesehen, wie schnell und konsequent hier in Schritten runtergetaxt wurde wurde, bis Ziel 0.20 EUR erreicht war >Folge: Umsatz 153K schlagartig.
Anschließend wieder Umsatz Richtung Pari. Würde ich als MM auch so machen.
Fishing-Action
Umsatzgenerierung.
Ihr habt ja gesehen, wie schnell und konsequent hier in Schritten runtergetaxt wurde wurde, bis Ziel 0.20 EUR erreicht war >Folge: Umsatz 153K schlagartig.
Anschließend wieder Umsatz Richtung Pari. Würde ich als MM auch so machen.
unter 2 Euronen gebe ich nichts her--falls ich`s
noch erlebe
noch erlebe
VB in usa noch nix verändert
rt 0,4 2000 gehandelt
[posting]20.403.938 von Zentimeter am 27.02.06 15:31:56[/posting]mit 2 k 10 % runter ist doch lächerlich. ich dachte, da kommt richtig VK-Druck.
bisher alles Quatsch.
kassier-
bisher alles Quatsch.
kassier-
15 k gehandelt...3 x 0,40 $ bid
1 x ask 0,41
letzte 0,41 $...waere 0,35 e
1 x ask 0,41
letzte 0,41 $...waere 0,35 e
aktuell Verkaufsstimmung
mal abwarten
mal abwarten
ist auch nicht verwunderlich wenn man den chart anschaut.
schoentach
schoentach
ich erwartw eine Shclusskurs deutlich im Plus bei 0,46 bis 0,48 Dollar
dann wirste eine dicke 10 cents daneben liegen
0,34 x 0,38 $ z.Zt.
dollar also
0,34 x 0,38 $ z.Zt.
dollar also
jerry Luft holen für 1 Dollar
nur, weil wir drin sind, können wir doch nicht erwarten, dass es einfach nur raufgeht...
kassier-
kassier-
Eröffnung morgen wohl leider nur bei 0,30 / 0,32 EURO
@kassier
gut Ding braucht Weile
gerade an der OTC wird der Kleinanleger nach allen Regeln
der Kunst ausgenommen!
da gibt`s nur Eins--Geduld oder verkaufen!
Meiner Meinung nach ist Northwest auf einen guten Weg,also
ich bin Long
MfG
gerl
gut Ding braucht Weile
gerade an der OTC wird der Kleinanleger nach allen Regeln
der Kunst ausgenommen!
da gibt`s nur Eins--Geduld oder verkaufen!
Meiner Meinung nach ist Northwest auf einen guten Weg,also
ich bin Long
MfG
gerl
Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
WEDNESDAY, MARCH 01, 2006 7:31 AM
- PR Newswire
NWBT
0.35 -0.01
Enter Symbol:
Enter Keyword:
BOTHELL, Wash., March 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced new preclinical data on the efficacy of a monoclonal antibody to CXCR4, one of the most important cancer targets discovered in recent years. The new data showed a significant reduction in metastases to the lung, as well as a significant reduction in primary breast cancer tumor growth and significant extension of survival, after treatment with NWBT`s monoclonal antibody to CXCR4. A growing body of research and literature has shown that CXCR4 plays a central role in all three stages of cancer progression, and does so in over 75% of all cancers. NWBT holds broad issued patent coverage for the use of antibody therapeutics targeting CXCR4, as announced in March 2005. The data were presented at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri-Conference, February 22nd and 23rd, in San Francisco, CA.
It is now well documented that CXCR4 plays an important role in all three major aspects of cancer progression: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. Northwest Biotherapeutics conducted a series of preclinical studies to test a monoclonal antibody to CXCR4 in three cancer models. The studies were designed to determine whether blocking CXCR4 function would impact primary tumor growth, metastases and survival. The findings reported showed that anti-CXCR4 antibodies significantly impacted all three of these aspects:
-- Median survival more than doubled, with 95% of the treated animals
surviving >110 days compared with median survival of 45 days in
control animals;
-- Lung metastases were reduced by 75%;
-- Growth of primary breast tumors were reduced by 60%.
"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."
CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008 (Pacific)
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
WEDNESDAY, MARCH 01, 2006 7:31 AM
- PR Newswire
NWBT
0.35 -0.01
Enter Symbol:
Enter Keyword:
BOTHELL, Wash., March 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced new preclinical data on the efficacy of a monoclonal antibody to CXCR4, one of the most important cancer targets discovered in recent years. The new data showed a significant reduction in metastases to the lung, as well as a significant reduction in primary breast cancer tumor growth and significant extension of survival, after treatment with NWBT`s monoclonal antibody to CXCR4. A growing body of research and literature has shown that CXCR4 plays a central role in all three stages of cancer progression, and does so in over 75% of all cancers. NWBT holds broad issued patent coverage for the use of antibody therapeutics targeting CXCR4, as announced in March 2005. The data were presented at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri-Conference, February 22nd and 23rd, in San Francisco, CA.
It is now well documented that CXCR4 plays an important role in all three major aspects of cancer progression: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. Northwest Biotherapeutics conducted a series of preclinical studies to test a monoclonal antibody to CXCR4 in three cancer models. The studies were designed to determine whether blocking CXCR4 function would impact primary tumor growth, metastases and survival. The findings reported showed that anti-CXCR4 antibodies significantly impacted all three of these aspects:
-- Median survival more than doubled, with 95% of the treated animals
surviving >110 days compared with median survival of 45 days in
control animals;
-- Lung metastases were reduced by 75%;
-- Growth of primary breast tumors were reduced by 60%.
"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."
CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008 (Pacific)
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
[posting]20.420.716 von gerl28 am 28.02.06 12:58:14[/posting]Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
WEDNESDAY, MARCH 01, 2006 7:31 AM
- PR Newswire
NWBT
0.35 -0.01
Enter Symbol:
Enter Keyword:
BOTHELL, Wash., March 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced new preclinical data on the efficacy of a monoclonal antibody to CXCR4, one of the most important cancer targets discovered in recent years. The new data showed a significant reduction in metastases to the lung, as well as a significant reduction in primary breast cancer tumor growth and significant extension of survival, after treatment with NWBT`s monoclonal antibody to CXCR4. A growing body of research and literature has shown that CXCR4 plays a central role in all three stages of cancer progression, and does so in over 75% of all cancers. NWBT holds broad issued patent coverage for the use of antibody therapeutics targeting CXCR4, as announced in March 2005. The data were presented at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri-Conference, February 22nd and 23rd, in San Francisco, CA.
It is now well documented that CXCR4 plays an important role in all three major aspects of cancer progression: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. Northwest Biotherapeutics conducted a series of preclinical studies to test a monoclonal antibody to CXCR4 in three cancer models. The studies were designed to determine whether blocking CXCR4 function would impact primary tumor growth, metastases and survival. The findings reported showed that anti-CXCR4 antibodies significantly impacted all three of these aspects:
-- Median survival more than doubled, with 95% of the treated animals
surviving >110 days compared with median survival of 45 days in
control animals;
-- Lung metastases were reduced by 75%;
-- Growth of primary breast tumors were reduced by 60%.
"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."
CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008 (Pacific)
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
WEDNESDAY, MARCH 01, 2006 7:31 AM
- PR Newswire
NWBT
0.35 -0.01
Enter Symbol:
Enter Keyword:
BOTHELL, Wash., March 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced new preclinical data on the efficacy of a monoclonal antibody to CXCR4, one of the most important cancer targets discovered in recent years. The new data showed a significant reduction in metastases to the lung, as well as a significant reduction in primary breast cancer tumor growth and significant extension of survival, after treatment with NWBT`s monoclonal antibody to CXCR4. A growing body of research and literature has shown that CXCR4 plays a central role in all three stages of cancer progression, and does so in over 75% of all cancers. NWBT holds broad issued patent coverage for the use of antibody therapeutics targeting CXCR4, as announced in March 2005. The data were presented at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri-Conference, February 22nd and 23rd, in San Francisco, CA.
It is now well documented that CXCR4 plays an important role in all three major aspects of cancer progression: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. Northwest Biotherapeutics conducted a series of preclinical studies to test a monoclonal antibody to CXCR4 in three cancer models. The studies were designed to determine whether blocking CXCR4 function would impact primary tumor growth, metastases and survival. The findings reported showed that anti-CXCR4 antibodies significantly impacted all three of these aspects:
-- Median survival more than doubled, with 95% of the treated animals
surviving >110 days compared with median survival of 45 days in
control animals;
-- Lung metastases were reduced by 75%;
-- Growth of primary breast tumors were reduced by 60%.
"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."
CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008 (Pacific)
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
Heute schon frühbörslicher Handel bei NWBT.
Weiß da jemand mehr?
Volumen 30000 Shares.
Weiß da jemand mehr?
Volumen 30000 Shares.
[posting]20.443.073 von paloma am 01.03.06 14:48:35[/posting]Wieder News der Extraklasse!
Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
Lung Metastases Reduced 75% in Preclinical Studies
Positiver Newsflow reisst nicht ab! Also, Shares festhalten!
Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
Lung Metastases Reduced 75% in Preclinical Studies
Positiver Newsflow reisst nicht ab! Also, Shares festhalten!
und schon zieht bid an!
0.36 $
0.36 $
[posting]20.443.532 von paloma am 01.03.06 15:09:35[/posting]Bid steigt weiter
RT 0.38 $
RT 0.38 $
Eröffnung
RT0.41 $
RT0.41 $
Es geht weiter!
RT 0.42 $
Bid 0.42 $
RT 0.42 $
Bid 0.42 $
Sorry
Bid 0.43 $[/B
Bid 0.43 $[/B
RT 0.44 $
Na,der Dollar bis Freitag rückt immer näher
[posting]20.444.914 von gerl28 am 01.03.06 15:54:03[/posting]Naja,
Dollar hin oder her!
Auf jeden Fall momentan
RT 0.50 $
und dies .... mit Ansage!
Dollar hin oder her!
Auf jeden Fall momentan
RT 0.50 $
und dies .... mit Ansage!
Hat jemand RT Frankfurt?
Ask-Seite mittlerweile bis 0.60 $ sehr dünn!
RT 0.48 $
RT 0.48 $
[posting]20.445.174 von paloma am 01.03.06 16:03:46[/posting]Frankfurt RT 0.38 EUR
Bid 0.38 / Ask 0.41 EUR
Bid 0.38 / Ask 0.41 EUR
hoffendlich wird den Shorties drüben mal ordentlich in
den A.... getreten
den A.... getreten
kaufe ein "t"
...sauber !!!
RT 0,39 €
Zur Info an Alle:
RT 0.49 $
RT 0.49 $
RT 0,36 € FFM
17.25Uhr
17.25Uhr
leute laßt euch das mal auf der zunge zergehen
75 % heilungsrate
leute 75 % mit CXCR4
da rede ich noch nicht mal von DCVAX
wo 5 von 10 keine anzeichen mehr auf einen tumor
vorweisen, nach 32 monaten
also, wenn das ding nicht steigt,
was dann????????????????????????ßß
wir stehen immer noch bei einer mk 8 Mio.$
DAS IST JA EIN WITZ (auch wenn ich mich wiederhole)
75 % heilungsrate
leute 75 % mit CXCR4
da rede ich noch nicht mal von DCVAX
wo 5 von 10 keine anzeichen mehr auf einen tumor
vorweisen, nach 32 monaten
also, wenn das ding nicht steigt,
was dann????????????????????????ßß
wir stehen immer noch bei einer mk 8 Mio.$
DAS IST JA EIN WITZ (auch wenn ich mich wiederhole)
Das wird schon-da werden noch einige positive News folgen!
[posting]20.447.661 von CHICO999 am 01.03.06 17:34:20[/posting]Hi chico999,
die MK ist wirklich ein Witz, aber das wird schon noch. Da halten noch einige ihren Winterschlaf, die werden aber hier noch einsteigen. Dann steht der Kurs aber bereits viel höher.
NWBT wird der Renner, kaufen und liegen lassen!
Allen investierten viel Erfolg mit dieser Perle
die MK ist wirklich ein Witz, aber das wird schon noch. Da halten noch einige ihren Winterschlaf, die werden aber hier noch einsteigen. Dann steht der Kurs aber bereits viel höher.
NWBT wird der Renner, kaufen und liegen lassen!
Allen investierten viel Erfolg mit dieser Perle
aber bei der MK bin ich mir nicht so ganz sicher-dachte auch erst 19,08 millionen,aber das eben gefunden
Authorized Outstanding
Date Shares Source Date Shares Source
01/01/2005 300,000,000 10-K 11/14/2005 19,078,048 MGFS
Authorized Outstanding
Date Shares Source Date Shares Source
01/01/2005 300,000,000 10-K 11/14/2005 19,078,048 MGFS
also:
Autorisiert:300 millionen
ausstehende:19,08 millionen
oder wie?
Autorisiert:300 millionen
ausstehende:19,08 millionen
oder wie?
oh danke nochmal für die STücke in Frankfurt zu
0,2
0,2
[posting]20.449.476 von Zentimeter am 01.03.06 18:53:03[/posting]Das sind auch heute noch Kaufkurse! Der 1$ wird bald kommen
bis Freitag hoffe ich doch
[posting]20.450.250 von gerl28 am 01.03.06 19:27:11[/posting]Kann sehr schnell gehen! Momentan noch eine kleine Hürde bei 0.50/0.51 $.
Dann ist der Weg frei.
übrigens RT 0.50 $
Dann ist der Weg frei.
übrigens RT 0.50 $
Hallo gerl28,
das ist aber nur eine Zwischenstation auf dem Weg nach ganz oben. Nicht den Fehler machen bei 1$ zu verkaufen. Hier wird die Post abgehen!!!!!!!!!!!!!
das ist aber nur eine Zwischenstation auf dem Weg nach ganz oben. Nicht den Fehler machen bei 1$ zu verkaufen. Hier wird die Post abgehen!!!!!!!!!!!!!
Die Dinger ziehen heut noch ab!
Shares festhalten!
Ist nur eine Etappe nach oben!
Shares festhalten!
Ist nur eine Etappe nach oben!
...ihr verzeiht mir.
Aber ich bin erregt...bei dem Kurs !!!
Aber ich bin erregt...bei dem Kurs !!!
[posting]20.450.705 von benmuhs am 01.03.06 19:48:41[/posting]Entschuldige,
Du bist aber leicht zu erregen!
Wie sieht`s denn dann mit Frauen aus. Vermutlich nicht auszuhalten.
Du bist aber leicht zu erregen!
Wie sieht`s denn dann mit Frauen aus. Vermutlich nicht auszuhalten.
Sorry,
war nur ein kleiner Scherz.
war nur ein kleiner Scherz.
[posting]20.450.803 von paloma am 01.03.06 19:52:49[/posting]Kleiner Zwischenbericht:
RT 0.50 $
Bid 0.49 $ Volumen 540K.
Die Hürde bei 0.50/0.51 muß Weg, dann ist der Weg frei.
RT 0.50 $
Bid 0.49 $ Volumen 540K.
Die Hürde bei 0.50/0.51 muß Weg, dann ist der Weg frei.
Es wird nach wie vor eifrig an der Mauer bei 0.50 $
geknabbert.
Die fällt heute noch.
RT 0.50 $ Volumen 560K
geknabbert.
Die fällt heute noch.
RT 0.50 $ Volumen 560K
Kaum gesagt, schon geschehen.
RT 0.58 $
Bid 0.58 $
RT 0.58 $
Bid 0.58 $
RT 0.59 $
Kurz zur Info:
RT 0.58 $ Volumen 760K
Schaffen wir die 0.60 $ noch?
Bin ich hier Alleinunterhalter, oder was?
Die Seitenaufrufe zeigen mir, daß doch viel Interesse vorhanden. Also, laßt mich nicht so allein.
RT 0.58 $ Volumen 760K
Schaffen wir die 0.60 $ noch?
Bin ich hier Alleinunterhalter, oder was?
Die Seitenaufrufe zeigen mir, daß doch viel Interesse vorhanden. Also, laßt mich nicht so allein.
klar die 0,60 kommen
Hi paloma,
das Problem ist, das viele nicht dabei sind und nun sehen müssen wie der Kurs steigt und steigt. So ist das Leben. Kaufen Leute!
das Problem ist, das viele nicht dabei sind und nun sehen müssen wie der Kurs steigt und steigt. So ist das Leben. Kaufen Leute!
jo sie steigt,
ist aber nur der anfang
nach dieser zweiten hammermeldung
sehe ich kurzfristig mal 2-3 $,
dann sehen wir mal weiter
ist aber nur der anfang
nach dieser zweiten hammermeldung
sehe ich kurzfristig mal 2-3 $,
dann sehen wir mal weiter
klopf ... klopf
[posting]20.453.096 von prom am 01.03.06 21:21:17[/posting]Denke ähnlich.
übrigens ...
RT 0.60 $
Zumindes für`s erste schon `mal angekratzt.
übrigens ...
RT 0.60 $
Zumindes für`s erste schon `mal angekratzt.
übrigens ...
Bid auch nachgezogen auf 0.60 $
Wäre schön, wenn wir uns hier einnisten könnten - als Zwischetappe versteht sich.
Bid auch nachgezogen auf 0.60 $
Wäre schön, wenn wir uns hier einnisten könnten - als Zwischetappe versteht sich.
Ich schreib` zu langsam
RT 0.65 $
Bid 0.61 $
RT 0.65 $
Bid 0.61 $
stimmt
[posting]20.453.353 von Suum_Quique am 01.03.06 21:34:04[/posting]
So,
nun sagt `mal alle schöne "Danke" für meine selbstlosen Dienste und für Euch den Wasserträger spiele.
RT 0.60 $
Wäre ein schöne Tagesziel, über 0.60 $. Chart sieht auch sehr vielversprechend aus.
nun sagt `mal alle schöne "Danke" für meine selbstlosen Dienste und für Euch den Wasserträger spiele.
RT 0.60 $
Wäre ein schöne Tagesziel, über 0.60 $. Chart sieht auch sehr vielversprechend aus.
Paloma ich danke dir für deine guten Infos. Mach bitte weiter so, denn der Weg zum Ziel ist noch weit entfernt.
Ich glaube das schaffen wir
RT 61
RT 61
Ein Schluß nahe dem Tageshoch bei 0.65 $ wäre doch eine super Steilvorlage für die folgenden Tage.
RT 0.61 $
Bid 0.60 $
RT 0.61 $
Bid 0.60 $
Volumen mittlerweile 1 Mio Shares
Kommt bei NWBT auch nur alle Weihnachten vor! Leute, hier steckt jede Menge Phantasie drin.
Darum Shares ...
Shares festhalten!!!
der $ kommt
RT 0.62
Kommt bei NWBT auch nur alle Weihnachten vor! Leute, hier steckt jede Menge Phantasie drin.
Darum Shares ...
Shares festhalten!!!
der $ kommt
RT 0.62
0,62
Was für ein Abschluss.
Mal sehen wie es in Frankfurt abgeht morgen.
Was für ein Abschluss.
Mal sehen wie es in Frankfurt abgeht morgen.
Stell meine über Pari Morgen zu 0,70! Nach Eröffnung bei den Amis gibts dann erstmal kurze Mitnahmen und zu 0,50 wieder rein ,klappt garantiert! Habe das selbe Spiel schon zu 0,53 auf 0,28 gespielt! Feine Aktie...
Na,
war heute ein erfolgreicher Tag. Lage heute sehr richtig mit meinen Statements (ausnahmsweise) .
SK 0.62 $
Bid 0.62 $
Volumen 1045 k - phenomänal
Denke, alles bestens für Morgen. Geschlossen beinahe auf Tageshoch. Der Zug rollt weiter Richtung
1 $
Gute n8 an Alle
war heute ein erfolgreicher Tag. Lage heute sehr richtig mit meinen Statements (ausnahmsweise) .
SK 0.62 $
Bid 0.62 $
Volumen 1045 k - phenomänal
Denke, alles bestens für Morgen. Geschlossen beinahe auf Tageshoch. Der Zug rollt weiter Richtung
1 $
Gute n8 an Alle
Bis morgen auf dem Dollar-Kanal
Der Vollständigkeit halber:
Nachbörslich Trade zu 0.64 $
Nachbörslich Trade zu 0.64 $
was sehen meine entzündeten Augen da
@prom
bin long,sagte ich doch,und so lange dauert es nicht mehr
und spekust. fällt auch weg(naja nicht bei allen shares)
Allen noch nen schönen Abend--gucke mir die deutsche Deppentruppe noch ein wenig an(hoffentlich schenken se
Klinsi&Co. noch 3 Stück ein)
@prom
bin long,sagte ich doch,und so lange dauert es nicht mehr
und spekust. fällt auch weg(naja nicht bei allen shares)
Allen noch nen schönen Abend--gucke mir die deutsche Deppentruppe noch ein wenig an(hoffentlich schenken se
Klinsi&Co. noch 3 Stück ein)
[posting]20.454.684 von gerl28 am 01.03.06 22:26:31[/posting]Diesen Hühnerhaufen habe ich mir heute erspart!
Vogelgrippe kann mit diesen Deppenjongleur Klinsman nicht
schlimmer sein.
Der glaubt doch wirklich, er kann von California aus mit seinen
Ami-Allüren die Deutschen sportlich neu zu kultivieren.
Mit diesem Hirni wird das nichts.
Vogelgrippe kann mit diesen Deppenjongleur Klinsman nicht
schlimmer sein.
Der glaubt doch wirklich, er kann von California aus mit seinen
Ami-Allüren die Deutschen sportlich neu zu kultivieren.
Mit diesem Hirni wird das nichts.
Schöner Anstieg gestern in den USA.
Guter Newsflow.
Heute kann es so weitergehen.
Guter Newsflow.
Heute kann es so weitergehen.
Lasst uns den heutigen Tag mit
NWBT / WKN:728853
zelebrieren. Vorgaben aus US sind ja glänzend.
NWBT / WKN:728853
zelebrieren. Vorgaben aus US sind ja glänzend.
Ich stocke zur Feier des Tages gleich auf
Es fehlt eigentlich nur noch ein Börsenbrief.....
aber wir sehen auch so den Dollar.
Es fehlt eigentlich nur noch ein Börsenbrief.....
aber wir sehen auch so den Dollar.
[posting]20.456.995 von vergaser am 02.03.06 08:53:30[/posting]Der kommt noch! Mission hat erst begonnen!
Erster Kurs in Frankfurt
RT 0.56 Eur
RT 0.56 Eur
die 75% heilungsrate ist schon der oberhammer
wenn heute drüben nicht geschmissen wird, dann fällt bis heute abend die 1 dollar marke. das man hier kurse von 2-3 dollar kurzfristig erreichen kann, ist keine frage. jeder kann natürlich tun und lassen was er will hier aber ich gebe meine bestimmt nicht unter 2 dollar ab. bin jetzt schon gespannt, wie es heute mittag "drüben" weiter gehen wird
wenn heute drüben nicht geschmissen wird, dann fällt bis heute abend die 1 dollar marke. das man hier kurse von 2-3 dollar kurzfristig erreichen kann, ist keine frage. jeder kann natürlich tun und lassen was er will hier aber ich gebe meine bestimmt nicht unter 2 dollar ab. bin jetzt schon gespannt, wie es heute mittag "drüben" weiter gehen wird
bei uns wird man auch so langsam munter immerhin sind schon 0,58 euronen bezahlt worden more to come
NORTHWEST BIOTHER.DL-,001
WKN Börse Kurs Trade Vol. Tages Vol. Zeit Datum Bid Bid Vol. Ask Ask Vol. T.hoch T.tief Vortag Diff. Änd. Realtime
728853 FRA 0,59 2.500 41.544 10:12 02.03.2006 0,56 10.000 0,60 5.000 0,59 0,54 0,39 0,20 +51,28% ja
RT +51%
ASK 0,60
denke wir sehen gegen 16h einen Kurs von 0,86 Dollar,um bescheiden zu bleiben.
Zudem 1 Dollar am Freitag.
Diese Aktie und PTSC sind die hottest today!
americanbulls.com postst zudem BUY!
http://americanbulls.com/StockPage.asp?CompanyTicker=NWBT&Ma…
WKN Börse Kurs Trade Vol. Tages Vol. Zeit Datum Bid Bid Vol. Ask Ask Vol. T.hoch T.tief Vortag Diff. Änd. Realtime
728853 FRA 0,59 2.500 41.544 10:12 02.03.2006 0,56 10.000 0,60 5.000 0,59 0,54 0,39 0,20 +51,28% ja
RT +51%
ASK 0,60
denke wir sehen gegen 16h einen Kurs von 0,86 Dollar,um bescheiden zu bleiben.
Zudem 1 Dollar am Freitag.
Diese Aktie und PTSC sind die hottest today!
americanbulls.com postst zudem BUY!
http://americanbulls.com/StockPage.asp?CompanyTicker=NWBT&Ma…
RT 0,59 euronen
zu 0,58 Euro gibt es kein Teilchen mehr.
RT 0,61 euronen es begreifen anscheinend immer mehr, was da im bush ist beim kurs more to come
das wird ein heisser ritt heute
bin leider beruflich unterwegs und kann`s nicht mitverfolgen
bin leider beruflich unterwegs und kann`s nicht mitverfolgen
[posting]20.458.807 von BarceloFuerte am 02.03.06 10:10:14[/posting]da versteh einer den deutschen Anleger??? Vorgestern 40% unter pari und heute 20% über pari Hoffentlich kommt da heute nicht das böse Erwachen.
Aber mir soll`s recht sein; vieleicht sehen wir diese Woche tatsächlich noch den Dollar.
Good trades
TB
Aber mir soll`s recht sein; vieleicht sehen wir diese Woche tatsächlich noch den Dollar.
Good trades
TB
RT 0,57 euronen gedrückt mit 1000 stücken con 0,61 euronen
RT o.54
was geht?
was geht?
347: und sollten wir heute auf den dollar zu steuern, dann fangen wir hier erst richtig an hinterher zu laufen vor börsenschluß gestern in den usa war deutlich zu sehen, daß der kurs stark angezogen ist. folgedessen sollte die eröffnung in den usa mit einem positiven verlauf beginnen.
nur meine meinung.
nur meine meinung.
[posting]20.460.631 von BarceloFuerte am 02.03.06 11:42:16[/posting]was soll`s, handelt ja jeder mit seinem eigenen Geld. Mir persönlich ist es lieber unter pari zu kaufen Und da gab`s ja genügend Gelegenheiten diese Woche.
TB
TB
RT 0,61 !!!!!!!!!!!!
Nur soviel zur Message vorher!
Sie sollten sie genauer informieren!
Aber den RT Kurse sollte jeder selbst überprüfen!
Hatte ja schon heute morgen auf den Anstieg verwiesen, der sie bestätigt hat!! auf mindesten 0,9! Wahrscheinlich sogar 0,95
Nur soviel zur Message vorher!
Sie sollten sie genauer informieren!
Aber den RT Kurse sollte jeder selbst überprüfen!
Hatte ja schon heute morgen auf den Anstieg verwiesen, der sie bestätigt hat!! auf mindesten 0,9! Wahrscheinlich sogar 0,95
352: RT kurs 0,61 euronen überprüft ! die uhrzeit war 10:52:45 bei einem umsatz von 1000 stücken !!! also 100% richtiges posting. im übrigen wären die 0,9 nicht übel
RT 0,57 euronen more to come
eines sollte jedem hier klar sein. wenn, ja wenn die marke von 1 dollar geknackt werden sollte, dann handelt es sich bei diesem unternehmen nicht mehr um eine "penny-klitsche"
und was dies dann heißt, könnt ihr euch ja selbst vorstellen ich sage nur "fonds" jeder hat aber eine andere denk bzw. sichtweise und das ist auch gut so. meine kennt man und die lautet unter 2 dollar werfe ich nichts auf den markt. weitere meldungen kommen und diese werde bestimmt nicht schlecht ausfallen
und was dies dann heißt, könnt ihr euch ja selbst vorstellen ich sage nur "fonds" jeder hat aber eine andere denk bzw. sichtweise und das ist auch gut so. meine kennt man und die lautet unter 2 dollar werfe ich nichts auf den markt. weitere meldungen kommen und diese werde bestimmt nicht schlecht ausfallen
Na,
wie entwickelt sich unser Road-Runner. Denke, wir können allseits zufrieden sein.
Vorbörslicher Anstieg läßt Gutes erwarten.
BID 0.64 $
NITE bereits bei 0.745$ positioniert.
... und nicht vergessen. Ab 1 $ wird`s haben die Institutionellen die Chance unseren Blockbuster zu begleiten
wie entwickelt sich unser Road-Runner. Denke, wir können allseits zufrieden sein.
Vorbörslicher Anstieg läßt Gutes erwarten.
BID 0.64 $
NITE bereits bei 0.745$ positioniert.
... und nicht vergessen. Ab 1 $ wird`s haben die Institutionellen die Chance unseren Blockbuster zu begleiten
357: wenigstens eine bzw. einer weiß was ab 1 dollar passieren wird. steht ja schon in 355
[posting]20.464.686 von BarceloFuerte am 02.03.06 15:01:11[/posting]Sei zufrieden!
Das ergibt heute noch ein schönes GAP-UP!
Wirst sehen!
Das ergibt heute noch ein schönes GAP-UP!
Wirst sehen!
[posting]20.463.080 von mfierke am 02.03.06 13:41:47[/posting]@mfierke,
bist auch immer dort, wo Eisen zu Gold veredelt wird.
bist auch immer dort, wo Eisen zu Gold veredelt wird.
die letzten ungläubigen hatten heute den ganzen tag genügend zeit gehabt sich unter 0,60 euronen einzudecken. nach eröffnung in den usa dürfte dies wohl vorbei sein
[posting]20.464.967 von BarceloFuerte am 02.03.06 15:11:31[/posting]Schau Dir die Umsätze in Frankfurt und Berlin an.
Finde, ist nicht unerheblich ... und dies war sicherlich
heute erst der Anfang.
Bid steigt weiter! RT 0.65 $
Finde, ist nicht unerheblich ... und dies war sicherlich
heute erst der Anfang.
Bid steigt weiter! RT 0.65 $
Jetzt einsteigen, sonst wird hinterhergehechelt!
heute 50% hoch, vielleicht eine utopische aussage meinerseits aber dann kommt "richtiger umsatz" rein durch die großen in deutschland kann man sich dann morgen bei 1 euro eindecken, falls es heute so kommen sollte ??
Luft unter 0.70 $ in US wird dünn.
Vermutlich Eröffnung darüber.
Vermutlich Eröffnung darüber.
...bin ganz schön aufgeregt was heut in Amiland abgeht...
RT 0,60 euronen in frankfurt. dort umsatz über 100.000 stücke
So Leute,
jetzt sprecht bzw. schreibt mit uns! 1309 `mal gelesen, und konstruktive Beiträge bzw. Infos nur eine Handvoll.
übrigens BID UP 0.66 $
jetzt sprecht bzw. schreibt mit uns! 1309 `mal gelesen, und konstruktive Beiträge bzw. Infos nur eine Handvoll.
übrigens BID UP 0.66 $
366: das weiß niemand von uns ?!?!
Und wieder Up!
BID 0.67 $
BID 0.67 $
WAAAAHHH !!!!
RT 0,66
Schon überholt!
RT 0.678 $
Bid 0.67 $
RT 0.678 $
Bid 0.67 $
Börsenplatz Frankfurt
Datum 02.03.06
Abfrage 02.03.06 15:35:21
Kursstellung 02.03.06 15:25
Kurs 0,60
Gehandelte Stücke 103.949
Währung EUR
Datum 02.03.06
Abfrage 02.03.06 15:35:21
Kursstellung 02.03.06 15:25
Kurs 0,60
Gehandelte Stücke 103.949
Währung EUR
...wo bekommt ihr realtime amiland her ?
auf alle fälle geht es am anfang genau so weiter wie gestern abend, nämlich aufwärts go baby go
www.pcquote.com
...danke !
ohne Worte!
RT 0.68 $
RT 0.68 $
RT 0,67
Abwarten.
Was macht den Frankfurt mit 0,55?
ffm passt den kurs an den us kurs an,
0,66$ sind ~ 0,55 cent.
mp*
0,66$ sind ~ 0,55 cent.
mp*
Naja,
liebe MM-Heinis in US. Jetzt reichts mit GAP-Close.
Jetzt könnt ihr wieder hochziehen.
liebe MM-Heinis in US. Jetzt reichts mit GAP-Close.
Jetzt könnt ihr wieder hochziehen.
Jetzt nur keine Shares verschleudern.
Die MM-Heinis haben wieder `mal ihr geliebtes Gap-Close zelebriert.
RT 0.58 $
Die MM-Heinis haben wieder `mal ihr geliebtes Gap-Close zelebriert.
RT 0.58 $
Zur Info:
RT 0.61 $
RT 0.61 $
Heute noch mal zugegriffen, ein paar zu 0.47 in ffm, mal schaun was wird,
[posting]20.474.212 von evamar am 02.03.06 20:20:16[/posting]hast Recht, bei 100 Stk. kann nicht viel anbrennen
habe mir zwar viel mehr vom heutigen tag versprochen aber erzwigen kann man halt nichts dennoch bin ich felsenfest davon überzeugt, daß man hier sehr gut aufgehoben ist
sag ich jakleinvieh macht auch misthab ja noch mehr davon-du nase-sorry
Hab mal die Abstände der letzten 3 Newsmeldungen angeschaut.
Es sind immer ca. 5-7 Tage dazwischen.
Dürfen wir also am 6. bis 8. März wieder mit News rechnen?
Schon klar. Nur Zufall. Aber man darf doch hoffen oder.
Es sind immer ca. 5-7 Tage dazwischen.
Dürfen wir also am 6. bis 8. März wieder mit News rechnen?
Schon klar. Nur Zufall. Aber man darf doch hoffen oder.
Guten Morgen
Wie gehts heute weiter. Stand Gestern erstaunlich stabil nach dem vulminanten Anstieg vom Vortag.
AmericanBulls signalisiert weiterhin "Buy If".
Auf einen guten Börsentag
Wie gehts heute weiter. Stand Gestern erstaunlich stabil nach dem vulminanten Anstieg vom Vortag.
AmericanBulls signalisiert weiterhin "Buy If".
Auf einen guten Börsentag
Bin auch mal gespant, wie sich die Aktie heute so entwickelt!Möchte auch gerne noch einmal einsteigen.Bin vor einigen Wochen zu 0,14Euro leider rausgegangen.Ciao Lars!!
...uhhh. Das tut weh.
Das würd mich auch ärgern.
Das würd mich auch ärgern.
HALLO - IST NOCH EINER AN BORD!!!!!!!
KURS HÄLT SICH IN DEN USA!!!!!!!!
KURS HÄLT SICH IN DEN USA!!!!!!!!
Bin gerade bei GSHF!°
Alles sehr ruhig und das ist ein gutes Zeichen. Hier sind noch viele nicht dabei und das wird den Kurs in der nächsten Zeit explodieren lassen. Bin mir sicher das nächste Woche die ersten Börsenbriefe Empfehlungen geben werden. Das wird der Renner 2006.
Was sind denn Eure wagemutigen Einschätzungen für den Zielkurs?
Gruss
und schönes Wochenende
Gruss
und schönes Wochenende
[posting]20.498.076 von staecker am 03.03.06 22:19:10[/posting]Denke,
heutiger Verlauf ist mehr als zufriedenstellend.
Warte noch etwas ab, mit Sicherheit kommen hier noch Neuigkeiten. Ob Anal yst oder Investor, die Oel ins Feuer giessen.
Investoren springen nicht beim ersten Hype auf.
In diesem Sinne ...
schönes Wochenende
heutiger Verlauf ist mehr als zufriedenstellend.
Warte noch etwas ab, mit Sicherheit kommen hier noch Neuigkeiten. Ob Anal yst oder Investor, die Oel ins Feuer giessen.
Investoren springen nicht beim ersten Hype auf.
In diesem Sinne ...
schönes Wochenende
Bekomme keine Kurse rein von Frankfurt!!!!
Was ist los, weiss jemand was?
Was ist los, weiss jemand was?
[posting]20.529.859 von staecker am 06.03.06 09:52:59[/posting]Es gibt auch noch keine Kurse.
Bid 0,46 / Ask 0,50
Wahrscheinlich wird gewartet, bis uns die Amis wieder vorwärtsprügeln.
Bid 0,46 / Ask 0,50
Wahrscheinlich wird gewartet, bis uns die Amis wieder vorwärtsprügeln.
Alles klar, dachte schon ihr werdet ohne mich reich
Bin auf Amiland gespannt.
das sieht ja noch nicht soooo toll aus.
Warten wir mal.
Warten wir mal.
Da verschenkt jemand seine Aktien Normale konso bis zu den nächsten News. Weiterhin strong buy!!!!!!!!!!!
Amiland steigt wieder....
RT 0.51
RT 0.51
leute helft mir mal weiter
heute nachmittag
Shares Outstanding 21,000,000
jetzt 19.26 UHR
Shares Outstanding 22,000,000
bei www.pcquote.com
spinn ich oder was, woher kommen die 1 Mio. shares,
und ich könnte schwören vor ein paar tagen wares es noch
20 Mio.
heute nachmittag
Shares Outstanding 21,000,000
jetzt 19.26 UHR
Shares Outstanding 22,000,000
bei www.pcquote.com
spinn ich oder was, woher kommen die 1 Mio. shares,
und ich könnte schwören vor ein paar tagen wares es noch
20 Mio.
Bei mir stehn 21`000`000 (pcquote.com)
jo jetzt stehen wieder 21 Mio.,
komisch
komisch
Und ich jetzt 22`000`000
Die machen mich mürre
Die machen mich mürre
jo wollte ich auch gerade schreiben,
was läuft da
was läuft da
LOL jetzt
Shares Outstanding 23,000,000
Shares Outstanding 23,000,000
Ganz ruhig bleiben.
Grundsätzlich zu den OS, die bei pcquote.com angezeigt werden, sind nur permanente FAKES.
Ignore it!
Grundsätzlich zu den OS, die bei pcquote.com angezeigt werden, sind nur permanente FAKES.
Ignore it!
ist ja wohl scheiße,
fakes, dann soll man es gleich lassen,
verwirrt nur
fakes, dann soll man es gleich lassen,
verwirrt nur
Share-Volume:
163,120
163,120
Korrektur zu vorherigen Posting:
Outstanding Shares:
19,078,000 entspricht MK wie bekannt: 8,5 MIO
Outstanding Shares:
19,078,000 entspricht MK wie bekannt: 8,5 MIO
Immer locker bleiben, das wird der Renner 06. Warten auf die nächsten News und es geht steil nach oben.
Hier nochmal von Nasdaq.com
NWBT NORTHWEST BIOTHERAPEUTICS IN | NWBT
Portfolio Tracking Ticker
Mar. 6, 2006 13:41 ET Market Open
Common Stock Market : OTCBB
Last Sale: $ 0.49
Net Change: 0.07 12.5%
Share Volume: 168,120
Previous Close: $ 0.56
Today`s High: $ 0.58
Today`s Low: $ 0.47
Best Bid: $ 0.48
Best Ask: $ 0.50
52 Week High: $ 0.69
52 Week Low: $ 0.085
P/E Ratio: NE
Shares Outstanding: 19,078,000
Earnings Per Share (EPS): $ -0.65
Market Value: $ 9,348,220
NWBT NORTHWEST BIOTHERAPEUTICS IN | NWBT
Portfolio Tracking Ticker
Mar. 6, 2006 13:41 ET Market Open
Common Stock Market : OTCBB
Last Sale: $ 0.49
Net Change: 0.07 12.5%
Share Volume: 168,120
Previous Close: $ 0.56
Today`s High: $ 0.58
Today`s Low: $ 0.47
Best Bid: $ 0.48
Best Ask: $ 0.50
52 Week High: $ 0.69
52 Week Low: $ 0.085
P/E Ratio: NE
Shares Outstanding: 19,078,000
Earnings Per Share (EPS): $ -0.65
Market Value: $ 9,348,220
jaja die liebe MK
ist ein witz verstehe nicht warum das ding nicht fliegt,
bei solchen aussichten zu diesen preisen verkaufen
bleibt mir ein rätsel
ist ein witz verstehe nicht warum das ding nicht fliegt,
bei solchen aussichten zu diesen preisen verkaufen
bleibt mir ein rätsel
denke ist langsam Zeit aus Trading-Gewinnen neue Positionen aufzubauen
vielleicht kommt ja bald ein deal über ca. 40 Millionen Forschungsgelder und eine möglich Beteiligung
aber immer riskant
aber bei Erfolg wurde ja schon oft dargelegt
vielleicht kommt ja bald ein deal über ca. 40 Millionen Forschungsgelder und eine möglich Beteiligung
aber immer riskant
aber bei Erfolg wurde ja schon oft dargelegt
immerhin von € 0.34 auf € 0.37
staecker der Anstieg hat nix zu sagen der Kurs stammt von mir, hatte keinen Bock zu warten
bin damals zu 0,38 und 0,55 Euro großteils raus
bin damals zu 0,38 und 0,55 Euro großteils raus
Hi,
habe auch ein Teil verkauft,nach so einen Anstieg nie
verkehrt
Kann nur jedem raten SL Kurse setzen und auch einhalten!
Bin bei der Mk auch erst von 19 Millionen Aktien ausgegangen,
aber insgesamt haben wir 300 Millionen.
Naja,habe ich ja schon mal geschrieben
MfG
gerl
habe auch ein Teil verkauft,nach so einen Anstieg nie
verkehrt
Kann nur jedem raten SL Kurse setzen und auch einhalten!
Bin bei der Mk auch erst von 19 Millionen Aktien ausgegangen,
aber insgesamt haben wir 300 Millionen.
Naja,habe ich ja schon mal geschrieben
MfG
gerl
übrigens hat von Euch jemand Titan Pharmaz. im Depot?
also deine Epfehlung:
raus.
richtig
raus.
richtig
Du ich weiss es nicht!
Bin schon länger dabei und habe nen Durschnittskurs von 0,14
mein Geld habe ich raus und der Rest bleibt liegen,da
die Aussichten nicht schlecht sind!
Den Teilverkauf habe ich getätigt,als ich auf die 300 Mill.
Shares gestossen bin.
Ich kann und werde keinen zum Verkauf oder Kauf raten,nur
an der Otc ist immer vorsicht angesagt-ob NWBT Erfolg haben
wird kann glaube ich noch niemand sagen.
Im Biotechsektor irgenwelche Prognosen abzugeben ist sehr,sehr schwer.
Man,was war ich mal überzeugt von Millenium Pharmac. und was habe
ich mit denen für Kohle verloren (verliebe Dich nie
in eine Aktie)
MfG
gerl
Bin schon länger dabei und habe nen Durschnittskurs von 0,14
mein Geld habe ich raus und der Rest bleibt liegen,da
die Aussichten nicht schlecht sind!
Den Teilverkauf habe ich getätigt,als ich auf die 300 Mill.
Shares gestossen bin.
Ich kann und werde keinen zum Verkauf oder Kauf raten,nur
an der Otc ist immer vorsicht angesagt-ob NWBT Erfolg haben
wird kann glaube ich noch niemand sagen.
Im Biotechsektor irgenwelche Prognosen abzugeben ist sehr,sehr schwer.
Man,was war ich mal überzeugt von Millenium Pharmac. und was habe
ich mit denen für Kohle verloren (verliebe Dich nie
in eine Aktie)
MfG
gerl
was labberst du von 300 Millionen Aktien
wären die ja 150 Millionen wert
Schwachsinn
denke gehen demnächst auf 0,6 ca.
wären die ja 150 Millionen wert
Schwachsinn
denke gehen demnächst auf 0,6 ca.
Titan ist auch so ne hop oder top Aktie
streuen streuen und nochmals streuen
streuen streuen und nochmals streuen
OTCBB Company Profile
NWBT - NORTHWEST BIOTH Click here to order Full Report
Northwest Biotherapeutics, Inc.
Canyon Park Building 8
22322 20th Avenue S.E.
Suite 150
Bothell, WA 98021
United States
Phone: 425-608-3000
Fax: (425) 608-3146
Alton L. Boynton, Ph.D., CEO
SIC Number: 2834
Fiscal Year End: 12-31
Industry: Drugs
Transfer Agent: Mellon Investor Services, LLC
CIK: 1072379
Market Maker List
Share Data
Authorized Outstanding
Date Shares Source Date Shares Source
01/01/2005 300,000,000 10-K 11/14/2005 19,078,048 MGFS
Business Summary
NWBT - NORTHWEST BIOTH Click here to order Full Report
Northwest Biotherapeutics, Inc.
Canyon Park Building 8
22322 20th Avenue S.E.
Suite 150
Bothell, WA 98021
United States
Phone: 425-608-3000
Fax: (425) 608-3146
Alton L. Boynton, Ph.D., CEO
SIC Number: 2834
Fiscal Year End: 12-31
Industry: Drugs
Transfer Agent: Mellon Investor Services, LLC
CIK: 1072379
Market Maker List
Share Data
Authorized Outstanding
Date Shares Source Date Shares Source
01/01/2005 300,000,000 10-K 11/14/2005 19,078,048 MGFS
Business Summary
@ geri
Stimmt,
an der OTC nur mit Spielgeld operieren und niemals Long !
Bei 5 Werten im Depot reicht es, wenn einmal ein Kracher dabei ist.
Habe gestern meine PTSC verkauft und mit dem Rohertrag
NWBT aufgestockt.
Stimmt,
an der OTC nur mit Spielgeld operieren und niemals Long !
Bei 5 Werten im Depot reicht es, wenn einmal ein Kracher dabei ist.
Habe gestern meine PTSC verkauft und mit dem Rohertrag
NWBT aufgestockt.
Authorized 300 millionen oder nicht?
Wie berechnest Du die Mk nur nach Ausstehenden Aktien?
Wie berechnest Du die Mk nur nach Ausstehenden Aktien?
Hi vergaser,
warum hast du noch mal aufgestockt? Was ist dein Kursziel? Willst du beim nächsten Anstieg Gewinne mitnehmen, oder erwartest du mehr?
Danke prom
warum hast du noch mal aufgestockt? Was ist dein Kursziel? Willst du beim nächsten Anstieg Gewinne mitnehmen, oder erwartest du mehr?
Danke prom
@vergaser
bin ich genau Deiner Meinung!
Zu Anfangszeiten wurde ich dort auch rasiert ohne Seife
Bin z.Z. noch in Neomedia,Mobilepro und Rocketinfo naja mal
sehen was daraus wird-aber Bullvestor steht ja zur Zeit mehr
auf Explorer
bin ich genau Deiner Meinung!
Zu Anfangszeiten wurde ich dort auch rasiert ohne Seife
Bin z.Z. noch in Neomedia,Mobilepro und Rocketinfo naja mal
sehen was daraus wird-aber Bullvestor steht ja zur Zeit mehr
auf Explorer
@ Prom
Natürlich werden Gewinne realisiert, aber davon kann im Moment noch nicht die Rede sein , da ich erst recht spät auf NWBT aufmerksam geworden bin.
Von dem Management habe ich einen poitiven Eindruck.
Wie die PR`S andeuten, stehen wir kurz vor der Zulassung
eines hochwirksamen Medikamentes.
Wenn der Fall eintritt, ist eine Verzehnfachung der Marktkapitalisierung möglich.
Natürlich werden Gewinne realisiert, aber davon kann im Moment noch nicht die Rede sein , da ich erst recht spät auf NWBT aufmerksam geworden bin.
Von dem Management habe ich einen poitiven Eindruck.
Wie die PR`S andeuten, stehen wir kurz vor der Zulassung
eines hochwirksamen Medikamentes.
Wenn der Fall eintritt, ist eine Verzehnfachung der Marktkapitalisierung möglich.
[posting]20.581.168 von vergaser am 08.03.06 18:44:38[/posting]Der letzte Satz ist wichtig. Genau mein Ziel. Warten wirs ab.
Gruss prom
Gruss prom
Die Ruhe vor dem Sturm. Es geht bald wieder los, positiv ist das noch keine Börsenbriefe dabei sind. Die werden auch noch einsteigen, da werden wir aber wesentlich höher stehen. Strong buy
Ich denke, solange der Kurs so dümpelt, wird auch kein Börsenbrief aufspringen....
Guten Tag! Alles wird gut!
ja prom
es geht bald los
es geht bald los
[posting]20.602.145 von staecker am 09.03.06 18:19:28[/posting]Der kurs war bei 0,08€ und keiner wollte kaufen, auch ich nicht, da ich bereits etwas höher eingestiegen war. Ich dachte schon an Verkauf weil sich nichts bewegte. Aber dann zündete die Rakete und das ist erst der erste kleine Schritt gewesen.Strong buy, das sind immer noch beste Kaufkurse.
20 UHr Start in alter Manier?
[posting]20.581.168 von vergaser am 08.03.06 18:44:38[/posting]Welche PR´S meinst du, die auf ein hochwirksames Produkt "kurz vor Zulassung" hindeuten?
Gab es da nicht mal Probleme in der Phase III - oder irre ich.. (wollen wir es hoffen!)
Gab es da nicht mal Probleme in der Phase III - oder irre ich.. (wollen wir es hoffen!)
egal die Kaufmonster sitzen in den Startlöchern
wird die Aktie 2006
wird die Aktie 2006
[posting]20.581.168 von vergaser am 08.03.06 18:44:38[/posting]Welche PR´S meinst du, die auf ein hochwirksames Produkt "kurz vor Zulassung" hindeuten?
Gab es da nicht mal Probleme in der Phase III - oder irre ich.. (wollen wir es hoffen!)
Gab es da nicht mal Probleme in der Phase III - oder irre ich.. (wollen wir es hoffen!)
Vergaser der Gummihund hat mal ne Frage an dich
Folgende Antwort bezieht sich auf Beitrag Nr.: 20.581.168 von vergaser am 08.03.06 18:44:38
--------------------------------------------------------------------------------
Welche PR´S meinst du, die auf ein hochwirksames Produkt " kurz vor Zulassung" hindeuten?
Gab es da nicht mal Probleme in der Phase III - oder irre ich.. (wollen wir es hoffen!)
Grüße an Vergaser und den zweifelnden Gummihund
Folgende Antwort bezieht sich auf Beitrag Nr.: 20.581.168 von vergaser am 08.03.06 18:44:38
--------------------------------------------------------------------------------
Welche PR´S meinst du, die auf ein hochwirksames Produkt " kurz vor Zulassung" hindeuten?
Gab es da nicht mal Probleme in der Phase III - oder irre ich.. (wollen wir es hoffen!)
Grüße an Vergaser und den zweifelnden Gummihund
@gummihund
du irrst leider nicht. im anderen NWBT Thread steht was darüber.
Aber aus Fehlern lernt man, nicht war. Diesmal machen sie hoffentlich alles richtig.
Oh News ihr kommed, so kommed doch bald...
du irrst leider nicht. im anderen NWBT Thread steht was darüber.
Aber aus Fehlern lernt man, nicht war. Diesmal machen sie hoffentlich alles richtig.
Oh News ihr kommed, so kommed doch bald...
Gummihund nun brauchst du den Vergaser auch net mehr fragen den der staecker hats ja schon gemeint
0,4
SK Tageshöchstkurs
where is the 1$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
1 Dollar nächste Woche
Detailed Quote Snapshot 03/09/2006 03:51 PM
Last:
0.385 nwbt - NORTHWEST BIOTHERAPEUTICS IN
Change:
-0.01 % Change:
-2.56% High:
0.4 Low:
0.37 Volume:
95,096
Price Data Table
Open 0.37
Previous Close 0.385
Exchange of Last Sale OTCBB
Time of Last Sale 15:52:35
Tick Up
Bid 0.38
Ask
Size Bid/Ask 50x50
Symbol Type Equity
Fundamental Data Table
52 Week High 0.69
52 Week Low 0.09
EPS -0.65
P/E Ratio 0.00
Shares Outstanding 19,000,000
Market Cap 7,440,000
Beta 3.855
Dividend Frequency
Ex-Dividend Date
Dividend Amount
Yield 0.00
Primary Exchange OTCBB
Last:
0.385 nwbt - NORTHWEST BIOTHERAPEUTICS IN
Change:
-0.01 % Change:
-2.56% High:
0.4 Low:
0.37 Volume:
95,096
Price Data Table
Open 0.37
Previous Close 0.385
Exchange of Last Sale OTCBB
Time of Last Sale 15:52:35
Tick Up
Bid 0.38
Ask
Size Bid/Ask 50x50
Symbol Type Equity
Fundamental Data Table
52 Week High 0.69
52 Week Low 0.09
EPS -0.65
P/E Ratio 0.00
Shares Outstanding 19,000,000
Market Cap 7,440,000
Beta 3.855
Dividend Frequency
Ex-Dividend Date
Dividend Amount
Yield 0.00
Primary Exchange OTCBB
ask sofort weggekauft
Detailed Quote Snapshot 03/09/2006 03:52 PM
Last:
0.375 nwbt - NORTHWEST BIOTHERAPEUTICS IN
Change:
-0.02 % Change:
-5.13% High:
0.4 Low:
0.37 Volume:
106,896
Price Data Table
Open 0.37
Previous Close 0.375
Exchange of Last Sale OTCBB
Time of Last Sale 15:54:01
Tick Down
Bid 0.37
Ask
Size Bid/Ask 50x50
Symbol Type Equity
Fundamental Data Table
52 Week High 0.69
52 Week Low 0.09
EPS -0.65
P/E Ratio 0.00
Shares Outstanding 20,000,000
Market Cap 7,440,000
Beta 3.855
Dividend Frequency
Ex-Dividend Date
Dividend Amount
Yield 0.00
Primary Exchange OTCBB
Kauforder zu 0,4 geht nicht mehr durch
zum k....
sk 0,37$
genug geheult
genug geheult
Vielleicht müssen wir noch bis Juli warten???
Rund um den World Cancer Congress 2006 tut sich dann bestimmt was.
http://www.2006conferences.org/u-index.php
Rund um den World Cancer Congress 2006 tut sich dann bestimmt was.
http://www.2006conferences.org/u-index.php
Mal sehn wie weit es bis dahin noch runtergeht
Ich glaube wir sehen weiterfallende Kurse, denn diese
eigentlich geile News hat den Hype verursacht und nach
einigen Gewinnmitnahmen, Spekulationen und Zocks kommt
der Kurs wieder zurück und dürfte solange leicht schwanken
bei 20-30 Cents bis eine Zulassung o.ä. kommt.
Bis dahin Zock vorbei
eigentlich geile News hat den Hype verursacht und nach
einigen Gewinnmitnahmen, Spekulationen und Zocks kommt
der Kurs wieder zurück und dürfte solange leicht schwanken
bei 20-30 Cents bis eine Zulassung o.ä. kommt.
Bis dahin Zock vorbei
na super.
dann bleibe ich halt.
`extreme long`
dann bleibe ich halt.
`extreme long`
mal schaun ob das dem Kurs auf die Sprünge hilft
BUY-IF
0.3700
-0.0200 -5.13%
Candlestick Analysis
Today’s Candlestick Patterns:
Doji
Bullish (Doji) Star
Today a Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.
For more about this candlestick click here.
The last two candlesticks formed a Bullish (Doji) Star Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation.
BUY-IF
0.3700
-0.0200 -5.13%
Candlestick Analysis
Today’s Candlestick Patterns:
Doji
Bullish (Doji) Star
Today a Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.
For more about this candlestick click here.
The last two candlesticks formed a Bullish (Doji) Star Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation.
und gleich noch hinterher
Recent CandleStick Analysis
Very Bullish
Date Candle
Mar-09-2006 Inverted Hammer
Mal abwarten was sich tut.
Recent CandleStick Analysis
Very Bullish
Date Candle
Mar-09-2006 Inverted Hammer
Mal abwarten was sich tut.
Kann mir bitte jdm. den Realtimekurs USA reinstellen???
und Bid/Ask
Danke!!!
und Bid/Ask
Danke!!!
0,36$
0,35
der endgültige Boden
nächste Woche wieder um 0,6
der endgültige Boden
nächste Woche wieder um 0,6
schön wärs
hope
hope
typisch bei 0,6 wo ich fast alles abgestossen hatte , haben alle geschwärmt nun ist es wieder billig und alle sind skeptisch
na nicht alle wenn ich mir das Orderbuch anschaue
na nicht alle wenn ich mir das Orderbuch anschaue
[posting]20.618.220 von Zentimeter am 10.03.06 17:12:25[/posting]Da bist du richtig ausgestiegen, hoffe aber du hast bei diesen Kursen wieder zugegriffen bevor die Rakete wieder startet.
na logisch gestern und heute
man hat so richtige Kauflust
[posting]20.618.869 von Zentimeter am 10.03.06 17:36:09[/posting]So ist es richtig.
goanix im bid?
viel bid zwischen 0,35-0,36
[posting]20.417.184 von baluweb am 28.02.06 10:06:44[/posting]NWBT - bereit für den Rebound?
Diese Biotechrakete war v. 7 Tagen in FRA über 0.6 Euro und hat sich nun bei 0.3 Euro eingependelt.
Demnächst könnte ein techn. Rebound einsetzen bzw. eher der positive Trend könnte fortfahren.
Das wird von den führenden US-Chartechnikern gepostet:
1)
http://www.stockta.com/cgi-bin/analysis.pl?symb=NWBT&num1=13…
" Signal 09.03. INVERTED HAMMER - VERY BULLISH "
2)
http://quotes.barchart.com/texpert.asp?sym=NWBT
" Long Term 100% buy,overall 56% buy "
3)
http://americanbulls.com/StockPage.asp?CompanyTicker=NWBT&Ma…
" white candlestick,buy if "
etc.
Zudem gibt es ja das ungeschriebene Gesetz der 50% Regel.
---------------------------------------------------------
Aufgrund folg. NEWS stieg am 01.03. NWBT intraday um 83%.
Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
WEDNESDAY, MARCH 01, 2006 7:31 AM
- PR Newswire
BOTHELL, Wash., March 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced new preclinical data on the efficacy of a monoclonal antibody to CXCR4, one of the most important cancer targets discovered in recent years. The new data showed a significant reduction in metastases to the lung, as well as a significant reduction in primary breast cancer tumor growth and significant extension of survival, after treatment with NWBT`s monoclonal antibody to CXCR4. A growing body of research and literature has shown that CXCR4 plays a central role in all three stages of cancer progression, and does so in over 75% of all cancers. NWBT holds broad issued patent coverage for the use of antibody therapeutics targeting CXCR4, as announced in March 2005. The data were presented at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri-Conference, February 22nd and 23rd, in San Francisco, CA.
It is now well documented that CXCR4 plays an important role in all three major aspects of cancer progression: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. Northwest Biotherapeutics conducted a series of preclinical studies to test a monoclonal antibody to CXCR4 in three cancer models. The studies were designed to determine whether blocking CXCR4 function would impact primary tumor growth, metastases and survival. The findings reported showed that anti-CXCR4 antibodies significantly impacted all three of these aspects:
-- Median survival more than doubled, with 95% of the treated animals
surviving >110 days compared with median survival of 45 days in
control animals;
-- Lung metastases were reduced by 75%;
-- Growth of primary breast tumors were reduced by 60%.
"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."
CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008 (Pacific)
Diese Biotechrakete war v. 7 Tagen in FRA über 0.6 Euro und hat sich nun bei 0.3 Euro eingependelt.
Demnächst könnte ein techn. Rebound einsetzen bzw. eher der positive Trend könnte fortfahren.
Das wird von den führenden US-Chartechnikern gepostet:
1)
http://www.stockta.com/cgi-bin/analysis.pl?symb=NWBT&num1=13…
" Signal 09.03. INVERTED HAMMER - VERY BULLISH "
2)
http://quotes.barchart.com/texpert.asp?sym=NWBT
" Long Term 100% buy,overall 56% buy "
3)
http://americanbulls.com/StockPage.asp?CompanyTicker=NWBT&Ma…
" white candlestick,buy if "
etc.
Zudem gibt es ja das ungeschriebene Gesetz der 50% Regel.
---------------------------------------------------------
Aufgrund folg. NEWS stieg am 01.03. NWBT intraday um 83%.
Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
WEDNESDAY, MARCH 01, 2006 7:31 AM
- PR Newswire
BOTHELL, Wash., March 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced new preclinical data on the efficacy of a monoclonal antibody to CXCR4, one of the most important cancer targets discovered in recent years. The new data showed a significant reduction in metastases to the lung, as well as a significant reduction in primary breast cancer tumor growth and significant extension of survival, after treatment with NWBT`s monoclonal antibody to CXCR4. A growing body of research and literature has shown that CXCR4 plays a central role in all three stages of cancer progression, and does so in over 75% of all cancers. NWBT holds broad issued patent coverage for the use of antibody therapeutics targeting CXCR4, as announced in March 2005. The data were presented at the Cambridge Healthtech Institute`s 13th Annual Molecular Medicine Tri-Conference, February 22nd and 23rd, in San Francisco, CA.
It is now well documented that CXCR4 plays an important role in all three major aspects of cancer progression: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. Northwest Biotherapeutics conducted a series of preclinical studies to test a monoclonal antibody to CXCR4 in three cancer models. The studies were designed to determine whether blocking CXCR4 function would impact primary tumor growth, metastases and survival. The findings reported showed that anti-CXCR4 antibodies significantly impacted all three of these aspects:
-- Median survival more than doubled, with 95% of the treated animals
surviving >110 days compared with median survival of 45 days in
control animals;
-- Lung metastases were reduced by 75%;
-- Growth of primary breast tumors were reduced by 60%.
"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."
CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company`s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008 (Pacific)
[posting]20.417.184 von baluweb am 28.02.06 10:06:44[/posting]
aktuell:
FRA 0.31€ +3%
BER 0.31€ +15%
aktuell:
FRA 0.31€ +3%
BER 0.31€ +15%
@mindgames
denke diese Woche wieder rauf auf 0,5 USD bei relativ hohen Umsätzen
denke diese Woche wieder rauf auf 0,5 USD bei relativ hohen Umsätzen
[posting]20.659.102 von Zentimeter am 13.03.06 12:14:19[/posting]Da man am FR auf dem TH bei 0.46 Dollar schloß finde Ich die Kurse von 0.42€ ok und denke auch dass 0.50 Dollar heute schon drin sind,da ja auch heute neben SKY und BLUE PEARL die SUWN sehr gefragt ist und die GTEC nach oben zieht!
sorry falscher Thread!
Klar bei ca. 0.35 Dollar ist der Boden und charttechnisch ist es ein INVERTED HAMMER.
Ein absoluter Selbstläufer!
Klar bei ca. 0.35 Dollar ist der Boden und charttechnisch ist es ein INVERTED HAMMER.
Ein absoluter Selbstläufer!
aktuell:
FSE 0.32 +7%
BER 0.31 +15%
FSE 0.32 +7%
BER 0.31 +15%
wie erwartet es geht wieder los
bid zieht an
bid zieht an
0,38
85 k gehandelt
85 k gehandelt
Last:
0.38
NWBT - NORTHWEST BIOTHERAPEUTICS IN
Change:
+0.01
% Change:
+2.71%
High:
0.38
Low:
0.36
Volume:
85,059
Price Data Table
Open 0.36
Previous Close 0.38
Exchange of Last Sale OTCBB
Time of Last Sale 10:45:48
Tick Up
Bid 0.37
AHA... INVERTED HAMMER very bullish!
0.36 = der Boden zu 100%
0.38
NWBT - NORTHWEST BIOTHERAPEUTICS IN
Change:
+0.01
% Change:
+2.71%
High:
0.38
Low:
0.36
Volume:
85,059
Price Data Table
Open 0.36
Previous Close 0.38
Exchange of Last Sale OTCBB
Time of Last Sale 10:45:48
Tick Up
Bid 0.37
AHA... INVERTED HAMMER very bullish!
0.36 = der Boden zu 100%
[posting]20.663.602 von Zentimeter am 13.03.06 16:51:04[/posting]
letzte Umsätze
16:45:12 5.500 0,38
16:42:04 6.000 0,38
16:45:12 5.500 0,38
16:42:04 6.000 0,38
sobald Umsatz reinkommt sind wir bei ca. 0,42 DOllar
und dann geht es schneller als man schaut auf 0,6X
und dann geht es schneller als man schaut auf 0,6X
nix dagegen einzuwenden
up,up and away
up,up and away
der Umsatz fehlt aktuell
ruf mal in Amerika an,die sollen gefälligst kaufen
sie werden kaufen
mir egal ob jetzt oder 20.00 MEZ oder morgen
Wert gehört in jedes biotech-depot
denke mal es gibt Finanzierungsgerüchte
0,6 up up and go away
mir egal ob jetzt oder 20.00 MEZ oder morgen
Wert gehört in jedes biotech-depot
denke mal es gibt Finanzierungsgerüchte
0,6 up up and go away
gutes Zeichen wenn die Deutschen übervorsichtig taxen
0,4
Das sieht doch füe den ANfang schon mal gut aus
Das mit den Finanzierungsgerüchten vermutest Du nur ?
Das mit den Finanzierungsgerüchten vermutest Du nur ?
yep
denke es kommt Geld rein wie auch immer
denke es kommt Geld rein wie auch immer
kaum 10 Prozent im Plus schauen wieder mehr in den thread
denke ab 0,48 werden die ersten wieder mit schreiben
denke ab 0,48 werden die ersten wieder mit schreiben
Wie Ich es gesagt habe!
0,4 Dollar!
+9%
aber das ist erst der Anfang!
0,4 Dollar!
+9%
aber das ist erst der Anfang!
[posting]20.665.367 von mindgames1001 am 13.03.06 18:15:20[/posting]Hallo Mindgames,
auch mit dabei?
Gruß
auch mit dabei?
Gruß
jetzt kommen alle angeschlichen
Habe im Netz und Newstickers noch nichts gefunden? Ihr?
Habe im Netz und Newstickers noch nichts gefunden? Ihr?
hab bei ragingbull mal nix gefunden
[posting]20.665.484 von staecker am 13.03.06 18:22:35[/posting]Hier fehlen noch viele, selber schuld. Strong buy
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
63 | ||
58 | ||
44 | ||
31 | ||
23 | ||
19 | ||
13 | ||
12 | ||
11 | ||
10 |
Wertpapier | Beiträge | |
---|---|---|
9 | ||
8 | ||
8 | ||
7 | ||
7 | ||
7 | ||
7 | ||
7 | ||
7 | ||
7 |